Characterisation of a novel pluripotent stem cell survival compound by Cowan, Scott
  
 
 
 
 
 
 
 
 
Cowan, Scott (2013) Characterisation of a novel pluripotent stem cell 
survival compound. PhD thesis. 
 
 
 
http://theses.gla.ac.uk/4920/  
 
 
 
 
Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, without prior 
permission or charge 
This work cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
Characterisation of a novel 
pluripotent stem cell survival 
compound 
 
 
Scott Cowan 
B.Sc (hons) 
 
 
Submitted in the fulfilment of the requirements of the 
degree of 
Doctor of Philosophy in the College of Medical, Veterinary 
and Life Sciences, University of Glasgow 
 
 
 
Institute of Cardiovascular and Medical Sciences, College of 
Medical, Veterinary and Life Sciences, University of 
Glasgow. 
September 2013 
 
 
 
 
© S. Cowan 2013   
2 
 
Summary 
Human pluripotent stem cells (hPSC) such as human embryonic stem cells (hESC) 
and induced pluripotent stem cells (hiPSC) are incredibly valuable tools for 
investigations within a number of scientific fields including developmental 
biology, toxicology, pharmacology and perhaps most importantly, regenerative 
medicine. HPSC have an unlimited capacity for self-renewal which allows the 
expansion of clinically relevant cell numbers from a relatively small supply of 
starting material. Furthermore, hPSC are pluripotent, meaning they retain the 
capacity to differentiate into all the somatic cell types within the human body.   
In order for the huge potential of hPSC to be realised, many hurdles must first 
be overcome. The most basic of these is the development of consistent and 
scalable culture systems that allow sufficient expansion of hPSC without the loss 
of the stem cell identity. Critical to this matter is the susceptibility of hPSC to 
apoptosis upon enzymatic disaggregation wherein approximately 80% of hPSC 
begin the process of apoptosis. Recent efforts to overcome this issue have 
focussed on the Rho associated coiled-coil kinase (ROCK) inhibitor Y27632. 
However there is increasing evidence that the use of Y27632 can lead to an 
increased risk of karyotypic instability, a decrease in proliferative capacity and a 
reduced capacity to differentiate in to specific cell types such as haematopoietic 
cell types.  
The work presented within this thesis describes the characterisation of T16, a 
novel hPSC survival compound which did not inhibit ROCK in a previously 
performed in vitro kinase assay.  
Initial experiments confirmed the capacity of T16 to support hPSC survival upon 
enzymatic dissociation to a comparable level to that obtained through use of 
Y27632, regardless of culture medium or extracellular matrix (ECM) used. 
Furthermore T16 was shown to support enzymatic passage of hPSC for at least 20 
consecutive passages when used either transiently or continuously without any 
detrimental effect on stem cell marker profile, karyotypic stability or 
differentiation capacity.  
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The hyperphosphorylation of myosin light chain (MLC) has been reported to be 
the cause of dissociation induced apoptosis, with ROCK inhibition able to prevent 
this. Experimentation confirmed that T16 does not share this mechanistic target 
and does not prevent the hyperphosphorylation of MLC, or mediate its pro-
survival effect upstream of ROCK activation via inhibition of RhoA (Ras 
homologous member A). Furthermore T16 does not promote survival by 
promoting activation of Rac1. 
Further experimentation revealed that the pro-survival effect of T16 was 
dependent upon re-attachment to the ECM, however T16 did not increase the 
expression of a panel of integrins or other adhesion related proteins. Kinase 
inhibition studies identified a critical role for src-family kinases in T16 mediated 
survival of hPSC. Biochemical analysis showed that T16 did not alter the 
phosphorylation status of src-family kinases. Transcriptional analysis revealed 
Receptor for activated protein kinase C (RACK1) to be highly expressed in hPSC 
and subsequent experiments confirmed RACK1 as a binding partner for src-family 
kinases in hPSC, and that treatment with T16 alters this relationship. 
The transcriptional response to dissociation was analysed via microarray analysis 
and identified the Pi3K and integrin signalling pathways as highly regulated 
pathways upon dissociation of hPSC.  
In summary, the work presented within this thesis identifies T16 as a novel pro-
survival molecule that mediates its effect in a RhoA/ROCK/MLC independent, 
src-family kinase dependent manner. 
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1.1 Pluripotent stem cells 
Human pluripotent stem cells (hPSC) such as human embryonic stem cells (hESC) 
and induced pluripotent stem cells (hiPSC) are incredibly valuable tools for 
investigations within a number of scientific fields including developmental 
biology, toxicology, pharmacology and perhaps most importantly, regenerative 
medicine. HPSC hold great appeal to scientists primarily due to two key 
features; their capacity for unlimited self-renewal and their pluripotency. 
Pluripotency refers to their ability to derive any of the 220+ cell types 
encompassing the three germ layers that make up the human body (mesoderm, 
endoderm and ectoderm) (Amit et al, 2000; Thomson et al, 1998). This means 
that from a single cell line, scientists can generate huge numbers of cells that 
can be further expanded or differentiated into the various somatic cell types.  
1.1.1 Human embryonic stem cells 
Embryonic stem cells have been extensively studied for a number of years, 
having been first isolated from mice in 1981 (Evans and Kaufman, 1981; Martin, 
1981) and non-human primates in 1995 (Thomson et al, 1995). However, a major 
breakthrough occurred in 1998, when Thomson and colleagues described the 
isolation and characterisation of hESC for the first time. HESC were isolated 
from the inner cell mass (ICM) of the pre-implantation blastocyst which had been 
produced as a result of clinical in vitro fertilisation (IVF) treatments (figure 1.1). 
The cells of the ICM were isolated via immunosurgery during which the 
extraembryonic trophectoderm cells were lysed and washed away, before being 
cultured on irradiated mouse embryonic fibroblast (MEF) cells and allowed to 
further expand (Thomson et al, 1998). Since then there have been a large 
number of additional hESC lines produced using variations on this methodology. 
Although there is inherent heterogeneity between hESC lines (Allegrucci and 
Young, 2007), there are a number of criteria that all hESC must meet. These 
include the expression of a number of pluripotency related cell surface markers 
and transcription factors such as stage specific embryonic antigen 4 (SSEA4), 
SSEA3, tumour receptor antigen 1-81 (Tra1-81), Tra-1-60, octamer-binding 
transcription factor 4 (Oct4), Nanog and Sry-box 2 (Sox2). Further essential 
properties include an expanded capacity for proliferation (self-renewal), multi-
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lineage differentiation potential and the retention of normal euploid karyotype 
of 46, XY/XX (Hoffman and Carpenter, 2005).  
Although there are now many different hESC lines, they are all morphologically 
similar, growing in small colonies characterised by tight cell-cell adhesions 
mediated by cadherin proteins and have large nuclear to cytoplasmic ratios with 
very prominent nucleoli (Oh et al,2005).  
1.1.2 Induced pluripotent stem cells 
Although still considered by many to be the ‘gold standard’, there are a number 
of issues with the use of hESC not least the ethical issues relating to the 
destruction of embryos. Furthermore their use in regenerative medicine may be 
hampered given that the resulting cells would most likely be allogenic and would 
therefore require the subsequent and persistent use of immunosuppressive drugs 
(Preynat-Seauve et al, 2009). These issues were potentially circumvented in 
2007 when Takahashi and colleagues reported the derivation of the first ever 
human induced pluripotent stem cell (hiPSC) line. This landmark and Nobel Prize 
winning research used a cocktail of retroviruses containing the pluripotency 
related transcription factors Oct4, Sox2, Klf4 or c-Myc to reprogram terminally 
differentiated somatic cells, specifically skin fibroblasts, to an embryonic like 
state (figure 1.1). Not only were these cells morphologically indistinguishable 
from hESC, but they had equivalent expression of pluripotency markers, similar 
proliferative potential and were able to generate tissues from all three germ 
layers. These reprogrammed cells have a number of advantages over standard 
hESC lines in that they have the potential to be used as personalised therapies 
by reprograming the patient’s own cells to provide subsequent autologous 
treatments (Beltrão-Braga et al, 2013). Furthermore they can be used as 
excellent models for understanding the development of genetic diseases, with 
models already being generated for a range of disorders such as Parkinsons 
(Soldner et al, 2009), Huntington disease (Park et al, 2008) and Downs syndrome 
(Mou et al, 2012). 
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Figure 1.1. Derivation of hPSC. HESC are derived from the ICM of the pre-implantation 
blastocyst. HiPSC are created by the direct reprogramming of somatic cell types using key 
reprogramming factors such as Oct4, Sox2, Klf4 and c-Myc. Both cell types can be cultured 
indefinitely in vitro and can be used as potential tissues in regenerative medicine.  
 
The use of hiPSC is not however without issue. There have been many questions 
raised regarding the use of viruses as a means of introducing the reprogramming 
factors as this introduces the risk of insertional mutagenesis. Furthermore, the 
use of oncogenes such as c-Myc, which is one of the key transcription factors 
used during reprogramming, has also caused concern (Yamanaka, 2012; 
Medvedev et al, 2010; Okano et al, 2013). There has been a large body of data 
published that details the use of non-integrating methods of reprogramming as 
well as variations on the factors required for efficient reprogramming. For 
example, Yu et al (2007) successfully produced hiPSC without the use of c-myc, 
instead using a combination of Oct4, Nanog, Lin28 and Sox2. Furthermore, Okita 
and colleagues achieved reprogramming by using episomal plasmid vectors to 
introduce a number of factors and further enhanced reprogramming efficiency 
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and safety by suppression of p53 and the substitution of c-Myc with l-Myc (Okita 
et al, 2011). Similarly, Fusaki et al (2009) used the non-integrating RNA based 
Sendai virus coupled with the original Yamanaka factors to achieve non-
integrative reprogramming.  
Another interesting method of reprogramming utilises cell penetrating peptides 
directly linked to reprograming proteins (Yamanaka factors) which entirely 
circumvents the requirement of any carrier (Kim et al, 2009). A comparison of 
the advantages and disadvantages of hESC and hiPSC as well as the derivation 
methods of hiPSC can be seen in tables 1.1 and 1.2 respectively.  
 
Cell type Potency Origin Disadvantages Advantages 
hESC 
 
 
 
Pluripotent 
 
 
 
ICM of pre-
implantation 
blastocyst 
 
 
 
Ethical issues regarding 
source 
Complex tissue culture 
Teratoma potential 
Allogeneic 
Pluripotency 
More efficient 
derivation 
 
 
 
hiPSC 
 
 
 
 
Pluripotent 
 
 
 
 
Somatic cells via 
reprogramming 
 
 
 
 
Poor reprogramming 
efficiency 
Use of oncogenes 
Teratoma potential 
Complex tissue culture 
Insertional mutagenesis 
Pluripotency 
Autologous 
Disease modelling 
Ethical consent 
 
Table 1.1- Comparison of hESC and hiPSC. Table showing the sources and potency of hiPSC 
and hESC as well as the various advantages and disadvantages associated with each. 
 
Recent efforts to improve hiPSC efficiency and safety have focussed on the use 
of small molecules to induce reprogramming rather than transcription factors, as 
well as the use of less mature precursor cells as reprogramming targets. For 
example, Kim et al (2008) have shown that neural stem cells can be 
reprogrammed through the use of only Oct 4 and Klf4, or with Oct4 alone using 
mouse cells (Kim et al, 2009). It is thought that reprogramming is more effcieint 
in these less mature cells because they  already express endogenous Sox2. 
24 
 
It has been reported that small molecules such as BIX-01294 and BayK8644 are 
able to facilitate the production of mouse iPSC when used in combination with 
only 2 factors; Oct4 and Klf4 (Shi et al, 2008). This work was further advanced 
by Hou et al (2013) who recently managed to produce mouse iPSC using a 
cocktail of 7 small molecules without the need for any additional reprogramming 
factors. Although this work provides proof of concept, reprogramming with small 
molecules alone has not yet been achieved using human cells, however Zhu et al 
(2010) have generated hiPSC using small molecules in combination with Oct4 
alone. Further investigations into the control of hPSC behaviour will lead to a 
greater understanding of the mechanisms that regulate pluripotency and 
survival, and may elucidate alternative or more efficient reprogramming factors 
that might present additional targets for small molecule intervention, removing 
the need to use genetic reprogramming factors. 
1.1.3 Somatic cell nuclear transfer 
The possibility of somatic cell nuclear transfer (SCNT) as a means to reprogram 
terminally differentiated adult cells has been investigated since initial research 
performed on amphibians in the 1960s (Gurdon, 1962), however, the research is 
perhaps most well recognised as the technology that was used in the seminal 
experiments that resulted in the first cloned mammal, Dolly the sheep (Wilmut 
et al, 1997). The great hope for SCNT in humans was that the resulting 
reprogrammed oocytes could be fertilised and used as a means to produce 
personalised hESC that could be used to either study disease development, or for 
autologous tissue production (Yang et al, 2007). Despite great interest, 
researchers struggled to produce embryos of sufficient quality that were able to 
develop beyond the 8-cell stage (French et al, 2008). However, these problems 
were recently overcome by Tachibana et al (2013), who reported the successful 
derivation of hESC following SCNT. Although this development was reported very 
recently and will require additional investigation, it demonstrates an alternative 
source of hPSC that may be compared to both the standard IVF derived hESC and 
hiPSC in the coming years (Tachibana et al, 2013). 
Type of vector Method Genomic integration Factors Reference 
Virus 
 
 
 
Retrovirus Yes Oct4, Sox2, KLF4, c-Myc Takahashi et al, 2007 
Lentivirus Yes Oct4, Sox2, nanog, Lin28 Yu et al, 2007 
Adenovirus No Oct4, Sox2, KLF4, c-Myc Zhou and Freed, 2009 
Sendai Virus No Oct4, Sox2, KLF4, c-Myc Fusaki et al, 2009 
DNA 
 
 
Episomal Plasmid No Oct4, Sox2, KLF4, c-Myc Yu et al, 2009 
Transposon No Oct4, Sox2, KLF4, c-Myc Woltjen et al, 2009 
Minicircle No Oct4, Sox2, nanog, Lin28 Jia et al, 2010 
RNA RNA No Oct4, Sox2, KLF4, c-Myc Warren et al, 2010 
Protein Cell permeable proteins No Oct4, Sox2, KLF4, c-Myc Kim et al 2009 
Table 1.2- Summary of hiPSC derivation methods. Overview of the various methods used for the derivation of hiPSC, including the reprogramming factors and 
information on genomic integration. Adapted from Okita and Yamanaka, 2011.  
1.1.4 Regenerative medicine 
The use of haematopoietic stem cells as an effective treatment for a number of 
conditions such as haematological cancers (leukaemia) has demonstrated the 
incredible potential of stem cells as therapeutics (Van Zant and Liang, 2012). 
The possibility of deriving replacement cell types for future transplantation 
remains one of the most exciting applications reported for hPSC. However, in 
order to produce viable clinical applications for hPSC a number of hurdles will 
need to be circumvented these include the development of efficient lineage 
specific differentiation protocols at good manufacturing practice (GMP) quality, 
the effective removal of undifferentiated cells to eliminate the risk of teratoma 
formation, and the development of appropriate strategies to enable delivery or 
to target hPSC to the required tissues (figure 1.2) (Wu and Hochedlinger, 2011). 
Although these are substantial issues, they are not insurmountable and a number 
of recent trials using hESC have been approved. The earliest approved trial was 
performed by Geron, and was an investigation into the use of hESC derived 
oligodendrocytes as a means of treating spinal trauma injuries. Although this 
trial was unfortunately stopped prematurely, with Geron citing financial 
reasons, the preliminary results were promising, with none of the patients 
reporting any adverse side effects to the treatment (Strauss, 2010; Ichim et al, 
2011). Perhaps the most promising outcome from this venture was that although 
not without issue, the trial did reach the rigorous safety standards required by 
the FDA (Food and Drug Administration) for approval in the USA.  
More recently, Schwartz et al (2012) started clinical trials that aimed to use 
hESC derived retinal pigmented epithelial cells as a means of treating blindness 
induced by macular degeneration. The directed differentiation protocol used 
resulted in 99% pure population of retinal pigmented epithelial cells, which 
successfully engrafted with the host. Reassuringly, these implanted cells showed 
no signs of uncontrolled proliferation, tumorigenicity or rejection after 4months. 
In addition to this, although difficult to accurately assess, there were signs of 
improved vision in a number of patients (Scwartz et al, 2012). Although 
promising, the long term effect of such treatments must still be determined, and 
thorough follow up will be performed on patients from both trials.  
 Figure 1.2- Work flow and associated problems for regenerative medicine. The use of hiPSC as a source of autologous cells for regenerative medicine would be a 
multi-step process, with each step presenting a number of scientific problems such as the production and isolation of high quality hiPSC, efficient differentiation and 
successful engraftment. Image adapted form Wu and Hochedlinger, 2011. 
  
1.1.5 Culture of hPSC 
In order for the huge potential of hPSC to be realised, many challenges must be 
faced; the first and most basic of these is the consistent culture of hPSC. During 
normal embryological development in vivo, pluripotent cells are present only 
transiently before they become committed towards precursor and mature 
somatic cell types of all three germ layers (Adachi and Niwa, 2013). Control of 
this process is extremely complicated and not yet fully understood, although it is 
certainly reliant on cell-cell contact and soluble mediators. Consequently, 
maintaining hPSC in a pluripotent state in vitro involves the manipulation of a 
number of signalling pathways. 
Historically, culture of hPSC has been heavily reliant upon the use of inactivated 
feeder cells such as mouse embryonic fibroblasts (MEFS) to support adhesion and 
maintain pluripotency (Thomson et al, 1998) (figure 1.3). However, exposure of 
hPSC to animal products or cells raises substantial concerns including a risk of 
transfering non-human pathogens and also introduces a source of potential 
variation into the system. In an attempt to overcome these issues, various 
strategies have been developed such as the use of human fibroblast feeder cells 
for propagation (Ellerstrom et al, 2006), or more commonly, the utilisation of 
feeder-free culture conditions (an example of feeder-free hPSC colony can be 
seen in figure 1.3). As hPSC do not grow directly on standard tissue culture 
plastics, feeder-free culture utilises extracellular matrix (ECM) proteins such as 
fibronectin (FN), vitronectin (VN) or most commonly, Matrigel, to facilitate hPSC 
attachment in combination with MEF-conditioned medium (CM) supplemented 
with basic fibroblast growth factor (bFGF) to support maintenance of 
pluripotency (using feeder cells to condition culture medium as described in 
section 2.2.2.1). However, CM and ECM proteins such as Matrigel are poorly 
characterised and are often derived using animal sources. Matrigel for example 
is isolated from Engelbreth-Holm-Swarm mouse sarcoma cells and has a variety 
of growth factors integrated within (Hughes et al, 2010). This leads to a high 
degree of batch to batch variability that introduces inconsistences into 
experimental work flows that can make culture of hPSC variable, confounding 
the analysis of results. As a consequence of this, there has been a drive towards 
fully defined, xeno-free culture systems that use recombinant ECM proteins or 
protein fragments rather than feeder cells (Hoffman and Carpenter, 2005; Beers 
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et al, 2012). There have also been attempts to circumvent the requirement of 
ECM proteins by modifying the surface chemistry of tissue culture plates or 
through the use of synthetic substrates (Jin et al, 2012; Klim et al, 2010). 
The drive towards fully defined culture systems will be essential if hPSC are to 
achieve their huge potential as clinical tools for regenerative medicine. At the 
heart of this are the culture media used to propagate hPSC, which must be 
produced at good manufacturing practice (GMP) grade (Ausubel et al, 2012). As 
previously stated, hPSC were historically cultured in conditioned medium 
supplemented with bFGF to support pluripotency. However the undefined nature 
of CM will not be acceptable if the cells are to be used clinically. In an attempt 
to avoid this issue, a number of groups have developed more defined media 
types including basic compositions such as that described by Furue et al (2008) 
who used a combination of bFGF, insulin, transferrin, albumin and heparin to 
support feeder-free growth. However, a recent study undertaken by The 
International Stem Cell Initiative Consortium), performed a thorough 
investigation of 8 commonly used hPSC culture mediums and found that only 2 
media types were able to support successful maintenance for at least 10 
passages in each of the hPSC lines tested to a comparable level of the feeder 
dependent control culture system (Akopian et al, 2010). The culture mediums in 
question were those with the most complex requirement for growth factor 
supplementation i.e. StemPro and mTeSR. However these culture mediums are 
still not fully defined; mTeSR is still reliant on the use of human serum albumin 
(Ludwig et al, 2006) and StemPro is routinely supplemented with BSA (Wang et 
al, 2007). 
Another problem with hPSC culture media, especially those which are complex in 
nature or include serum albumin, is the inherent batch to batch variability 
associated with the various components. Akopian et al (2010) observed 
inconsistencies between laboratories who independently acquired media 
components, which resulted in considerable differences in the performance of 
the same media types. This is a substantial problem when it is considered that 
mTeSR for example, requires the addition of 18 factors to a DMEM based basal 
media which already consists of 52 components (Chen et al, 2011). 
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The dependence of many hPSC culture media on serum was recently addressed 
by a group who described a complex relationship between many of the media 
components (Chen et al, 2011). Chen and colleagues reported that in the 
absence of serum, other media additives such as β-mercaptoethanol became 
more toxic to the hPSC. Using a combinatorial approach this group produced a 
completely defined, xeno and serum free culture medium that required only 7 
additions to the basal DMEM/F12 culture medium; this media is now 
commercially available under the name of Essential 8. Essential 8 medium 
requires the addition of insulin, selenium, transferrin, l-ascorbic acid, bFGF, 
TGF-β and NaHCO3 (to adjust the final pH of the media) and can be used for 
routine culture as well as differentiation of hPSC (Chen et al, 2011) and is 
compatable with GMP-grade production.  
The culture of hPSC is further complicated by their susceptibility to apoptosis 
upon enzymatic dissociation. Upon dissociation to single cell or small cellular 
aggregates, approximately 80% of hPSC begin the process of apoptosis. This issue 
can be overcome by using partial dissociation methods or by mechanically 
passaging cells using cutting tools (images of this can be seen in figure 1.3). This 
however is only suitable for routine passage at small scale in open vessels and 
requires skilled staff. This sensitivity to disaggregation poses a more significant 
problem in regards to cell expansion and also for genetic manipulation of cells 
(Watanabe et al, 2007). In order to produce the large number of cells required 
for study or indeed clinically applicable cell quantities, this issue must be 
overcome. This matter will be discussed in more detail in section 1.3.  
 
Figure 1.3- HPSC cell culture pictures. Images taken using phase microscopy at x10 
magnification showing hPSC (H1 hESC) colonies growing on MEF (left), a feeder-free hPSC 
colony (centre) and confluent hPSC that have been mechanically cut into small clumps using a 
cutting tool prior to passage (right). Scale bar represents 100µm. 
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1.1.6 Self-renewal 
As previously stated, one of the important characteristics of hPSC is their 
capacity for unlimited proliferation and self-renewal. All stem cells regardless of 
potency are able to replicate indefinitely (Morrison and Kimble, 2006), however, 
the proliferative capacity of adult stem cells in vitro is significantly decreased, 
with cells undergoing more asymmetric divisions, which can limit the expansion 
of these cells and therefore their usefulness in regenerative medicine (Siddappa 
et al, 2007). 
HPSC on the other hand have been reported to have been propagated 
continuously for at least 2 years whilst avoiding replicative senescence (Zeng 
and Rao, 2007). HPSC are able to replace the ends of the telomeres normally 
lost during cellular divisions through the enzymatic activity of telomerase, which 
helps them evade the effects of replicative senescence (Thomson et al, 1998). 
The control of self-renewal is also linked to and regulated by the same 
mechanisms that regulate pluripotency. 
1.2 Maintenance of pluripotency 
Although great strides have been made in recent years, the mechanisms that 
underlie the maintenance of pluripotency and early differentiation events 
remain poorly understood. Much of the recent research into this area has 
focussed on the key transcription factors (TF) associated with pluripotency. 
Transcription factors are protein or protein complexes that are able bind to 
promoter regions of genes and act to either activate or repress gene activation 
by controlling the activity of RNA polymerase (Herdegen and Leah, 1998). There 
are a number of key transcriptions factors that have been found to be essential 
for the maintenance of pluripotency in hPSC, of which, Oct4, Nanog and Sox2 
are considered to be at the core of the transcriptional regulation of 
pluripotency. Most of the early research performed on these TF’s was performed 
in mouse embryonic stem cells (mESC) and subsequently found to be broadly 
similar in hESC. However, as might be expected, there are also significant 
differences between the different species.  
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1.2.1 Oct4  
Oct4 is a POU domain transcription factor that is sometimes referred to as 
POUF51 or OCT3/4. It is a very well conserved TF that has been shown to be 
present in the ICM of the blastocyst of all mammalian embryos, and loss of Oct4 
expression the cells within the ICM results in loss of pluripotency (Nichols et al, 
1998). Many studies have been carried out to determine the function of Oct4, 
most of which have used RNA interference (RNAi) to reduce (knockdown) Oct4 
expression. Studies such as that performed by Babaie et al (2007) have shown 
that upon loss of Oct4 expression, hPSC lose other markers of stemness and 
begin to change morphologically within as little as 24hours accompanied by  a 
concomitant increase in differentiation markers such as cytokeratin 18 and BMP2 
(Babaie et al, 2007; Hay et al, 2004; Matin et al, 2004). In addition to this, 
aberrant expression of Oct4 has been reported to drive hPSC to differentiate 
towards both endoderm (Hay et al, 2004) and mesoderm (Zeineddine et al, 2006) 
cell types. 
Full transcriptome analyses of hPSC have shown the presence of the Oct4 
consensus binding site in the promoter regions of over 600 known coding genes, 
including many of those that have been linked to pluripotency (Boyer et al, 
2005). It is particularly interesting that the Oct4 gene itself is a target of the 
Oct4 transcription factor, indicating that the expression of Oct4 may be self-
regulated in feedback and feedforward loops. Although Oct4 directly targeted 
600 genes, over 1100 genes were shown to have altered expression in response 
to Oct4 knockdown, demonstrating the contribution to indirect regulation of 
genes by Oct4 (Barbaie et al, 2007). Critically, Oct4 not only target genes 
involved in promoting pluripotency, but also targets genes and pathways 
involved in triggering development and therefore differentiation (Figure 1.4). Of 
the 1100 genes with altered gene expression due to Oct4 knockdown, 705 of 
these are up regulated rather than down regulated. This suggests that Oct4 not 
only acts to up regulate key pluripotency genes, but also suppresses the 
expression of developmentally important genes. 
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Figure 1.4- Effect of pluripotency related transcription factors on gene expression. 
Schematic showing that the key transcription of Oct4, Nanog and Sox2 factors not only promote 
the expression of pluripotency related genes, but inhibit the expression of differentiation associated 
genes. This also shows the presence of feedback loops as the core transcription factors all target 
each other. Adapted from Boyer et al, 2005. 
 
1.2.2 Nanog 
Nanog is a homeodomain TF that has also been heavily associated with the 
maintenance of hPSC pluripotency. Again, loss of Nanog expression is associated 
with loss of pluripotency, with hPSC differentiating towards extra-embryonic 
lineages (trophectoderm). In a study carried out by Hyslop et al (2005), reduced 
expression of Nanog resulted in reduction of other markers of pluripotency as 
well as increasing levels of extra-embryonic endoderm markers such as GATA4 
and GATA6, within 4 days of reduced Nanog expression.  
Further studies have also implicated Nanog in a series of feedback and 
feedforward loops, increasing the complexity of transcriptional regulation. For 
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example, the transcription factor smad2/3 (Mothers against decapentaplegic 
homolog 2/3), a downstream effector of the activin/nodal signalling pathway, 
has been shown to drive Nanog expression. Nanog thereafter negatively 
regulates smad 2/3 which prevents the differentiation of hPSC towards 
endoderm (Vallier et al, 2009; Darr et al, 2006).  
Transcriptome analysis of Nanog has shown that there are >1600 genes which can 
be activated or supressed by binding of Nanog, which again covers those 
reinforcing pluripotency associated signalling as well as those involved in 
suppression of differentiation, a number of which overlap with those targeted by 
Oct4 (figure 1.5) (Barbaie et al, 2007).  
Nanog has been linked closely to the maintenance of the pluripotent ground 
state in all mammalian cells. In particular, work performed on mESC has shown 
that Nanog regulation may be the key to both maintaining pluripotency and 
initiating differentiation; with Nanog low cells being more likely to 
differentiation and Nanog high cells being less likely to differentiate (Nichols and 
Smith, 2009; Wray et al, 2010). 
1.2.3 Sox2 
The third of the three core transcription factors involved in maintenance of 
pluripotency is Sox2, an HMG domain containing TF. As with Oct4 and Nanog, 
Sox2 is highly expressed in hPSC and is quickly downregulated upon 
differentiation. Sox2 has long been recognised as an important factor in hPSC 
pluripotency, however until recently, its function remained relatively unknown.  
A number of recent studies have suggested that a key role of Sox2 is to suppress 
the differentiation of hPSC into trophectoderm and endoderm. Adachi et al 
(2010) have shown that the loss of Sox2 leads to a change in morphology and a 
switch in surface antigens from the hPSC marker SSEA4 to the differentiation 
marker SSEA1. Interestingly, a similar result was seen when Sox2 was 
overexpressed, indicating that the expression level of this TF has to be well 
regulated to maintain pluripotency, and furthermore, that it may have a role in 
differentiation pathways. Although expression of Oct4 and Nanog are reportedly 
specific to hPSC, the expression of Sox2 has also been detected and shown to 
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have a critical role in the regulation of neuronal precursor cells (Cimadamore et 
al, 2013; Johnston et al, 2013; Thiel, 2013).  
Again as with the previous TFs, Sox2 binding sites were seen to be present in a 
large number of genes. Sox2 was linked to the regulation of 1271 genes, which 
was more than Oct4 but less than Nanog (figure 1.5) (Barbaie et al, 2007). 
 Transcription factor interactions 1.2.3.1
During their full analysis of the human hPSC transcriptome, Boyer et al (2005) 
highlighted a key relationship between the three master TFs. This work showed 
that although the three TFs had many distinct targets, there were a great 
number of target genes shared between them (Figure 1.5A). There has 
previously been a suggested relationship between Oct4 and Sox2 indicating that 
these factors dimerise to allow activation or suppression of some target genes 
(Ferraris et al, 2011). Findings showing that approximately 50% of the promoter 
regions occupied by Oct4 were also occupied by Sox2 suggest that this role is 
also conserved in hPSC. Furthermore, a huge 90% of promoter regions bound by 
Oct4/Sox2 were also occupied by Nanog. The authors have suggested that the 
proximity of these promoter regions as well as the fact that all three co-occupy 
353 separate genes in hPSC is strong evidence that the three factors work 
together to regulate large proportions of key pluripotency associated genes 
(figure 1.5A)(Boyer et al, 2005).  
Another significant point of note is that the target genes of these TFs include 
the Oct4, Sox2 and Nanog genes themselves suggesting that they are also able to 
regulate each other and indeed themselves (figure 1.5B). Taking this into 
consideration, it is not at all surprising to see that upon down regulation of one 
of these factors, the others are usually subsequently down regulated.  
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Figure 1.5- Core transcription factor interactions. Venn diagram showing the number of genes 
regulated by each of the key transcription factors associated with pluripotency. Each TF has unique 
targets as well as a large degree of common targets (A). Schematic of the auto-regulatory 
mechanism of Oct4, Nanog and Sox2 (B). Modified from Boyer et al (2005). 
 
1.2.4 Extrisic pathways regulating pluripotency 
As previously stated, there are a number of pathways that have been linked to 
the maintenance of pluripotency. The pathways discussed here are a mixture of 
those supporting pluripotency through positive regulation of key hPSC genes, and 
those that support differentiation by suppressing pathways integral to 
maintenance of pluripotency.  
 Fibroblast growth factor signalling 1.2.4.1
Fibroblast growth factors, or FGF’s, are a family of growth factors comprised of 
22 known members. These growth factors facilitate their function by binding and 
activating a group of receptor tyrosine kinases (RTKs), FGF receptors (FGFR). At 
present, there are 4 known FGFR (FGFR1-4), all of which have been shown to be 
expressed in hPSC (Ding et al, 2010). Activation of FGF signalling has for a long 
time been implicated as a key component in the maintenance of pluripotency, so 
much so that in almost all culture conditions, basic FGF (bFGF/FGF-2) is added 
to support pluripotency (Greber et al, 2010; Kang et al, 2005).  
Due to the apparently indispensable nature of FGF signalling in hPSC, there have 
been many studies into its possible roles, however, the mechanisms through 
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which bFGF elicits these positive effect remain an issue of debate, with many 
studies claiming it to have different roles. 
One suggested role for FGF signalling is that it acts to suppress signalling caused 
by bone morphogenetic protein 4 (BMP4). Introduction of BMP4 to culture 
conditions that would normally support undifferentiated growth of hPSC results 
in a change in hPSC morphology, loss of pluripotency markers and an increase in 
trophoblast and primitive endoderm markers characteristic of differentiation (Xu 
et al, 2005). However, it is known that even those culture conditions able to 
support undifferentiated growth of hPSC retain low levels of BMP’s, which are 
largely attributed to the serum replacement products used in cell culture 
mediums or by autocrine production by the hPSC (Chase and Firpo, 2007; 
Lifantseva et al, 2013). BMP signalling results in activation of the TGFβ pathway 
via smads1/5/8, which upon phosphorylation, are able to translocate to the 
nucleus where they can directly influence gene expression and trigger 
differentiation pathways. Addition of high levels of bFGF, or a combination of 
bFGF and the BMP antagonist noggin, to hPSC culture systems has however been 
shown to ameliorate this deleterious effect of BMP. It has been suggested that 
bFGF may achieve this regulatory affect by inhibiting smad1 phosphorylation, or 
blocking the phosphorylated form from functioning within the nucleus and 
thereby preventing the activation of pathways associated with differentiation 
(Xu et al, 2005).  
Another suggested route of action for FGF signalling is through regulation of the 
MEK/ERK pathway. The MEK/ERK pathway is a known downstream target of FGF 
signalling in a number of somatic cells types, but has also been shown to be 
highly active in hPSC (Kang et al, 2006). A recent study by Ding et al (2010) 
indicated that as early as 15minutes after bFGF stimulation of previously FGF 
starved cells an upregulation of phosphorylated ERK within the hPSC could be 
measured in response to the bFGF. The importance of MEK/ERK signalling in the 
maintenance of pluripotency has also been tested by targeting MEK with 
chemical inhibitors as well as using RNA interference. Within 3days of MEK 
inhibition in pluripotent culture conditions, there was a morphological change in 
the hPSC, and after a further 2days, transcriptional changes were evident. These 
changes included a reduction in pluripotency markers TRA1-60, TRA1-81, Oct4 
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and Nanog as well as an increase in markers of trophectoderm and primitive 
endoderm (Li et al, 2007). This supports previous work showing that FGF 
signalling is important in preventing the differentiation of hPSC into trophoblast 
and primitive ectoderm lineages (Xu et al, 2005).  
In addition to these previously mentioned roles, Bendall et al (2007) have 
suggested another more controversial role for FGF signalling. In this study, the 
authors took advantage of techniques that allow separation of cells from a 
heterogeneous hPSC population into separate populations for subsequent 
analysis. Using fluorescence activated cell sorting (FACS), they found a discreet 
population of fibroblast like cells that were produced within cultures by the 
hPSC. These cells were lacking in OCT4 and SSEA3 expression whereas the colony 
forming hPSC were not. What was striking about this finding was that there was 
also a difference in the cell surface receptors being expressed by these two cell 
types. In contrast to previous studies showing high FGF receptor expression in 
hPSC, Bendall and colleagues suggested that the hPSC derived fibroblast cells 
within the cultures had the majority of these receptors and that hPSC were 
instead rich in insulin-like growth factor receptor (IGFR1). The suggested role for 
bFGF here was to help maintain a supportive niche within which it triggered the 
release of IGF2 (and TGFβ) from the hPSC derived fibroblasts, which then 
activated IGFR1 to support hPSC growth (Bendall et al, 2007).  
In addition to showing the potential importance of this regulatory niche that 
forms within hPSC cultures, Bendall et al also showed the importance of IGF 
signalling by using exogenous IGF2 (the agonist of IGFR1) to support hPSC in the 
absence of bFGF. Activation of the IGFR1 receptor is thought to subsequently 
activate, by means of phosphorylation, the phosphatidylinositol-3-OH kinase 
(Pi3K) pathway which has been shown to be an essential for the maintenance of  
hPSC by activation of smads 2/3 and the subsequent activation of Nanog (Wi et 
al, 2007; Wang et al, 2009).   
 Transforming Growth Factor Beta 1.2.4.2
The transforming growth factor beta (TGFβ) superfamily of proteins is a well-
represented group not only in hPSC, but also throughout the body in a number of 
somatic cell types. Their suggested roles include regulation of proliferation, 
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differentiation, migration and they are also involved in apoptotic pathways 
(reviewed by Valdimarsdottir and Mummery, 2005). The TGFβ family 
encompasses a number of key pathways involved in regulation of pluripotency, 
such as activin/nodal, BMP and Wnt signalling. 
The activin/nodal pathways have garnered great interest in recent years, and 
their role in pluripotency is well accepted. In a manner similar to that seen 
when the key TFs Oct4, Nanog and Sox2 are inhibited, knockdown of the 
activin/nodal pathway results in differentiation of hPSC. Activin and nodal share 
a number of key features, such as having the same type 1 and type 2 receptors 
and both utilise smad2 and smad3 as downstream effectors and regulators of 
transcription. Upon activation, the type 2 receptor phosphorylates the type 1 
receptor, which in turn causes the phosphorylation of intracellular smad2 and 
smad3 (Xu et al, 2008). Phosphorylated smad2/3 forms a complex with co-smad4 
which is then translocated to the nucleus where, as a known TF, it functions to 
activate relevant pluripotency associated genes (Vallier et al, 2009). 
Immunofluorescent microscopy has shown the presence of smad2/3 in the 
nucleus of cells expressing OCT4 and SSEA3, and the subsequent loss of this 
nuclear expression upon differentiation (Vallier et al, 2005). 
Although it is clear from this that the activin/nodal signalling pathway is 
involved in the maintenance of hPSC pluripotency, the downstream mechanisms 
and indeed target genes are largely unknown. However, the bridge between 
extrinsic signalling pathways and intrinsic TFs has recently been alluded to by 
Vallier and colleagues when they showed that Nanog can both regulate and be 
regulated by smad2/3 (Vallier et al, 2009). The observation that the loss of 
activin/nodal signalling leads to a sudden downregulation of Nanog, as well as 
the identification of consensus binding sights for smad2/3 within the Nanog 
promoter region is strong evidence of a direct relationship between extrinsic and 
intrinsic components of pluripotency (Xu et al, 2008; Vallier et al, 2005; Vallier 
et al, 2009).   
There has also been a suggestion of a cooperative interaction between 
activin/nodal signalling and FGF signalling. When nodal and bFGF were used in 
combination, there was higher expression of pluripotency marker SSEA4 in hPSC 
than when either of these receptor agonists were used alone. The importance of 
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the activin/nodal signalling pathway has been confirmed through use of the 
specific activin/nodal receptor inhibitor SB431542. Upon inhibition, even high 
doses of bFGF were unable to inhibit hPSC differentiation, demonstrating that 
both the FGF and activin/nodal pathways are crucial (Vallier et al, 2009).  
As previously stated BMPs in hPSC have been shown to have a negative impact on 
pluripotency. BMPs such as BMP2/4/7 act similarly to activin/nodal signalling, 
activating similar receptors, but instead of activating smads 2/3, they activate 
smads 1/5/8. Once phosphorylated, smad 1/5/8 also bind to co-smad4 and 
translocate to the nucleus where rather than support Nanog expression, they 
inhibit Nanog. These smad 1/5/8 targets are predicted to be genes involved in 
differentiation pathways, including BMP2, Sox17 and FOXA2 (Pera and Tam, 
2010; Teo et al, 2012). There has also been a suggestion that some of the 
beneficial effect of culturing hPSC on MEF could be due to the release of TGF 
signalling pathway agonists and antagonists such as nodal and GREM1 (Gremlin 1) 
respectively which form regulatory loops within the cultures (Pera and Tam, 
2010).  
1.2.5  Wnt signalling 
Another extrinsic signalling pathway that has been associated with pluripotency 
in hPSC is the canonical Wnt pathway. There have been contradicting reports of 
Wnt signalling being involved in both the maintenance of pluripotency and 
induction of differentiation. For example, there have been suggestions that 
bFGF mediated regulation of the canonical Wnt pathway can lead to the 
upregulation of important hPSC transcription factors. Ding et al (2010) reported 
that bFGF regulates downstream targets of Wnt signalling in the absence of the 
Wnt ligand Wnt3a. Their suggested model for this proposes that the bFGF 
activated Pi3K pathway can mimic Wnt signalling by phosphorylation of GSK3, 
resulting in the release of β-catenin and subsequent nuclear translocation. Once 
present in the nucleus, β-catenin, as a transcription factor, can activate Wnt 
related genes. 
An overview of the extrinsic pathways involved in maintaining the pluripotent 
identity of hPSC can be seen in figure 1.6. It is clear that maintenance of 
pluripotency and the suppression of differentiation are complex and dynamic 
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processes resulting from the tight regulation of multiple intrinsic and extrinsic 
signals. 
 
 
Figure 1.6- Extrinsic pathways involved in hPSC maintenance.  Cell surface receptor ligands 
such as activin and nodal are able to trigger the translocation of smad 2 and smad 3 to the nucleus 
where they can drive the expression of pluripotency related genes such as Nanog. Similarly, BMPs 
can activate smads 1/5/8 to stimulate the activation of differentiation associated genes. This can be 
effectively blocked by antagonists such as Noggin. Pi3K and MEK/ERK signalling can be activated 
in response to FGF and IGF2 which can reinforce pluripotency related signals. 
 
 
 
1.2.6 Epigenetic regulation of hPSC 
Epigenetics refers to the regulation of gene expression and the resulting 
phenotypes independent of any modification to the gene sequence and explains 
why cells such as cardiomyocytes and neurones have such distinct morphology 
and functions despite containing the same basic DNA sequence (Capell and 
Berger, 2013). Epigenetic status is largely dependent upon histone modifications 
and changes in DNA methylation which can result in changes in chromatin 
structure. By changing chromatin structure, epigenetic modifications can 
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effectively control access to the regulation machinery of genes such as promoter 
regions. The epigenetic status of hPSC has been investigated at length and 
shown to be vastly different to that of their differentiated progeny (Watanabe et 
al, 2013; Han and Yoon et al, 2012). HPSC have been shown to have increased 
levels of bivalently marked domains than terminally differentiated somatic cells 
or multipotent precursor cells (Meissner et al, 2008; Mekkelsen et al, 2007). 
Additionally, the promoter regions of critical regulators of pluripotency such as 
Nanog and Oct4 are shown be more highly methylated in differentiated cells 
when compared to pluripotent cells and are therefore inactive (Maherali et al, 
2007; Han and Yoon, 2012).  
Given the role of epigenetics in regulating gene expression, it is not surprising 
that this has become an area of great interest when considering hiPSC derivation 
and differentiation. The field of epigenetics has become synonymous with the 
visual metaphor of Waddingtons epigenetic landscape, wherein he compares cell 
commitment to marbles rolling downhill (Goldberg et al, 2007). However groups 
have now likened the reprogramming of somatic cell types towards pluripotency 
as pushing the marble slowly back up a mountain (Watanabe et al, 2013; 
Hochedlinger and Plath, 2009).  
Epigenetic regulation is currently an area of very active research, however, it is 
not directly relevant to the work described in this thesis, so whilst its 
importance cannot be ignored it will not be considered in detail herein. 
1.3 Apoptosis in hPSC 
The maintenance and expansion of hPSC is further complicated by their 
susceptibility to apoptosis during routine culture and passage.  Although 
apoptosis occurs in all cell types, it has been reported that cells of the early 
embryo including those of the ICM from which hESC are derived, are particularly 
sensitive to apoptosis. It has been reported that upwards of 30% of hPSC 
apoptose spontaneously under standard tissue culture conditions (Qin et al, 
2007). Of greater concern is that upon dissociation to single cell or small cellular 
aggregates, approximately 80% of hPSC begin the process of apoptosis. A recent 
study by Madden et al (2011) has shown that hPSC express increased levels of 
pro apoptotic members of the Bcl2 family of proteins when compared to either 
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cancer cells or terminally differentiated cells. Furthermore, hPSC have also been 
shown to have constitutively active Bak, another pro-apoptotic member of the 
Bcl2 family suggesting that hPSC may be primed for rapid apoptosis upon 
exposure to cellular stress (Dumitru et al, 2012). This sensitivity to dissociation 
poses significant problems with regards to basic enzymatic passage of hPSC as 
well as expansion to clinically relevant cell numbers. In addition, this severely 
limits the use of techniques that require single cells such as clonal selection of 
genetically manipulated cells or cell sorting via FACS (Watanbe et al, 2007; Pyle 
et al, 2006).  
1.3.1 Intrinsic and extrinsic apoptotic pathways 
Apoptosis is an evolutionary conserved form of programmed cell death that is 
critical for normal tissue homeostasis and is a means through which the body can 
remove excess or damaged cells. Apoptosis can be triggered by either intrinsic or 
extrinsic signalling pathways which lead to the activation of a group of cysteine 
proteases known as caspases (cysteine aspartic proteases). Activation of 
caspases results in the cleavage of a large number of cell substrates such as 
protein kinases and adhesion molecules, which leads to biochemical and 
morphological change, nuclear condensation and fragmentations and ultimately 
results in death and formation of apoptotic bodies (Nicholson, 1999; Coleman 
and Olson, 2002). 
The extrinsic pathway, sometimes referred to as the receptor pathway, is 
triggered by activation of cell surface ‘death receptors’ such as Fas (CD95) 
receptor and is largely mediated by caspase 8 dependent activation of effector 
caspases such as caspase 3. 
The intrinsic or mitochondrial pathway is activated in response to cellular stress 
such as DNA damage, and results in the release of apoptotic activators such as 
cytochrome c. This again results in the eventual activation of caspase 3, but is 
largely mediated by upstream caspase 9 activation rather than caspase 8. 
Although the intrinsic and extrinsic pathways are activated and induce apoptosis 
via independent mechanisms, there is a certain degree of crossover between the 
pathways. An example of this is the activation of the intrinsic pathway via 
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caspase 8 mediated cleavage of Bid, resulting in Bid translocation to the 
mitochondria and subsequent release of cytochrome c (Fulda and Debatin, 
2006). Schematic representation of the apoptotic pathways can be seen in figure 
1.7.  
 
 
Figure 1.7- Intrinsic and extrinsic pathways in apoptosis. Schematic representation of both the 
extrinsic and intrinsic pathways of the process of apoptosis. The extrinsic pathway is activated by 
cell surface receptors and activates caspase 3 via cleavage by caspase 8. The intrinsic pathway is 
activated by release of cytochrome c from the mitochondria which results in activation of caspase 3 
in a caspase 9 dependent manner. Adapted from Fulda and Debatin, 2006. 
 
 Anoikis 1.3.1.1
Anoikis is a specialised form of apoptosis triggered by loss of cell to matrix 
adherence. Anoikis, suitably named from the Greek word for ‘homelessness’ is a 
physiologically important process which prevents detached cells from migrating 
and proliferating uncontrollably. The physiological relevance of anoikis can be 
seen with cancerous cells as one of the hallmarks of cancer is the acquisition of 
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anchorage independent growth and suppression of anoikis (Gilmore, 2005) which 
also permit metastatic migration and growth. 
Anoikis has been shown to facilitate apoptosis via both the intrinsic and extrinsic 
pathways and that the pro-apoptotic proteins Bim, Bid and Bad play a critical 
role. Under adherent conditions, Bim is located within a multi-protein complex, 
however, upon loss of integrin signalling Bim is released from the complex and 
translocates to the mitochondria where it can inactivate the pro-apoptotic 
protein Bcl-XL. Additionally, upon loss of integrin signalling there is a decrease 
in Pi3K dependent phosphorylation (and therefore inactivation) of Bim and Bad, 
which result in an augmented apoptotic response (Chiarugi and Giannoni, 2008; 
Cheng et al, 2001).  
Given the anchorage dependent status of hPSC, anoikis, or pathways relating to 
anoikis signalling have been discussed in relation to the dissociation induced 
apoptosis of hPSC (Watanabe et al, 2007; krawetz et al, 2009; Wang et al, 
2007). 
1.3.2 Overcoming dissociation induced apoptosis of hPSC 
A major breakthrough in the field occurred when Watanabe et al (2007) first 
described that the use of a small molecule inhibitor of the Rho associated 
coiled-coil kinase (ROCK), Y27632, dramatically improved the survival of hESC 
upon enzymatic disaggregation. They found that a brief (1hr) pre-treatment and 
supplementation in culture medium post passage resulted in an increase in 
clonal efficiency from 1% to 27% and a marked decrease in apoptosis (from 75% 
to ~ 15%) following dissociation.  
Since its discovery in 2007, Y27632 has quickly become a very well established 
and commonly used component of hPSC culture and has been employed for a 
number of purposes such as the cryopreservation and recovery of hPSC (Li et al, 
2008; Martin-Ibanez et al, 2009; Claassen et al, 2009), suspension culture 
(Watanabe et al, 2007; Wang et al, 2013) gene transfer and FACS (Kurosawa, 
2012).  
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With the discovery that Y27632 supported enzymatic passage of hPSC, the 
pathways regulating activation of ROCK as well as downstream targets became 
central to understanding the mechanistic mode of action of Y27632 and hPSC 
survival. 
 Rho GTPases 1.3.2.1
The Rho GTPases are a subset of the Ras superfamily of small GTPases with RhoA 
(Ras homologous member A), Rac1 (Ras-related C3 botulinum toxin substrate 1) 
and CDC42 (cell division cycle 42) being the most well characterised members 
(Parri and Chiarugi, 2010; Bishop and Hall, 2000). As with all GTPases, they act 
as molecular switches able to regulate a diverse range of cellular processes 
including differentiation, cell division, proliferation, apoptosis, adhesion and 
regulation of the cytoskeleton (Jaffe and Hall, 2005; Visvikis et al, 2010). Rho 
GTPases have this potential as sensitive molecular switches due to their affinity 
for GDP (guanine diphosphate) and GTP (guanine triphosphate) which allows 
them to cycle between inactive GDP bound state and active GTP bound state. 
The activation status is regulated by guanine nucleotide exchange factors 
(GEFs), GTPase activating proteins (GAPs) and Rho guanine nucleotide 
dissociation inhibitors (GDIs) (Cherfils and zeghouf, 2013). GEFs facilitate the 
activation of Rho GTPases by catalysing the exchange of GDP for GTP. Although 
Rho GTPases have intrinsic hydrolytic activity, this is relatively low, meaning 
GTP bound Rho GTPases will remain active until the GTP is hydrolysed via the 
activity of GAPs (Visvikis et al, 2010). RhoA, Rac1 and CDC42 have their own 
specific GEFs and GAPs of which there are >60 of each identified (Etienne-
Manneville and Hall, 2002). As a further level of control, the GDIs, act as 
negative regulators of Rho GTPases by altering their sub-cellular localisation 
(Garcia-Mata et al, 2011). A schematic of Rho GTPase regulation can be seen in 
figure 1.8. 
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Figure 1.8- Regulation of Small GTPases. Schematic detailing the control of Rho GTPases such 
as RhoA, Rac1. GEFs are able to facilitate the activation of GTPases by exchanging GDP for GTP. 
GAPs hydrolyse GTP and therefore facilitate the transfer from an active GTP bound state to an 
inactive GDP bound state. GDIs act as a chaperone and localise Rho GTPases away from the 
plasma membrane. Adapted from Huveneers and Danen, 2009. 
 
Signalling mediated by Rho GTPases can be initiated in response to upstream 
signals coming from a range a range of growth factor receptors, integrins, RTKs, 
cadherins or G-protein coupled receptors  (Parrai and Chiarugi, 2010). When in 
the active GTP bound state, Rho GTPases are able to activate their various 
downstream effector molecules, which in turn perform various functions (as 
exemplified in figure 1.9). Although there is a degree of overlap with some of 
the downstream effectors, most have unique downstream targets. Of particular 
interest is ROCK, the downstream effector of RhoA and target of the hPSC 
survival compound Y27632. The main function of ROCK is to regulate 
intracellular tension via ROCK-induced actinmyosin-based contraction; it does 
this by its dual role in both directly phosphorylating myosin light chain 2 (MLC2) 
and inhibiting myosin light chain phosphatase (Iden and Gollard, 2008). 
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Figure 1.9- Rho GTPase effectors and functions. Schematic showing the downstream effectors 
of the Rho GTPases RhoA, Rac1 and CDC42 and their role within the cell. Of particular interest is 
the actomysosin contraction caused by ROCK. Adapted from Iden and Gollard, 2008. 
 
Although RhoA, Rac1 and CDC42 work together to regulate this range of cellular 
processes, they have distinct roles and are therefore active at different times 
and within differing sub-cellular localisation. Of particular interest with regards 
to hPSC is their spatiotemporal regulation during the process of cell adhesion. At 
the onset of cell adhesion, there is an integrin mediated decrease in levels of 
GTP bound RhoA via activation of p190RhoGAP by Src kinase. This results in a 
loss of actinmyosin contractility and an increase in cellular protrusions such as 
lamellipodia and filopodia which is mediated by Rac1 activity. Initially these 
protrusions are rich in nascent adhesion which are either rapidly turned over or 
mature in to focal complexes. As the process of adhesion continues, the activity 
of Rac1 reduces and there is an increase in active RhoA. GTP bound RhoA 
mediates the activation of ROCK and the resulting actinmyosin contractility 
promotes the maturation of focal complexes into focal adhesions (FA) 
(Huveneers and Danen, 2008; Parsons et al, 2010; Playford and Shaller, 2004). 
Focal adhesion are integrin rich signalling complexes composed of actin linking 
proteins such as α-actinin and vinculin, adapter proteins such as paxillin, and 
protein kinases such as focal adhesion kinase (FAK) and Src-family kinases. This 
allows FA to regulate numerous downstream signalling pathways including the 
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small GTPases as well as pathways involved in stem cell differentiation and 
survival (Vicente-Manzanares et al, 2009). A schematic showing some of the 
signalling mediated by integrin activation and subsequent FAK activation is 
shown in figure 1.9.  
As previously mentioned, RhoA and Rac1 are regulated upstream by a number of 
proteins, however, it has recently been shown that they have an antagonistic 
relationship and are also able to regulate each other. An example of this would 
be the ROCK mediated phosphorylation of the Rac1 GAP FilGAP which results in 
reduced Rac1 activity. Conversely, Rac1 can lead to a decrease in RhoA activity 
via inhibition of protein phosphatases which leads to a subsequent rise in 
p190RhoGAP activity (Huveneers and Danen, 2004). Furthermore, there have 
also been reports that inhibition of ROCK can have a feedback effect on the 
activation status of both RhoA and Rac1 and it is suggested that inhibition of 
ROCK leads to a Rac1 activation via Tiam1, which subsequently decreases the 
activation of RhoA (Tang et al, 2012).  
 
Figure 1.10- Integrin and FAK mediated signalling. Integrin signalling is activated in response to 
engagement with ECM components. This results in recruitment of additional proteins such as FAK 
and Src to the integrin cytoplasmic tail. These can activate a range of pathways with roles in 
diverse processes such as apoptosis, cytoskeleton rearrangements, proliferation and cell 
migration. Image adapted from Larsen et al, 2006. 
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1.3.3 Mechanistic action of Y27632 
The cause of dissociation induced apoptosis of hPSC and the role that Y27632 
plays in preventing it has been the subject of intense debate in recent times. 
This issue is complicated given that ROCK, the target of Y27632, is a downstream 
effector of RhoA, which has a role in a number of potentially interesting 
pathways such as adhesion signalling as well as apoptosis. Initially, it was 
thought that Y27632 promoted survival of disaggregated hPSC through an anti-
apoptotic mechanism (Watanabe et al, 2007). One of the critical processes 
involved in apoptosis is the cleavage of ROCK by caspase 3 which results in a 
constitutively active form of ROCK leading to membrane blebbing and the 
eventual formation of apoptotic bodies (Coleman and Olson, 2002). However, it 
has been reported that although the inhibition of ROCK using Y27632 is able to 
prevent membrane blebbing and reduce formation of apoptotic bodies, it is not 
able to rescue cells from apoptosis. This suggests that ROCK inhibition only 
prevents the morphological changes associated with the regulation of the actin 
cytoskeleton rather than stopping cell death (Krawetz et al, 2009).  
An alternative mechanism proposed for Y27632 was based on observations that 
Y27632 treated cells were ‘stickier’ than untreated cells and more difficult to 
dissociate from each other. Research groups therefore began to focus on the role 
that ROCK has on cell-cell or cell-matrix interactions. Of particular interest was 
the transmembrane protein E-cadherin which is involved in homotypic adhesion 
between cells. Reports suggested that active ROCK was able to disrupt this cell-
cell signalling (Sahai and Marshall, 2002) which led groups such as Krawetz et al 
(2009) to suggest that ROCK inhibition led to increased cell-cell interaction 
which prevented the onset of apoptosis. Very simple experimentation by the 
same group provided strong support for this hypothesis when they used the Ca2+ 
chelator EGTA to prevent formation of Ca2+ dependent E-cadherin mediated 
homotypic interactions. Even in the presence of Y27632, hPSC treated with EGTA 
were unable to avoid apoptosis, with Y27632 treated cells having comparable 
levels of apoptosis to that of the control cells. However, in contrast, there have 
also been reports that inhibition of ROCK can lead to a decrease in cell-cell 
interactions in both mouse and human PSC. Interestingly, this loss of cell-cell 
contact was observed regardless of whether ROCK was inhibited directly with 
Y27632 or further upstream using the RhoA inhibitor C3 (Clostridium botulinum 
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C3 exoenzyme). Furthermore, the myosin inhibitor Blebbistatin also resulted in 
this phenotype, which suggests that the resulting inhibition of actinmyosin 
mediated contractility is the cause of this phenotype rather than the direct 
inhibition of ROCK (Harb et al, 2008). 
In 2010 three independent groups published data supporting these claims and 
further elucidated the mechanistic action of Y27632. These groups made a direct 
correlation between dissociation of hPSC and hyperphosphorylation of myosin 
light chain 2 (MLC2), which is a downstream target of ROCK. They proposed that 
this hyperphosphorylation was the cause of dissociation induced apoptosis and 
presented data showing that treatment with either ROCK inhibitor Y27632, the 
RhoA inhibitor C3, or the myosin inhibitor Blebbistatin were able to circumvent 
this. These groups also used a combination of RNAi mediated knockdown of ROCK 
I and II, myosin heavy chain II, as well as the overexpression of a dominant 
negative form of MLC2 that cannot be phosphorylated, to further dissect the 
mechanism of dissociation induced apoptosis. Each of these modifications led to 
a decrease in the phosphorylation of MLC and a subsequent rise in hPSC survival 
post dissociation (Chen et al, 2010; Ohgushi et al, 2010; Walker et al, 2010).  
Ohgushi and colleagues extended this work and also investigated signalling 
events upstream of ROCK and suggested that the loss of cell-cell adhesion 
mediated by E-cadherin lead to a sudden increase in RhoA activation in an Abr 
(active BCL related) dependent manner. Abr is known to have dual functionality, 
acting as both a RhoA GEF and a Rac1 GAP, which results in a high-Rho/low-Rac 
state post dissociation (figure 1.11). This work highlighted a potential 
antagonistic and protective role for Rac1 in hPSC, which was validated when 
hPSC with constitutively active Rac1 were shown to be insensitive to dissociation 
induced apoptosis. The authors ultimately hypothesised that the loss of cell-cell 
contact led to an Abl dependent shift from Rac1 activity to RhoA which leads to 
a sudden activation of ROCK and subsequent actinmyosin based contractility, 
which leads to apoptosis via the mitochondrial pathway (Figure 1.11).  
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Figure 1.11- Model of dissociation induced apoptosis is hPSC. Upon dissociation or loss of 
cell-cell contact, hPSC undergo a sudden upregulation of RhoA mediated actinmyosin based 
contractility. This is Abr dependent and leads to a concurrent decrease in Rac1 activity. Apoptosis 
can be avoided by inhibiting this pathway at various points such as with Y27632 or Blebbistatin 
(blue lines). The broken blue line represents potential rescue pathways downstream of MLC 
phosphorylation and includes upstream regulators of Pi3K signalling pathway. Adapted from 
Ohgushi et al, 2010.  
 
1.3.4 Protective pathways 
Although the RhoA/ROCK/MLC pathway has been shown to be the critical 
pathway involved in dissociation induced apoptosis, there have been a number 
of additional pathways that have been implicated in protecting hPSC from 
apoptosis.  
 Integrin signalling 1.3.4.1
Integrins are a major class of transmembrane glycoprotein receptors involved in 
mediating adhesion between the cell and the ECM. Since their original 
description in 1987, integrins have become some of the most studied and best 
characterised proteins in vertebrates (Hynes, 1987). Structurally, integrins 
contain a large extracellular domain and a small intracellular domain which are 
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linked via a single transmembrane helix (Hynes, 2002). Currently, there are 18 
known α-subunits and 8 known β-subunits which can bind to form any of 24 
known hetrodimeric integrin receptors (Brafman et al, 2013). Specific α and β 
subunit pairings allow integrins to specifically bind to individual ECM 
components. For example, integrin α5β1 will specifically recognise and bind to 
fibronectin whereas αVβ5 or α6β1 will bind to vitronectin and laminin 
respectively (Braam et al, 2008).  
Integrins not only support cell-ECM adhesion, but are considered to be signalling 
hubs, facilitating both outside-in (Schlaepfer and Mitra, 2004) and inside-out 
signalling (Katagiri and Kanishi, 2012). Activation of integrins via binding to their 
respective ECM components, leads to conformational changes in their 
cytoplasmic domain resulting in the recruitment of various scaffolding proteins 
and signal transducing proteins and leading to subsequent signalling events that 
can affect not only cell adhesion but also proliferation, differentiation and cell 
survival. Integrins are also linked to the actin cytoskeleton via adaptor proteins 
such as vinculin (Johnson and Craig, 1995) and talin and are therefore major 
mediators of intracellular tension and cellular response to physical cues. 
Integrins are also able to act directly upstream of the Rho GTPases as can be 
seen in figure 1.10. At present, the integrin ‘adhesome’ is thought to comprise 
of around 180 proteins (Zaidel-Bar and Geiger, 2010). 
As with other adherent cell types, hPSC have been shown to express a large 
range of both α and β integrin sub-units. Integrins αVβ3, α6, β1, and α2β1 have 
been suggested to be of most importance in regards to the adhesion of hPSC 
(Meng et al, 2010). Integrins have not only been shown to be critical in hPSC 
adhesion to ECM components, but have also been shown to activate pathways 
associated with prevention of apoptosis including the Pi3K/Akt signalling 
pathway. 
 Pi3K/Akt and FGF signalling pathways in hPSC survival 1.3.4.2
Pi3K signalling can be activated by growth factor receptors as well as by 
interaction between cell surface receptors such as integrins with ECM 
components. Upon activation, Pi3K phosphorylates Akt proteins such as Akt1, 
Akt2 and Akt3. Once phosphorylated, Akt proteins are able to interact with a 
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large array of downstream targets such as the direct regulator of apoptosis Bad 
(pro-apoptotic Bcl2 family member) as well as regulators of the apoptotic 
program such as IκK (IκB kinase) and MDM2 (mouse double minute 2 homolog) 
(Downward, 2004). 
Pi3K signalling has also been shown to be important in hPSC and activation has 
been reported to increase cell adhesion and decrease apoptosis in response to 
stress (Eiselleova et al, 2009). Furthermore, expression of a constitutively active 
Akt mutant has been able to at least partially prevent dissociation induced 
apoptosis of hPSC (Ohgushi et al, 2010) suggesting that the RhoA/ROCK/MLC 
pathway might not be the sole determinant of hPSC death and survival on 
dissociation.  
In addition to its critical role in the maintenance of pluripotency in hPSC, FGF 
mediated signalling has also been reported to play a significant role in the 
regulation of apoptosis. It has been suggested that ligand activation of the FGFR 
mediated by bFGF results in activation of Akt and Erk signalling which decreases 
caspase activation in a BIM dependent manner (Eiselleova et al, 2009; Wang et 
al, 2009). This mechanism of action has also been suggested to play a role in 
preventing anoikis of hPSC upon detachment.  
 Anoikis resistance 1.3.4.3
Another potential mechanism through which hPSC could prevent dissociation 
induced apoptosis is through resistance to mechanisms involved in anoikis. It has 
been previously shown that increased activity of FAK or integrin linked kinase 
(ILK) can protect cells from apoptosis even upon loss of ECM adhesion. This is 
likely due to downstream activation of Pi3K/Akt signalling as discussed above 
(Chiarugi and Giannoni, 2008).  
Atypical regulation of epidermal growth factor (EGF) signalling can also lead to 
suppression of anoikis. The EGF receptor (EGFR) is normally stimulated by EGF 
and can lead to activation of pro-survival pathways such as the Pi3K/Akt 
pathway, but there have also been reports of ligand independent activation of 
EGFR in an integrin and Src-family kinase dependent manner. Upon integrin 
activation, the cytoplasmic tail can contribute to a complex containing Src and 
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p130Cas which can tyrosine phosphorylate the EGFR at numerous sites. The 
downstream signalling resulting from this can lead to phosphorylation and 
subsequent degradation of pro-apoptotic proteins such as Bim. During normal 
growth, this pathway would not be activated upon loss of integrin/ECM contact, 
however there have been reports that this can be activated independent of 
integrin activation during incidences of cell stress resulting in the release of 
reactive oxygen species (ROS), which can subsequently activate Src (Moro et al, 
2002; Giannoni et al, 2008).  
1.3.5 Stem cell state and apoptosis 
Although functionally equivalent, there are major differences between hESC and 
mESC, such as their morphology, cell surface markers and growth factor 
requirements. Most interesting however, is the observation that mESC are not 
sensitive to enzymatic dissociation in the same way that hESC are. Although 
initially attributed to interspecies differences, recent evidence suggests that this 
sensitivity to dissociation is actually dependent on developmental stage rather 
than species dependent. It is now widely accepted that there are two distinct 
pluripotent cell types; the ICM or ‘naïve’ cells and the epiblast or ‘primed’ type 
cells which are developmentally more mature and are isolated from the post 
implantation embryo (Ohgushi and Sasai, 2011; Hanna I et al, 2010; Buecker et 
al, 2010). The comparison between mouse epiblast derived pluripotent cells 
(mEpiSC) and hPSC showed that not only do mEpiSC have similar colony 
morphology, surface markers and growth factor requirements, they are also 
sensitive to dissociation. In contrast, human epiblast like stem cells (hEpiSC) 
derived by nuclear reprogramming, are more comparable to mESC and are not 
sensitive to dissociation (see table 1.3 for a summary) (Buecker et al, 2010).  
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Pluripotent cell type Developmental stage 
Sensitivity to 
dissociation 
mESC Naive Not sensitive 
hESC/hiPSC Primed Sensitive 
mEpiSC Primed Sensitive 
hEpiSC Naive Not sensitive 
Table 1.3- Developmental stage and sensitivity to apoptosis. Summary showing the 
susceptibility of developmentally discrete pluripotent cell types in response to dissociation. 
 
1.4 Problems with ROCK inhibition 
The use of ROCK inhibitors has been incredibly useful, however there have been 
recent concerns raised over the use of Y27632. The first of which is that Y27632 
and other established ROCK inhibitors such as HA-1077 are not very specific and 
have been shown to inhibit a number of additional kinases with similar potency 
(Andrews et al, 2010; Davies et al, 2000). In addition to this, the small GTPases 
are a ubiquitously expressed protein family involved in a diverse range of 
biological processes including differentiation, cell division, apoptosis, adhesion 
and cytoskeleton regulation (figure 1.9) (Jaffe and Hall, 2005; Visvikis et al, 
2010; Gerecht et al, 2007). Interference with such a wide range of processes has 
the potential to impact the balance of numerous signalling pathways and the 
downstream effects of Y27632 exposure in hPSC has not been investigated 
extensively (Couture, 2010). Zweigerdt et al (2011) have recently developed a 
culture system capable of expanding hPSC in suspension culture, however they 
were unable to add Y27632 after day 1 of culture due to the reduced 
proliferation which had been observed by other groups (Zweigerdt et al, 2011; 
Singh et al, 2010). In addition to this negative effect on proliferation, the use of 
Y27632 has been associated with an increased incidence of chromosomal 
abnormalities (aneuploidy) (Riento and Ridley, 2003; Liu et al, 2012).  
Another major problem associated with the use of Y27632 is due to the critical 
role ROCK plays during hPSC differentiation. Our group and others are interested 
in the potential use of hPSC as an alternative source of red blood cells (RBC) for 
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transfusion, however, even transient use of Y27632 has resulted in decreased 
proliferative capacity (unpublished data, Mountford group) and reduced 
production of haematopoietic precursor cells (Yung et al, 2011). In support of 
this, Y27632 has also been shown to have a negative impact on the proliferative 
potential of adult CD34+ haematopoietic precursor cells (Bueno et al, 2010). 
Similarly, Y27632 has also been shown to impact the differentiation towards 
other cell types such as neuronal and endothelial lineages (Sivasubramaniyan et 
al, 2010; Sivasubramaiyan et al, 2009; Boissart et al, 2013; Joo et al, 2012).  
As research into hPSC develops, further issues with Y27632 may yet be 
uncovered. However, despite these reported problems, there continue to be 
reports of a number of novel applications particularly those designed for the 
large scale expansion and culture of hPSC and their derivatives for therapeutic 
use, that are dependent upon the use of hPSC survival compounds such as 
Y27632. This highlights a currently unmet demand for compounds that promote 
hPSC survival without inhibiting the ROCK signalling pathway.  
1.4.1 Alternatives to ROCK inhibitors 
A number of studies have been performed with the aim of discovering more 
specific or alternative pro-survival compounds. Despite screening over 20,000 
molecules, a study performed by our group identified 18 molecules with any pro-
survival effect on hPSC. It was subsequently shown by in vitro kinase assays that 
all of these compounds were inhibitors of ROCK (Andrews et al, 2010).  
In another high-throughput screen (50000 compounds), Xu and colleagues 
identified a further 2 compounds known as Thiazovivin (a 2,4-disubstituted 
thiazole) and Tyrintegin (a 2,4-disubstituted pyrimidine). The authors suggested 
that these compound supported increased survival by enhancing integrin 
signalling. However, upon further investigation, Thiazovivin was shown to act 
directly on the ROCK signalling pathway, significantly inhibiting ROCK activity at 
a concentration of 2µM. Although the in vitro kinase assay showed Tyrintegin 
was not an inhibitor of ROCK, the study did not further investigate this, which 
does not rule out the possibility of indirect inhibition. The supplementary data 
accompanying this article shows via TUNEL (Terminal deoxynucleotidyl 
transferase dUTP nick end labelling) assay that inhibition of Pi3K signalling 
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ablated the positive effect of Tyrintegin which is consistent with the accepted 
role of Pi3K in apoptosis (Wong et al, 2007; Yamaguchi and Wang, 2001).  
Alternative strategies to pharmacological prevention of apoptosis such as genetic 
manipulation of hPSC have also been investigated. It has been recently shown 
that the overexpression of BCL2 in either constitutively active or inducible 
systems was able to improve survival of hPSC post dissociation (Ardehali et al, 
2010), however the practicality of such systems has to be questioned. 
1.4.2 T16 discovery 
During the aforementioned work performed by our group (Andrews et al 2010), 
although all 18 compounds were shown to be ROCK inhibitors, we identified an 
additional 19th compound that promoted hPSC survival, but in vitro kinase assays 
it was shown that this compound, referred to as T16, did not have any inhibitory 
effect on ROCK or the closely related kinase PRK2. Further characterisation of 
the compound was not within the scope of that project and T16 was therefore 
not included in the resulting publication.  
1.5 Aims of thesis 
The aim of this thesis was to further characterise the activity of the hPSC 
survival compound T16 and to demonstrate its potential as a novel reagent for 
use in hPSC culture and for the development of hPSC-derived cell therapies. This 
included: 
 Optimisation of compound performance 
o Concentration and duration of treatment 
o Numerous cell lines including hiPSC 
 Confirmation of retained stem cell identity 
o Differentiation capacity 
o Expression of pluripotency markers 
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o Karyotypic stability 
 Investigation of potential upstream or downstream interaction with ROCK 
signalling pathway 
o RhoA/Rac1 activity 
o MLC phosphorylation status 
o Morphology analysis 
 Investigation novel, non-ROCK, mechanism of hPSC survival 
o mRNA analysis 
o Kinase inhibition assays 
o Pathway tracking 
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2 Materials and Methods
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2.1 General laboratory practice 
 
Laboratory reagents and equipment were of the highest commercially available 
standard. Unless otherwise stated, chemicals and reagents were supplied by 
Sigma-Aldrich, Dorset, UK. Hazardous chemicals were handled in compliance 
with Control of Substances Hazardous to Health (COSHH) guidelines. Laboratory 
coats, nitrile powder-free gloves, safety spectacles and fume hoods were used 
where appropriate. 
2.2 Biological tissue handling 
Tissue culture was performed in standard biological safety class II vertical 
laminar flow cabinets under sterile conditions. Cells were cultivated in 
humidified incubator at 37°C with a constant atmosphere of 5% CO2. Cells were 
regularly tested for Mycoplasma using MycoSEQ Mycoplasma scan kit (Invitrogen) 
and independently tested for karyotypic abnormalities upon removal from liquid 
nitrogen and after each subsequent 15-20 passages (Medical Genetics 
department, Yorkhill Hospital, NHS Greater Glasgow & Clyde). Table 1.1 shows a 
list of commonly used tissue culture plastics and reagents. 
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Item Supplier 
1ml syringes Fisher 
Bijou Fisher 
cell lifters Corning Incorporated 
Cryovials Starlab UK 
Culture dishes (all sizes) Corning Incorporated 
Culture flasks (all sizes) Corning Incorporated 
DMSO Sigma 
Falcon tubes (15ml and 50ml) Corning Incorporated 
Foetal calf serum (FCS) Life Technologies 
Knockout DMEM Life Technologies 
L-glutamine Life Technologies 
low binding pipette tips Scientific lab supplies 
Mitomyocin C Sigma 
Non-essential amino acids (NEAA) Life Technologies 
PBS (with Mg2+ and Ca2+ Life Technologies 
PBS (without Mg2+ and without Ca2+) Life Technologies 
Penicillin Life Technologies 
Pipette tips (all sizes) Starlab UK 
Reaction tubes (eppindorfs) Starlab UK 
Serological pipette (all sizes) Corning Incorporated 
Square petri dishes Fisher 
Stericup filter units (250ml and 500ml) Millipore 
Streptomycin Life Technologies 
Ultra low attachment dishes (6-well) Corning Incorporated 
Table 2.1- Commonly used tissue culture plastics and reagents. 
 
2.2.1 Human pluripotent stem cell culture 
2.2.1.1 Maintenance 
HPSC were cultured in adherent conditions in a feeder-free system with media 
being replenished every 24hours (6 out of 7 days). Maintenance of hPSC was 
performed using StemPro hESC SFM culture medium (Life technologies) which 
consisted of DMEM F12 with GlutaMAX, 1x StemPro hESC supplement and 1.8% 
bovine serum albumin (BSA). This was supplemented with 0.1mM 2-
mercaptoethanol and 20ng/ml bFGF. Cells were passaged mechanically using 
StemPro EZPassage disposable passage tools (Invitrogen) when approximately 80-
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90% confluent at a split ratio of 1 in 6. EZPassage tools produce a grid like 
pattern of hPSC in small colonies. Tissue culture vessels were pre-coated with 
extracellular matrix proteins as detailed in table 1.2.  
Throughout this study, a number of cell lines were used. The original Wisconsin 
hESC lines H1 and H9 (Thomson et al, 1998) and the GMP (good manufacturing 
practice) grade line RC9 (Roslin Cells LTD, Edinburgh) were used alongside the 
hiPSC line NMF-iPS6 (Sullivan et al, 2010). 
 
ECM Supplier 
Volume 
used 
Conc used Incubation Temperature 
Cellstart 
Life 
Technologies 
750µl/well 
N/A 
2hr 37°C 
Human 
Fibronectin 
Merck 
Millipore 
100µl/well 
0.3mg/ml 
20mins 37°C 
Recombinant 
Vitronectin 
Stemcell 
Technologies 
500µl/well 
25µg/ml 
1hr Room Temp 
BD Matrigel BD Biosciences 1ml/well 0.5mg/ml 1hr Room Temp 
Gelatin 
(Bovine skin) 
Sigma 1ml/well 
0.1% 
solution 
1hr Room Temp 
Table 2.2- Commonly used extracellular matrices. 
 
2.2.1.2 Single cell passage using survival compounds 
For dissociation to single cell suspension from hPSC, culture medium was 
removed and the cells were washed with PBS (-/-) (Invitrogen). TrypLE Select 
(Invitrogen) was added to the cells and incubated for 3-5mins at 37°C before 
being inactivated by the addition of an equal volume of basal medium. Cells 
were vigorously pipetted to dissociate any remaining clumps, counted using the 
haemocytometer then pelleted by centrifugation for 3mins at 300 x g in a 
Heraeus Multifuge 3 S-R. Cells were washed in PBS (-/-) and pelleted as before. 
Cells were resuspended in culture medium and seeded onto pre-coated tissue 
culture plates at a density of 5x105 cells/well of a 6 well culture dish. 
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As detailed in results chapter 3 the survival compounds T16 and Y27632 required 
different treatments in order to produce optimal results. Therefore, T16 and 
Y27632 were added to cells 24hr and 2hr prior to passage respectively.  
For long term exposure experiments, cells were passaged once they reached 90-
100% confluence which took between 3-5days. 
2.2.1.3 Survival assay 
Survival of hPSC upon dissociation to single cells was assayed 24hr post 
dissociation by counting cells that remained in suspension and subtracting these 
from the total cells input. This value was presented as a percentage of total 
cells input. This is a modified version of that used previously by Chen et al 
(2010). 
(Total cells input) - (cells in suspension) x 100 
(Total cells input)          1 
 
 
 Supply of T16 1.5.1.1
The structure of T16 was not disclosed during these studies, however the 
compound was identified from a screen of commercially available drug-like 
moieties and can be identified for future studies. The compound was synthesised 
when required by the chemical supplier Enamine (Ukraine) in quantities ranging 
from 10mg to 100mg and supplied as a lyophilised powder. T16 was 
reconstituted in DMSO at a stock concentration of 50mM and used routinely at 
30µM. 
2.2.1.4 Kinase inhibition studies 
In order to investigate the role of particular pathways in dissociation induced 
apoptosis of hPSC, kinase inhibitors were utilised. Unless otherwise stated, 
kinase inhibitors were added to cells 2hrs prior to passage and also 
supplemented in culture medium post passage. A list of inhibitors used and 
concentrations is in table 1.3. Unless otherwise stated, DMSO was used to 
reconstitute all inhibitors and an equal amount of DMSO (always <0.01% v/v) was 
used as a carrier control.  
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2.2.1.5 RhoA and Rac1 inhibition and activation 
To produce maximum effect, any compounds other than Y27632 that target RhoA 
or Rac1 signalling pathways were added to cells 24hours pre passage and culture 
medium also supplemented with compounds post passage. A list of inhibitors and 
activators used can be seen in table 1.3. 
2.2.1.6 Haematopoietic differentiation of hPSC 
Differentiation towards red blood cells (RBC) involved a 31day long multistage 
feeder-free protocol (Mountford lab, patent filed).  
2.2.1.7 Passive multi-lineage differentiation 
In order to confirm the pluripotent potential of hPSC, cells were passively 
differentiated as follows. One confluent well of cells had culture medium 
removed and cells washed twice in PBS (-/-). 2ml of differentiation medium 
consisting of Knockout DMEM, 20% FCS, 1% NEAA, 1% L-glutamine and 1% 
penicillin and streptomycin was added to cells. EBs were produced by 
mechanically passaging cells as described in section 2.2.1.1 and transferring 1ml 
of cells in to 2 wells of an ultra-low attachment culture dish. A further 2ml of 
differentiation medium was added to leave total volume of 3ml/well. Culture 
medium was partially replenished every 2-3days by removing 1.5ml and 
supplementing with 1.5ml of fresh differentiation medium, taking care to limit 
cell loss. After 2weeks in suspension culture, embryoid bodies were transferred 
to 12-well dishes that were pre-coated with 0.1% Gelatin for 1hour at room 
temperature using a split ratio of between 1in2 and 1in4. Cells were supplied 
with 3mls fresh differentiation medium every 2-3days for a further 2weeks 
before being fixed for subsequent staining as described in section 2.4.10.  
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Inhibitor/Activator Target 
Concentration 
used Supplier 
Lysophosphatidic 
Acid (LPA) RhoA (Activator) Various 
Tocris 
bioscience 
GF109203X PKC (α & β1 isoforms) 10µM 
Tocris 
bioscience 
API-2 AKT 10µM 
Tocris 
bioscience 
CGP53353 PKC (β2 isoform) 10µM 
Tocris 
bioscience 
PI828 Pi3K 10µM 
Tocris 
bioscience 
Rho inhibitor 1 RhoA (inhibitor) 20ng/µl 
Cytoskeleton 
Inc. 
BIBX1382 EGFR 10µM 
Tocris 
Bioscience 
LY 364947 
TGFβ 10µM 
Tocris 
Bioscience 
PP2 Src-family kinases 10µM 
Tocris 
Bioscience 
Y27632 (in dH2O) ROCK 10µM Sigma 
Blebbistatin Myosin II 10µM Sigma 
NSC23766 Rac1 (GEF inhibitor) Various Sigma 
TPCA-1 IκK 10µM 
Tocris 
Bioscience 
Table 2.3- List of inhibitors and activators used. Unless otherwise stated, all inhibitors were 
made up in DMSO at stock concentrations which ensured that no more than 0.01% v/v of DMSO 
was added to cultures. 
 
2.2.2 Tissue Culture 
2.2.2.1 Mouse Embryonic Fibroblasts (MEFS) and media conditioning 
Mouse embryonic fibroblasts or MEFS, were cultured in DMEM supplemented with 
10% FCS, 5% P/S, 2mM L-Glutamate and 1mM sodium pyruvate. MEFS were grown 
until 80-100% confluent and either passaged or mitotically inactivated using 
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mitomyocin C. To inactivate MEFS, 10ng/ml mitomyocin C was added to culture 
medium and incubated with cells for 2-3hours. Culture vessels were pre-coated 
with 0.1% gelatin solution at room temperature for 1hour. Culture medium 
containing mitomyocin C was removed from the culture vessels and cells washed 
3x in PBS (-/-) before being dissociated using TrypLE select. Cells were 
centrifuged at 300 x g for 3mins, resuspended in MEF media and replated onto 
the gelatin coated plates at a density of 6x104 cells per cm2. The following day, 
MEF media was removed, cells were washed 2x with PBS (-/-) and had the 
medium to be conditioned added (21mls per T150 culture vessel). At this point 
medium was supplemented with 4ng/ml of bFGF. Conditioned medium was 
harvested after 24hours and fresh medium added to MEFS. This was repeated 3-4 
times as dictated by the quality of the MEFS. Prior to use, conditioned medium 
was filtered and aliquoted into working volumes. If not used immediately, 
conditioned medium was stored at -80°C. MEFS were not used beyond passage 5.  
2.2.3 Cryo-preservation and recover of cells 
Cells were treated as described in section 2.2.1.1 above. The small colonies 
created by the EZPassage cutting tool were resuspended in 1ml of Stempro 
medium and 500µl added to 500µl of a freezing mixture composed of 10% culture 
medium, 30% FCS and 10% dimethyl sulphoxide (DMSO). This 1ml cell and 
freezing mix solution was added to 1 cryovial and placed in a Nalgene® Mr. 
Frosty® container containing isopropanol and placed in the -80°C freezer. This 
ensured the gradual decrease of temperature towards -80°C at a rate of 1°C per 
minute. Vials were subsequently transferred to liquid nitrogen and stored until 
required.  
Prior to removal from liquid nitrogen, pre-coated culture vessels were incubated 
at 37°C with culture medium for 30minutes. Cells were removed from liquid 
nitrogen and thawed quickly in a 37°C water bath until a single ice crystal 
remained. Cells were transferred to a 15ml tube and resuspended in the pre-
incubated culture medium by adding a drop at a time. Cells were then 
transferred to culture dish and returned to incubator. Culture medium was 
replaced the following day to ensure removal of any residual DMSO.  
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2.3 Gene expression analysis 
2.3.1 RNA extraction 
Total RNA was extracted from cells through the use of the Qiagen RNeasy mini 
kit as per manufacturer instructions. Briefly, cells were lysed either directly on 
the plate or after being dissociated as described previously. In both cases, 350µl 
of Buffer RLT was used per confluent well of a 6 well dish. Cell lysis was aided 
through the use of a rubber policeman if directly lysed on the plate or via 
pipetting 3-5 times if already dissociated. Lysates were either directly processed 
or stored at -80°C until required. In order to optimise the concentration of RNA 
that binds to the spin column, lysates were homogenised by passing them 
through QIAshredder spin columns using a benchtop Heraeus BIOFUGE pico for 
2mins at 10000 x g. RNA was precipitated by the addition of an equal volume of 
70% ethanol. The sample was then passed through an RNeasy spin column 
containing a silica based gel membrane which binds the RNA for 15secs at 6000 x 
g. Membrane bound RNA was treated with 700µl Buffer RW1 by spinning it 
through the column for 15secs at 6000 x g. RNA was then washed twice in 500µl 
Buffer RPE by addition to the spin column followed by spinning for 15secs at 
6000 x g and 2mins at 6000 x g for first and second washes respectively. RNA was 
then eluted by passing 30-50µl of RNase free water through the spin column for 
1min at 6000 x g. The eluate can be frozen at -80°C at this stage or further 
processed.  
2.3.2 DNase treatment 
Digestion of contaminating DNA was performed using the Ambion Turbo DNA free 
kit. The reaction was initiated by adding 2µl buffer, 12µl water and 1µl DNase to 
5µl RNA eluate and incubating this mixture for 30mins at 37°C. Samples were 
briefly centrifuged and another 1µl of DNase added for a further 30mins at 37°C. 
Samples had 2µl stop solution added and were left for 2mins at room 
temperature. Samples were centrifuged for 5mins at 6000 x g and the 
supernatant, which contains the DNased RNA was transferred to a fresh 
eppindorf and either used to produce cDNA or stored at -80°C for future use.  
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2.3.2.1 RNA Quality control 
RNA concentration and quality was assayed through use of the NanoDrop 
(Thermo Scientific) and the Agilent® 2100 bioanalyser respectively. The Agilent 
produced RNA integrity numbers or RIN values that were used to determine 
quality. Values of 7 or more were deemed as being of high quality. Briefly, 
DNAse treated RNA was produced as above, with 1µl per sample being used for 
Agilent analysis. Agilent gel was prepared by centrifuging 550µl gel matrix 
through a spin column at 1500 x g for 10mins. 65µl of the eluate was transferred 
to a new eppindorf and had 1µl RNA 6000 Nano dye concentrate added and 
mixed well. This Gel-Dye mix was centrifuged for 10mins at 13000g. RNA 6000 
nano chip was placed on the Agilent priming station and had 9µl Gel-Dye mix 
added and spread through the chip using a 1ml syringe attached to the priming 
station. After this another 9µl was added to two further wells. 5µl of RNA 6000 
Nano marker was added to all 12 sample wells as well as the ladder well. 1µl 
sample was added to each of the 12 samples wells (or Nano marker if well not 
required) and 1µl ladder added to the ladder well. The loaded chip was placed in 
the vortexer for 1min at 2400RPM. The chip was then immediately run on the 
Agilent® 2100 bioanalyser. A single quantitative real time polymerase chain 
reaction, or qRT-PCR, reaction can also be performed using a stably expressed 
housekeeping gene with DNAse treated RNA to check for any contaminating DNA. 
This is performed as detailed in section 2.3.4.  
2.3.3 cDNA synthesis 
In order to analyse cellular gene expression, total RNA must first be used to 
create cDNA (complementary DNA). cDNA synthesis was performed by adding 
10µl of DNase treated RNA to a reaction mix composed of 10mM dNTPs and 1µl of 
random hexamers (300ng/µl) (Invitrogen). The reaction was initiated by heating 
to 65°C for 5mins. Samples were chilled on ice, briefly centrifuged and 
combined with a reaction mixture containing 4µl buffer, 2µl DTT and 1µl 
RNaseOUT (Invitrogen) and left at room temperature for 2mins. 1µl of 
superscript II (Invitrogen) was added to samples before they were put through a 
temperature cycle consisting of 25°C for 10mins, 42°C for 50mins and 70°C for 
the remaining 15mins. As before, samples were then immediately used for 
analysis or frozen at -80°C. 
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2.3.4 TaqMan qRT-PCR transcript analysis 
TaqMan based qRT-PCR can be used as an efficient and reproducible method of 
analysing gene expression. This technique utilises small sequence specific probes 
for genes of interest that have a reporter fluorophore at the 5’ end and a 
quencher molecule at the 3’ end. During the amplification process, if the target 
sequence is present, the probes anneal and the quencher is subsequently 
cleaved during the amplification process by the enzyme Taq polymerase which 
has exonuclease activity, functioning in the 5’ to 3’ direction. Cleavage of the 
quencher molecule allows for detection of the reporter fluorophore, with the 
signal intensity increasing after each successful amplification cycle being 
directly proportional to the starting concentration of target sequence. This 
fluorescence signal can be normalised to that of a housekeeping gene which 
should be a gene that retains steady expression independent of experimental 
procedures. This process allows for the presence of genes of interest to be 
detected and quantified. Unless otherwise stated, the housekeeper gene GAPDH 
was used throughout.  
Samples were prepared for qRT-PCR analysis by adding 5µl of a 1 in 64 dilution 
(in water) of cDNA to a reaction mix containing 2.2µl H20, 7.5µl 2x TaqMan Gene 
Expression master mix  (ABI) and 0.3µl of primer. Reactions were performed in 
Optical 96-well Reaction Plates (ABI) with technical and biological replicates. 
Data is analysed by comparisons between the cycle thresholds (Ct) for each 
probe measured to that of a housekeeper gene. GAPDH was routinely used given 
its stable expression with hPSC. Ct is measured when the reporter dye emission 
intensity rises above that of the background level which occurs during the 
exponential phase of PCR. These Ct values are used to generate a ΔCt, which 
represents the difference between the gene Ct and the housekeeper Ct. The 
mean ΔCt between replicates was calculated and was used to calculate the 2
ΔCt x 
1000 value which was subsequently plotted on graphs. Using this this method, a 
relatively high 2ΔCt x 1000 of 400, would be indicative of a signal being detected 
within 1 cycle of the housekeeper, whereas a value of less than 0.1 would result 
from a signal being detected more than 15 cycles after the housekeeper. This 
method is particularly useful to give an indication of the absolute level of 
expression and relative quantification when an appropriate denominator is not 
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available for the 2-ΔΔCT method, for example when a genes is not expressed in 
the control undifferentiated cells but is induced by treatment and therefore 
comparing expression would result in an infinite fold increase. 
2.3.5 TaqMan Low Density Array cards (TLDA) 
TaqMan low density array cards (TLDA) plates operate under the same principles 
as single assay qRT-PCR only on a higher throughput scale. This platform utilises 
micro fluidic plates capable of simultaneously performing 384 reactions without 
requiring large amounts of sample. The cards allow a maximum of 8 samples to 
be processed using only 9µl of cDNA per sample. Briefly, 9µl of undiluted cDNA 
was added to 45µl water and 54µl 2x TaqMan Gene Expression master mix. 108µl 
of this mixture was directly added to one port on the TLDA card and analysed 
using the 7900HT Fast Real-Time PCR System.  
Data produced using TLDA was analysed as described above. 
2.3.6 Microarray 
Microarray analysis was performed in conjunction with the Glasgow Polyomics 
Facility using the Affymetrix HuGene ST 1.0 Human Array platform. RNA 
extraction was performed as discussed in section 1.3.1, however DNase 
treatment was performed on column through the addition of 10µl DNase and 70µl 
Buffer RDD directly onto the spin column membrane immediately following the 
Buffer RW1 wash step. This was incubated at room temperature for 15mins then 
washed again in Buffer RW1 before continuing with standard RNA extraction 
protocol starting with the first Buffer RPE wash step as described above. DNase 
treated RNA was processed on the Agilent and NanoDrop to ensure sufficient 
quality and concentration before continuing the protocol, with only samples 
obtaining a RIN value >7 being used.  
Samples were further processed via the use of two separate kits. The first kit 
was the Ambion WT Expression Kit which produces sense strand cDNA by firstly 
adding 5µl RNA to 5µl of First-Strand Master Mix composed of 4µl First-Strand 
Buffer Mix and 1µl First-Strand Enzyme Mix and incubating for 1hr at 25°C 
followed by 1hr at 42°C and then 2mins at 4°C. Samples were briefly centrifuged 
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and allowed to cool on ice for 2mins before processing was continued by adding 
50µl Second-Strand Master Mix which was composed of 32.5µl nuclease free 
water, 12.5µl Second-Strand Buffer Mix and 5µl Second-Strand Enzyme Mix. The 
First-Strand cDNA and Second-Strand Master Mix were put through a further 
temperature cycle this time consisting of 1hr at 16°C, 10mins at 65°C and 2mins 
at 4°C. Samples are once again centrifuged briefly before being cooled on ice. 
This Second-Strand cDNA was then used to produce anti-sense cRNA by 
incubating 60µl with 30µl of In Vitro Transcription (IVT) Mix composed of 24µl 
IVT Buffer Mix and 6µl IVT Enzyme Mix. This reaction mix was incubated for 
16hrs at 40°C and then left overnight at 4°C. cRNA was then purified by adding 
60µl cRNA Binding mix which was composed of 50µl Nucleic Acid Binding Buffer 
Concentrate and 10µl Nucleic Acid Binding Beads before transferring samples to 
a 96well U-Bottom Plate. Samples had 60µl of Isopropanol added and were 
subsequently placed on a plate shaker for 2mins, during which time the cRNA 
would bind to the beads. The plate was transferred to a magnetic plate which 
allowed the supernatant to be discarded. 100µl of Nucleic Acid Wash Solution 
was used to wash each sample 2x, again using the magnetic plate to capture 
beads. Washed cRNA was eluted from the beads by adding 40µl pre-warmed 
Elution Buffer (55°C) to samples for 2mins at room temperature followed by a 
further 3minutes on a plate shaker. The plate was returned to the magnetic 
plate to allow supernatants to be removed and transferred to fresh reaction 
tubes and placed on ice to cool. Sense strand cDNA is then synthesised by adding 
10µg of cDNA to 2µl Random Primers and putting through a heat cycle of 5mins 
at 70°C, 5mins at 25°C and 2mins at 4°C. After completion of these incubations, 
16µl of Second-Cycle Master Mix, which contains 8µl Second-Cycle Buffer Mix and 
8µl Second-Cycle Enzyme Mix, was added followed by a further heat cycle of 
10mins at 25°C, 90mins at 42°C, 10mins at 42°C, 10mins at 70°C and 2mins at 
4°C. Samples were briefly centrifuged and kept on ice. Following this, 2µl RNase 
H was added to each sample and incubated for 45mins at 37°C, then 5mins at 
95°C and 2mins at 4°C. This degrades the cRNA leaving the cDNA unaltered. 
cDNA was then purified using a cDNA Binding Mix and magnetic plate as 
described during cRNA purification step. Note that 120µl of ethanol is used 
rather than the isopropanol that was used during the cRNA purifying step. The 
eluted cDNA was transferred to fresh reaction tubes and stored on ice.  
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In order to fragment and label the cDNA, the Affymetrix GeneChip WT Terminal 
Labelling and Hybridization kit was used as per manufacturer instructions. 
Briefly, 5.5µg of single stranded, sense strand cDNA was incubated with 16.8µl of 
Fragmentation Master Mix ,which was composed of 10µl nuclease free water, 
4.8µl 10x cDNA fragmentation buffer, 1µl of 10units/µl UDG and 1µl of 
1000units/µl APE1, for 60mins at 37°C, 2mins at 93°C and 2mins at 4°C. 45µl of 
each sample was transferred to fresh reaction tubes, to which, 15µl of Labelling 
Reaction Mix (12µl 5x TdT Buffer, 2µl TdT and 1µl of 5mM DNA Labelling 
Reagent) was added and incubated for 60mins at 37°C, 10mins at 70°C and 
2mins at 4°C. At this point samples were added to a Hybridization Mix (50pM 
Control Oligonucleotide B2, bioB, bioC and bioD Eukaryotic Hybridization 
Controls at concentration of 2.5, 5, 25 and 100pM respectively, 1x Hybridization 
Mix and DMSO) and incubated at 99°C for 5mins then 45°C for a further 5mins. 
Samples were centrifuged at full speed for 1minute before being loaded in to 
the HuGene ST 1.0 Human Array Chips. The loaded chips were transferred to a 
hybridization oven set at 45°C and spun at 60RPM for 17hrs. Chips were then 
processed using the Affymetrix GeneChip Scanner 3000 7G system.  
2.4 Protein analysis 
2.4.1 Protein extraction 
As with RNA extraction, protein extraction was performed either directly on the 
plate or after dissociation as dictated by experimental design. Direct on the 
plate lysis was performed by removing culture medium and washing cells with 
ice cold PBS (-/-). 70-500µl lysis buffer # 6 (7.8ml H2O, 2ml lysis buffer #6 
concentrate (R&D), 3.604g urea, 100µl0.5M NaF) was added directly to wells and 
a rubber policeman was used to aid lysis. Lysates were then transferred to an 
eppindorf and gently agitated for 30mins at 4°C before being centrifuged at 
8000 x g again at 4°C. These cleared lysates were transferred to a new reaction 
tube and snap frozen on dry ice and placed in -80°C freezer. 
Cells that were harvested via dissociation were centrifuged at 8000 x g, washed 
in ice cold PBS (-/-) and centrifuged again with the same settings. Excess PBS 
was removed and cell pellet snap frozen on dry ice. Prior to use, cell pellets 
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were thawed and lysed by the addition of 70-500µl lysis buffer and treated as 
above. 
For time course experiments, cells that had reattached to the ECM were lifted 
using a cell scraper before being treated as above. Unless kit specific protocols 
dictated otherwise, lysis buffer #6 (R&D), supplemented with protease and 
phosohatase inhibitors (Thermo Scientific), was used to lyse cells. All subsequent 
analysis steps were performed on ice and spins performed at 4°C. 
2.4.2 Protein quantification (Bradfords Assay) 
Protein concentration was determined by diluting samples 1 in 50 in water and 
50µl added to triplicate wells of a 96 well culture dish (flat bottom). Protein 
standards ranging from 5µg/µl to 50µg/µl were also added in triplicate. To each 
well, 200µl Bradfords reagent (BIO-RAD) was added and samples immediately 
analysed via plate reader (BIO-RAD model680 microplate reader), reading 
absorbance at a wavelength of 595nm.  
2.4.3 SDS PAGE  
To ensure equal loading appropriate volumes of protein lysates (as calculated by 
Bradfords) were added to separate reaction tubes and made up to 24µl with 
water. Each sample had 6µl of 5x laemmli sample buffer added to give 1x final 
volume of 30µl. Laemmli buffer was composed of 10% SDS, 300mM Tris (pH 7.0), 
0.05% Bromophenol blue, 50% glycerol and 10% β-mercaptoethanol made up in 
dH2O. Samples were boiled for 10mins with a brief vortex after 5mins. Samples 
were briefly centrifuged before being loaded into each well of a 4-12% Bis-Tris 
midi gel (Life Technologies). Novex pre-stained protein standards (Life 
Technologies) were loaded into one well. Gel electrophoresis was performed 
using the XCell SureLock Mini-Cell coupled with a power pack running at 200v for 
approximately 45mins. 1x MES or MOPS running buffer (Life Technologies) was 
used to aid gel electrophoresis.  
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2.4.4 Western blot 
The proteins, now separated on the gel in a size dependent manner, were 
transferred to a nitrocellulose membrane (Sigma) with a 0.45µm pore size by 
western blotting. Transfer was performed for 90mins at 30v using an XCell II blot 
module and 1x transfer buffer (Life Technologies). Nitrocellulose membranes 
were then blocked for 30mins at room temperature using a 5% phosphoblocker 
solution (Cambridge Bioscience) made up in Tris buffered saline with tween 
(TBST). Primary antibody incubations were performed at 4°C overnight in a 1% 
phosphoblocker solution in TBST (Sigma-Aldrich). Table 2.4 shows a list of 
primary antibodies used. Membranes were washed three times with TBST for 5-
10minutes and incubated for 90minutes at room temperature with suitable 
secondary antibody solution conjugated to horseradish peroxidase (HRP). Table 
2.5 shows a list of secondary antibodies used. Membrane wash steps were 
repeated as described above before exposing the membrane to 6ml of Enhanced 
Chemiluminescence (ECL) reagent (Thermo Scientific) composed of equal parts 
of solutions A and B for 30seconds. Chemiluminescence was detected by 
developing films that had been exposed to the membrane using the X-OMAT. The 
resultant films were analysed using the densitometry analysis software Quantity 
One (BIO RAD). The protein α–tubulin was routinely used as a loading control due 
to its stable expression in hPSC. If required, nitrocellulose membranes were 
stripped by incubation at room temperature for 10-15mins with Restore Western 
Blot Stripping Buffer (Thermo Scientific) followed by a re-blocking step and 
subsequently probed for additional proteins. 
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Target Protein Species Raised In 
Dilution 
Used Supplier 
pMLC (ser19) Rabbit 1 in 1000 Sigma 
RACK1 Mouse 1 in 2000 SantaCruz 
Src-family kinases (pan Src) Rabbit 1 in 1000 
Cell Signalling 
Technologies 
pSrc-family kinases 
(Tyr416) (pan pSrc) Rabbit 1 in 1000 
Cell Signalling 
Technologies 
RhoA Mouse 1 in 500 Millipore 
Rac1 Mouse 1 in 1000 Millipore 
ILK Mouse 1 in 1000 
Cell Signalling 
Technologies 
α-tubulin Mouse 1 in 10000 Abcam 
Fyn (Tyr416) Rabbit 1 in 1000 
Cell Signalling 
Technologies 
Table 2.4- List of Primary antibodies used for western blot. 
 
Fluorophore 
Species 
Raised In 
Dilution 
Used Supplier 
Anti-Rabbit IgG (whole molecule) 
peroxidase linked Goat  1 in 10000 Sigma 
Anti-mouse IgG (whole molecule) 
peroxidase linked Goat 1 in 10000 Sigma 
Table 2.5- List of secondary antibodies used for western blot. 
 
2.4.5 RhoA and Rac1 Activation Assay 
In order to determine levels of active GTP bound RhoA and Rac1 proteins, 
affinity binding based assays were used. Briefly, cells were stimulated as 
required (dissociated with and without drug treatments) and cells processed as 
described in section 2.4.1. 500µl MLB lysis buffer (kit specific, Millipore) 
supplemented with protease and phosphatase inhibitors was used to lyse cells in 
place of lysis buffer number 6. Lysates were incubated at 4°C for 30mins with 
gentle agitation then centrifuged at 8000 x g for 5mins. 50µl of lysate was taken 
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for analysis of total protein levels and the remaining 450µl used for the affinity 
binding assay (with a minimum protein concentration of 5mg/ml). Agarose beads 
bound to GST tagged fusion proteins that only bind active GTP bound RhoA or 
Rac1 were added to the lysate and incubated for 1hour at 4°C with gentle 
agitation. RhoA and Rac1 kits utilised rhotekin and PAK bound beads 
respectively. Samples were briefly centrifuged at 8000 x g and supernatant 
discarded. Beads containing only GTP bound RhoA or Rac1 were then washed in 
MLB buffer and centrifuged again at 8000 x g. This wash step was repeated 2 
more times. After the final wash, extra care was taken to ensure removal of all 
the supernatant and the beads were then resuspended in 25µl of 2x sample 
buffer. 1µl of 1M DTT was added to samples to aid dissociation of RhoA or Rac1 
from the beads and samples boiled for 10mins with a brief vortex after 5mins. 
SDS PAGE and Western Blots were performed as described in sections 2.4.3 and 
2.4.4 respectively. Levels of GTP bound proteins were quantified using 
densitometry and normalised to total protein level (GTP and GDP bound 
protein). Total protein analysis was performed as described above (section 
2.4.4). 
2.4.6 G-LISA RhoA activation assay 
The G-LISA RhoA activation assay is a luminescence based kit used to specifically 
assess levels of active GTP bound RhoA. Cells were stimulated as required and 
lysates produced as described in section 2.4.1. A kit specific lysis buffer was 
used, supplemented with protease and phosphatase inhibitors. Protein 
concentrations were determined by adding 20µl of lysate to 1ml of precision red 
protein assay reagent and absorbance measured at 600nm in a 
spectrophotometer. Absorbance values were multiplied by 50 to achieve protein 
concentrations in mg/ml. Samples were diluted to 0.5mg/ml using lysis buffer 
and mixed with equal volume of Binding Buffer solution. 50µl of this solution was 
immediately added to a well of the G-LISA assay plate and incubated for 30mins 
at 4°C on an orbital shaker at 400RPM. Wells were coated with a RhoA binding 
protein specific for GTP bound RhoA only. After 30mins unbound sample was 
removed and wells washed 2x in wash buffer. Antigen presenting buffer (200µl) 
was added to each well for 2mins before washing a further 3x with 200µl wash 
buffer per wash. Primary and secondary antibodies were incubated in the wells 
for 45mins at room temperature on an orbital shaker at 400RPM with 3x washes 
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performed between incubations. Wells were given 3 final washes after removal 
of the secondary antibody solution. Wells were then exposed to 50µl ECL reagent 
and immediately analysed via plate reader (POLAR star Omega). Results 
generated were in RFU (Relative fluorescence units) and expressed as a 
percentage of the positive control. Positive control was performed as above, 
using recombinant RhoA protein supplied within the kit rather than protein 
sample.  
2.4.7 Co-immunoprecipitation of RACK1 and Src 
In order to assess intracellular protein to protein interactions, co-
immunoprecipitations were performed. Cells were stimulated/treated as 
required and cell pellets generated and snap frozen as described in section 
1.4.2. During cell lysis, it is critical that protein to protein complexes are not 
disrupted. In order to do this, a non-reducing lysis buffer was used in 
combination with sonication. Briefly, 500µl of non-reducing lysis buffer (Cell 
Signalling Technology) supplemented with protease and phosphatase inhibitors 
was added to cell pellet and titrated vigorously. Lysates were then sonicated on 
ice for 10 seconds and subsequently centrifuged at 6000 x g for 5mins. 
Supernatant was removed and transferred to a fresh tube on ice. At this point, a 
small aliquot was taken for analysis of total protein levels via SDS PAGE and 
western blot as described above. The remaining samples had 10µl of RACK1 
primary antibody added and were incubated with gentle agitation for 1-2hours at 
4°C. Following this, samples had 20µl of protein G agarose beads added using a 
pipette tip with 5mm cut off the top to avoid the shearing of beads. Samples 
were incubated for a further hour at 4°C with gentle agitation. During this time, 
protein G agarose beads, which are coated with covalently bound recombinant 
protein G with high affinity for IgG subclasses, binds to the IgG portion of the 
primary antibody. The RACK1 antibody in turn binds the specific epitope of 
RACK1 which will still be linked to any binding partners. Protein G agarose beads 
were pelleted by brief centrifugation at 6000 x g and supernatant discarded. 
Beads were washed by resupending in 500µl non-reducing lysis buffer. This step 
was repeated a further 2 times with extra care being taken after the third wash 
to remove as much supernatant as possible. 25µl of sample buffer (as described 
in section 2.4.3) was added to each sample before being boiled for 10mins with 
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a brief vortex after 5mins. SDS page and western blot were performed and 
samples analysed by densitometry as described previously.   
2.4.8 GST RACK1 fusion protein 
2.4.8.1 Expression and purification 
GST RACK1 fusion protein was generated from frozen glycerol stocks of e.coli 
containing pGEX-RACK1. Briefly, 50ml of L-broth was inoculated with pGEX-
RACK1 e.coli and incubated overnight in a shaker maintained at 37°C. The 
following day, the overnight culture was used to inoculate 450ml of L-broth 
containing 100µg/ml ampicillin. Cultures were grown at 37°C in the shaker until 
they had an OD600 of between 0.6-1.0 as determined by spectrophotometer 
readings taken after each hour of incubation. Once within this range, 0.2mM of 
IPTG (isopropylthio-β-galactoside) was added to induce production and cultures 
incubated for another 4hours at 30°C. Cultures were then pelleted by 
centrifugation at 5000x g for 10mins at 4°C and stored at-80°C overnight. Cells 
were then thawed and resuspended in 10ml of ice cold resuspension buffer 
(50mM TrisCl pH 8, 10mM NaCl, 1mM EGTA, 1.92mM MgCl2, 1mM DTT) 
supplemented with protease and phosphatase inhibitors. This solution was then 
sonicated on ice 4 times for 30seconds each, with a 30second gaps between each 
cycle, then had a 1 in 500 dilution of 10% Triton X-100 added. This mixture was 
vortexed then centrifuged for 15mins at 6000 x g at 4°C. Supernatant was 
removed and transferred to a 15ml tube and had 1ml of glutathione beads that 
were pre-equilibrated in wash buffer comprised of resuspension buffer and 0.02% 
Triton X-100. This solution was incubated for 1hr at 4°C with gentle agitation. 
Glutathione beads, now with GST-RACK1 bound to them were centrifuged at 4°C 
for 2mins at 600 x g and supernatant discarded. Beads were then washed in 5ml 
of wash buffer, centrifuged again as described above and then transferred to a 
fresh 2ml tube on ice. A further 3 washes were performed using 1ml wash buffer 
and centrifuged as previous. The incubation of beads with 600µl elution buffer 
(10mM glutathione in 50mM Tris pH 8) for 20mins at 4°C with gentle agitation 
facilitated the release of GST-RACK1 from the glutathione beads. Beads were 
then pelleted by a 10second full speed centrifugation and supernatant 
containing GST-RACK1 transferred to fresh tube on ice. This step was repeated 
two more times and eluates pooled before being transferred to a dialysis 
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cassette. Dialysis cassettes containing the eluted GST-RACK1 were added to 
650ml of chilled dialysis buffer (50mM TrisCl Ph 8, 100mM NaCl and 5% glycerol) 
and incubated over night with three buffer changes. This allowed glutathione to 
diffuse into the buffer whilst keeping the GST-RACK1 within the dialysis 
cassette. This was then removed and GST-RACK1 stored at -80°C for future use. 
Concentration of GST-RACK1 was quantified via Bradford’s assay as described in 
section 2.4.2.  
2.4.8.2 Src pulldown using GST-RACK1 fusion protein 
GST-RACK1 fusion protein was used as a tool to investigate RACK1 interaction 
with Src in response to various drug treatments. In order to do this, cells were 
treated as described previously and cell pellets generated. Cells were lysed with 
non-denaturing lysis buffer as described in section 2.4.7. As Src is unable to bind 
unphosphorylated RACK1, an in vitro phosphorylation reaction was performed by 
adding 30µl of GST-RACK1 and 40µl 1x mix of kinase buffer and ATP (Cell 
Signalling Technology) to 400µl of lysate. This mixture was incubated at 37°C 
with gentle agitation for 45mins then samples were stored on ice.  Glutathione 
beads (30µl) were added to each sample before being incubated at 4°C for 1 
hour with gentle agitation. The glutathione beads, now bound to GST-RACK1, 
were pelleted by brief centrifugation at 600 x g and washed three times in non-
reducing lysis buffer (Cell Signalling Technology) with the supernatant being 
discarded each time. Beads were then resuspended in 25µl 2x sample buffer and 
boiled for 10minutes with a brief vortex after 5mins. Samples were processed by 
SDS PAGE and Western Blot as described previously.  
2.4.9 Proteome Profiler™ antibody kits 
Human Phospho-MAPK and Human Phospho-Kinase Proteome Profiler antibody 
arrays (R&D) utilise immobilised capture antibodies spotted in duplicate onto 
nitrocellulose membranes in combination with a cocktail of biotinylated 
detection antibodies. Signals are detected through the use of streptavidin-HRP 
conjugate and ECL reagent. Arrays were performed as per manufacturer’s 
instructions. Briefly nitrocellulose membranes were incubated for 1hr at room 
temperature on a rocking platform with Array Buffer 5 which acts as a blocking 
buffer. 500µg of protein lysates prepared as described previously and made up to 
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a volume of 1.5ml in Array Buffer 1 were incubated with 20µl Detection Antibody 
Cocktail for 1hour at room temperature. After the hour incubation, Array Buffer 
5 was removed from the nitrocellulose membranes and replaced with lysate-
antibody mixture and incubated overnight at 4°C on a rocking platform. 
Membranes were washed 3 times in 1x Wash Buffer for 10mins per wash. 
Membranes were then incubated with 2ml of Buffer Array 5 and streptavidin-HRP 
mixture for 30mins at room temperature followed by a further 3 washes. 
Membranes were exposed to ECL reagent for 1minute and detected as described 
previously. Densitometry was used to measure signal intensity.  
2.4.10 Immunocytochemistry 
Cells grown on either culture plates or slides had culture medium removed, were 
washed 3x in PBS (-/-) and then had 4% paraformaldehyde (PFA) added 
(200µl/well of 12 well dish) for 20mins at room temperature. PFA was removed 
and cells washed a further 3x in PBS (-/-). After the final wash, a small volume 
of PBS was used to cover cells. Culture plates were sealed with parafilm and 
could be stored at 4°C before staining was performed. To continue with the 
staining protocol, PBS was removed and 200µl of permeabilisation solution (10% 
goat or donkey serum, 1% BSA, and 0.01% Triton X-100 made up in PBS (-/-)) was 
added to the cells for 30mins on a rocking platform. Following this, 
permeabilisation solution was removed and primary antibody added for 1-2hr at 
room temperature. Primary antibodies were diluted in permeabilisation solution 
and 200µl used per well. Cells were then washed 3x in PBS (-/-) for 5mins each 
on a rocking platform. Fluorescently conjugated secondary antibodies were 
added, again diluted in permeabilisation solution and incubated for 1 hour at 
room temperature on a rocking platform. During the secondary antibody 
incubation and all subsequent steps, culture vessels were wrapped in foil to 
avoid photo bleaching. The wash step was repeated, taking extra care to ensure 
all PBS was removed after the final wash. At this point 1 drop of Prolong Gold 
with DAPI (Invitrogen) was added to the cells and an appropriately sized glass 
cover slip placed on top with care being taken to avoid bubble formation. Images 
were produced using the Zeiss Axiovert 200M microscope and camera. Tables 2.6 
and 2.7 show lists of primary and secondary antibodies used for 
immunocytochemistry. 
  82 
 
 
Target  Species Raised In 
Dilution 
Used Supplier 
E-Cadherin Rabbit 1 in 200 R&D systems 
Oct 4 Rabbit 1 in 200 R&D systems 
Nanog Rabbit 1 in 1000 
Cell Signalling 
Technology 
PAX6 Mouse 1 in 500 Sigma 
AFP Mouse 1 in 500 Abcam 
SMA Rabbit 1 in 200 Sigma 
F-actin (FITC 
conjugated phalloidin) N/A 1 in 200 Invitrogen 
Tra-1-81 Mouse 1 in 200 Abcam 
Table 2.6- Primary antibodies used for immunocytochemistry. 
 
Fluorophore Species Raised In Dilution Used Company 
Alexafluor-555 Goat Anti-Mouse 1 in 400 Invitrogen 
Alexafluor-488 Donkey Anti-Goat 1 in 400 Invitrogen 
Alexafluor-488 Goat Anti-Rabbit 1 in 400 Invitrogen 
Alexafluor-555 Goat Ant-Rabbit 1 in 400 Invitrogen 
Table 2.7- Secondary antibodies used for immunocytochemistry. 
 
2.5 Flow Cytometry 
Cells were prepared for analysis by dissociating to single cell as described 
previously. Single cells were washed 3x in PBS (-/-), counted and resuspended in 
FACS sheath fluid (BD Biosciences). 1x105 cells were transferred to FACS tubes 
and stained with required antibody by addition of 1µl antibody per 1x105 cells. 
Antibodies were incubated for 30mins at room temperature and were protected 
from light. Cells were washed 3x in 2ml of sheath fluid 2mins of 300 x g 
centrifugation used to pellet cells between washes. Cells were finally 
resuspended in 500µl sheath fluid and analysed using the FACS Canto II with a 
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two laser setup (Red and Blue lasers). Subsequent analysis was performed using 
FloJo analysis software (Tree Star). Table 2.8 shows a list of antibodies used.  
2.5.1 Apoptosis assays 
Flow cytometry can be used as a means of determining if cells are healthy, 
necrotic, early apoptotic or late apoptotic by staining for the cell membrane 
phospholipid phosphatidylserine (PS) in combination with the nucleic acid dye 
propidium iodide (PI). One of the early steps of apoptosis is the translocation of 
PS from the intracellular to extracellular side of the plasma membrane. Annexin 
V has high affinity for PS and can be conjugated to fluorochromes such as FITC 
(Fluorescein isothiocyanate) that can be subsequently detected via flow 
cytometry. Those cells staining double positive for Annexin V and PI are late 
apoptotic as they have also lost membrane integrity. Cells staining positive for PI 
only are deemed to be necrotic as they have lost membrane integrity without 
actively apoptosing. Cells staining positive for Annexin V only are early apoptotic 
as they still retain membrane integrity. The BD Biosciences FITC Annexin V 
Apoptosis Detection Kit II was used as per manufacturer instructions. Briefly, 
cells were washed 2x in PBS (-/-) before being dissociated to single cell as 
discussed previously. After a further 2 washes, cells were resuspended in 1x 
Binding Buffer at a cell density of 1x106/ml. 100µl of cell Binding Buffer solution 
was added to each reaction tube and incubated with 5µl of both FITC Annexin V 
and PI for 20mins at room temperature and protected from light. Samples were 
made up to 500µl by the addition of 400µl Binding Buffer and analysed using the 
FACS Canto II.  
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Target Protein Species Raised In Conjugate Supplier 
SSEA4 mouse APC BD Biosciences 
Tra-1-60 mouse PE BD Biosciences 
Tra-1-81 mouse PE BD Biosciences 
SSEA1 mouse FITC BD Biosciences 
SSEA3 mouse PE eBioscience 
Annexin V mouse FITC BD Biosciences 
Integrin α2 mouse APC eBioscience 
Integrin α4 mouse PE BD Biosciences 
Integrin α5 mouse APC eBioscience 
Integrin αv mouse PE eBioscience 
Integrin α6 mouse PE eBioscience 
Integrin β1 mouse FITC BD Biosciences 
Integrin β2 mouse FITC BD Biosciences 
Integrin β3 mouse PE eBioscience 
Integrin β5 mouse PE eBioscience 
CD34 mouse APC eBioscience 
CD36 mouse PE BD Biosciences 
CD45 mouse APC BD Biosciences 
CD71 mouse APC BD Biosciences 
GlyA mouse PE eBioscience 
CD31 mouse PE BD Biosciences 
CD43 mouse APC eBioscience 
Table 2.8- Antibodies used during flow cytometric analysis. 
 
1.6 Statistical analyses 
Where appropriate, data was presented as mean values ± standard error of the 
mean (SEM). Experimental analysis between multiple treatment groups was 
performed by repeated measures analysis of variance (ANOVA). To determine 
statistical significance, Tukey post-hoc testing was performed, with the cut off 
for significance being P=<0.05. Statistical analysis was performed using 
GraphPad Prism software.  
 
 
 
 
 
 
 
 
 
 
3 Characterisation of T16 as a Survival Molecule 
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3.1 General Introduction 
T16 was originally identified using a high throughput screen that used a set 
concentration of 30µM in combination with a feeder-free culture medium 
composed of an equal volume of CM and a chemically defined medium with FN 
used as an ECM. In order to further investigate and optimise the performance of 
T16, these parameters were expanded and the usefulness of T16 as a survival 
compound tested.  
The aims of these studies were to: 
 Investigate the capacity of T16 to promote survival in multiple culture 
mediums, including more chemically defined options. 
 Investigate T16 compatibility with multiple ECM components. 
 Directly compare the survival mediated by T16 to that of Y27632. 
 Investigate the capacity for long term and continuous use of T16.  
 Determine if T16 use has any detrimental effect on the stem cell identity 
(retention of pluripotency markers, differentiation capacity and 
karyotypic stability). 
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3.2 T16 Concentration and Pre-Treatment Length 
A variety of hPSC lines including the hESC lines H1, H9 and RC9 as well as an 
hiPSC line (NMF-iPS6); Sullivan et al, 2010) were tested over various 
concentrations including 10µM, 20µM, 20µM, 40µM and 50µM, as well as different 
pre-treatment durations ranging from 2hrs to 24hrs. Cells were enzymatically 
passaged as described in section 2.2.1.2, and assayed for survival 24hrs post 
passage. The data presented in figure 3.1 shows that T16 improves cell survival 
when compared to untreated cells in all but the 50µM samples. There is a 
significant increase in cell survival versus the untreated control cells when cells 
are treated with 10, 20, 30 or 40µM of T16 (P=<0.001). However, a treatment of 
30µM resulted in significantly higher cell survival than any other concentrations 
(P=<0.001). There is no significant difference between untreated cells and cells 
treated with 50µM T16 which suggests that at this high concentration, T16 may 
be toxic to cells. T16 produced a similar pro-survival effect between all hPSC 
cell lines tested with there being no significant difference between these cell 
lines.  
The data shown in figure 3.2 demonstrate that T16 treatment produced 
significantly increased cell survival when added to the cells 24hr prior to cell 
passage (P=<0.005). The general trend was towards increasing cell survival the 
longer the hPSC were exposed to T16, with all pre-treatment lengths producing 
significantly greater hPSC survival than cells with no pre-treatment (P=<0.001). 
Again there were no differences between cell lines used.   
Based on the data shown in figures 3.1 and 3.2, all subsequent experiments were 
performed using a concentration of 30µM and with a 24hr pre-treatment. 
3.2.1 Compatibility with Multiple ECM and Culture Mediums 
There are a number of culture mediums and ECM available, each of which has its 
own pros and cons. To determine whether the pro-survival effect of T16 
treatment was reproducible regardless of the ECM or culture medium used 
further experiments were performed. HPSC were treated with T16 then 
enzymatically passaged on to either Matrigel, fibronectin, CellStart or 
vitronectin (human recombinant) at a cell density of 5x105 cells per well of a 6-
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well culture dish with Stempro SFM used as the culture medium. Similarly, hPSC 
were passaged in to several different culture mediums including Stempro SFM, 
mTeSR and MEF CM, under standard conditions (fibronectin used as ECM with 
each media type). HPSC survival was assayed 24hrs post passage into the various 
culture mediums and ECM conditions. T16 produces similar cell survival 
regardless of the ECM or culture medium used (figure 3.3). Furthermore, there 
were no significant differences between cell lines used.  
Unless otherwise stated, all subsequent experiments were performed using 
Stempro SFM in combination with fibronectin.  
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Figure 3.1- Optimisation of T16 concentration.  HPSC were treated with varying concentrations of T16. Using a concentration of 10, 20, 30 or 40µM T16 resulted in 
significantly increased cell survival compared to either 50µM or untreated cells (P=<0.001). Cell survival after a 30µM treatment produced cell survival significantly 
higher than all other concentrations (P=<0.001). There was no significant difference between cell types. Data shown is the mean survival ±SEM, n=3.  
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Figure 3.2- Optimisation of T16 pre-treatment length. HPSC were pre-treated with T16 for various time lengths prior to dissociation and then assayed for survival 
24hrs later. Increasing length of time corresponded with an increase in cell survival, with all pre-treatment lengths producing significantly increased survival versus no 
pre-treatment (P=<0.001). The optimum pre-treatment was 24hr, which produced significantly increased hPSC survival compared to all other treatments (P=<0.005). 
There were no significant differences between cell lines. Data shown is the mean survival ±SEM, n=3. 
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Figure 3.3- Compatibility with multiple extracellular matrices and culture mediums. HPSC 
were pre-treated with T16 and  then passaged onto either fibronectin, vitronectin, CellStart or 
Matrigel using Stempro as the culture medium (A) or on to fibronectin with either Stempro SFM, 
mTeSR or MEF CM used as the culture medium (B). No condition produced cell survival that was 
significantly different. Data shown as mean survival ± SEM, n=3.  
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3.2.2 T16 treatment results in cell survival comparable to Y27632 
The survival compound Y27632 has been used successfully as a survival 
compound since its initial description in 2007 (Watanabe et al, 2007) so for any 
alternative to be seen as acceptable, it must be shown to support survival just as 
effectively. HPSC were either treated with T16, Y27632 or left untreated, before 
being enzymatically passaged. In all experiments untreated cells had an 
equivalent volume of DMSO added as a carrier control, with cell survival being 
assayed 24hrs post passage. HPSC treated with either T16 or Y27632 had average 
cell survival that was significantly higher than that observed in untreated 
controls (P=<0.001) (figure 3.4) regardless of cell line used. In H1 hESC T16 
treatment resulted in cell survival of 72% (±2.9), Y27632 produced survival of 
72% (±3.6) and untreated cells had only 18% survival (±2.2). In the hESC lines H9 
and RC9 and iPSC line NMF-iPS6, T16 treatment resulted in cell survival of 73% 
(±2.8), 69% (±1.9) and 74% (±2.6) respectively. In the same cell lines Y27632 
produced cell survival of 73% (±2.1), 71% (±1.2) and 74% (±4.0) and DMSO alone 
(untreated) cells had survival of 18% (±2.4), 15% (±3.0) and 19% (±2.4) 
respectively. This result was consistent regardless of cell line used. These results 
show that a 24 hour pre-treatment with30µM T16 supports the enzymatic 
passage of hPSC as effectively as the well-established survival compound 
Y27632. 
3.3 T16 can be used long term as a survival compound 
In order for T16 to be considered as a viable alternative to Y27632, it must be 
shown that cells treated with T16 are able to support long term growth of hPSC 
in a manner comparable to, or better than, Y27632 treated cells. The hESC cell 
line H1 was enzymatically passaged 30 consecutive times (over approximately 20 
weeks) using either T16 or Y27632 pre-treatment to support survival. Cells were 
passaged at 100% confluence which was approximately every 4-5 days and re-
plated at a density of 5x105 cells per well. HPSC survival was assayed 24hrs post 
passage each time. Data for untreated cells was only available after the initial 
passage due to the previously documented poor survival when no compound was 
added. T16 treated cells show similar survival to those treated with the 
commonly used Y27632, with there being no significant difference between 
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treatment types at any of the passages (figure 3.5). Similarly, no significant 
differences were observed when the experiment was repeated with a hiPSC cell 
line (Figure 3.6).  
T16 and Y27632 treated cells reached confluence on the same day throughout 
these experiments. As the seeding density was constant and the survival was not 
significantly different, this suggest similar growth rate between treatment 
types. 
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Figure 3.4-T16 supports survival as well as Y27632. HPSC were enzymatically passaged without a survival compound, or after treatment with either T16 or Y27632. 
The hESC lines H1, H9 and RC9 and the hiPSC NMF-iPSC6 had cell survival of 72% (±2.9), 73% (±2.8), 69% (±1.9) and 74% (±2.6) respectively when treated with 
T16. In the same lines, Y27632 resulted in cell survival of 72% (±3.6), 73% (±2.1), 71% (±1.2) and 74% (±4.0) and DMSO alone resulted in survival of 18% (±2.2), 18% 
(±2.4), 15% (±3.0) and 19% (±2.4) respectively. The survival produced in response to treatment with T16 or Y27632 was significantly higher than those of untreated 
cells (P=<0.001). Data shown is the mean survival ±SEM, n=3. 
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Figure 3.5- HPSC survival after long term exposure to survival compounds. T16 or Y27632 was used to enzymatically passage the hESC line H1 for 
30 consecutive passages. Survival was assayed 24hrs post passage. Data up to passage 20 represents mean survival ± SEM, n=3. Data after passage 
20 represents cell survival, n=1. The red line represents the average survival of untreated cells ± SEM, n=3 
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Figure 3.6-Long term survival produced using hiPSC. Cells were treated with either T16 or Y27632 and passaged enzymatically for 30 consecutive passages. Data 
represents survival from a single experiment (n=1). The red line represents the average survival of untreated cells ± SEM, n=3.   
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3.3.1 T16 treated cells retain cytogenetic stability 
In order to ensure that T16 treatment was not causing karyotypic abnormalities 
or positively selecting abnormal cells during enzymatic passage, karyotypic 
stability was routinely tested by G-band analysis. Cells that had been 
enzymatically passaged with survival factors for the required number of 
consecutive passages were delivered to Medical Genetics department at Yorkhill 
Hospital (NHS Greater Glasgow & Clyde) at approximately 50-70% confluence. 
Cells were karyotyped after 12, 20 and 30 consecutive passages. Both T16 and 
Y27632 treated cells retained normal karyotype of 46 XY for at least 30 
consecutive passages (Figure 3.7).  
 
Figure 3.7-Cytogentic stability of T16 treated cells. HPSC (H1 hESC) treated with T16 or 
Y27632 for 30 consecutive passages were independently tested for cytogenetic stability (Yorkhill 
hospital, NHS Greater Glasgow and Clyde). Cells remain karyotypically normal (46, XY) until at 
least P30.  
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3.3.2 T16 treatment does not alter expression of pluripotency 
markers 
A critical requirement of any reagent to be used for hPSC maintenance and 
culture is that it does not negatively impact the expression of pluripotency 
related genes. The long term maintenance of a range of pluripotent markers was 
determined by flow cytometry, immunocytochemistry and by mRNA transcript 
analysis.  
 Flow cytometric analysis of pluripotency markers 3.3.2.1
HPSC were analysed by flow cytometry after every 5 passage as described in 
section 2.5. Cells were harvested for analysis immediately following passage. 
Figure 3.8A shows representative data produced using the FACS Canto, with the 
left hand panel showing forward scatter on the X-axis and side scatter on the Y-
axis, the centre panel showing an isotype control sample, gated to include >97% 
of cells in the lower left quadrant double negative for FITC and PE. The right 
hand panel shows that >97% of cells were positive for SSEA4 (PE) and <0.5% 
positive for SSEA1 (FITC). Figure 3.8B shows the % of SSEA4 (stage-specific 
embryonic antigen 4) and SSEA1 (stage-specific embryonic antigen 1) positive 
cells after each subsequent 5 passages. SSEA4 is a cell surface marker present on 
all undifferentiated hPSC, whereas SSEA1 is only present on differentiated cells. 
These markers have been routinely used as positive and negative markers of 
pluripotency in hPSC since their initial isolation (Thomson et al, 1998). As can be 
seen, consistent enzymatic passage supported by either T16 or Y27632 has no 
effect on the expression level of the pluripotency marker SSEA4, with both 
remaining consistent with >90% positive cells. Furthermore the differentiation 
marker SSEA1 remains consistently low (expressed on <5% of cells). This shows 
that T16 maintains a cell surface marker profile consistent with that expected of 
hPSC, and comparable to that achieved with Y27632 treatment. 
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3.3.3 Analysis of pluripotency markers by immunocytochemistry 
In order to further analyse the expression of pluripotency markers after 
prolonged treatment with T16 or Y27632, ICC was performed. Cells were fixed 
and stained at passage one and passage 30 as described in section 2.4.10. The 
use of T16 or Y27632 did not influence the number of cells expressing the key 
pluripotency related transcription factor Oct4 or the commonly used 
pluripotency marker Tra-1-81 even after 30 consecutive passages (figure 3.9). 
Again this suggests that T16 treatment does not have a detrimental effect on 
expression of pluripotency related proteins. 
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Figure 3.8- Flow cytometric analysis of hPSC surface markers. HPSC (H1 hESC) were 
enzymatically passaged using T16 or Y27632 for 30 consecutive passages. Cells were harvested 
at the point of passage and analysed via flow cytometry for the pluripotency marker SSEA4 and 
differentiation marker SSEA1. (A) Shows representative data produced, with the cell population 
imaged using forward and side scatter in the left hand panel, isotype controls in the centre panel 
and cells double stained for SSEA4 (PE) and SSEA1 (FITC) in the right hand panel. (B) Shows that 
both T16 and Y27632 treated cells maintained consistently high expression of SSEA4 over 30 
consecutive passages, with negligible expression of SSEA1 being observed. Data shown as mean 
percentage of positive cells ±SEM (n=3) up to and including passage 20. Passages 25 and 30 
represent values from an n=1.  
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Figure 3.9- Expression of pluripotency markers. Cells passaged in T16 or Y27632 for 30 consecutive passages were fixed and stained for pluripotency markers 
Tra-1-81 (green) and Oct4 (red) and co-stained with DAPI (blue). Cells show maintained expression of these two markers over 30 passages, with the majority of cells 
staining double positive. Scale bar represents 100µm. 
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3.3.4 TaqMan qRT-PCR analysis of pluripotency and early 
differentiation markers 
Although it has been established that treatment with T16 does not have any 
detrimental effect on the expression of key pluripotency markers such as Oct4 
and SSEA4, the effect of prolonged exposure to either T16 or Y27632 on 
expression of a wider range of genes was still unknown. To investigate any 
alterations in gene expression, qRT-PCR was performed utilising the higher 
throughput TaqMan Low Density Array or TLDA platform. This platform utilises 
micro fluidic plates capable of simultaneously performing 384 reactions without 
requiring large amounts of sample. The cards allow a maximum of 8 samples 
(including 48 reactions/sample) to be processed using only 9µl of cDNA per 
sample. RNA was isolated from T16 and Y27632 treated hPSC (H1 hESC) at 
passages 1, 5, 10 and 15 with cDNA being synthesised as described in section 
2.3.3, and TLDA plates were processed as detailed in section 2.3.5. Genes 
analysed include the key transcription factors Oct4 (POU5F1), Nanog and SOX2, 
markers of ‘stemness’ as well as a range of differentiation markers. Figure 3.10 
shows expression of these key pluripotency factors as well as the early 
differentiation markers GATA4, PAX6 and FOXA2. As can be seen there are no 
significant differences in expression of the core pluripotency transcription 
factors between drug treatment and passage number. Furthermore, there is no 
significant change in the relatively low expression of GATA4 (mesoderm), PAX6 
(ectoderm) or FOXA2 (endoderm). As expected, expression of these genes (as 
well as other differentiation related genes) remains low, showing that cells were 
not undergoing differentiation.  
A table detailing the results for all analysed genes can be seen in appendix 1 
(Table A1).  
Cumulatively, the data presented in section 3.2.5.1 through 3.2.5.3 show that 
multiple and consecutive passage using T16 to support survival does not alter the 
key markers of pluripotency or differentiation, suggesting that T16 can be used 
as a long term hPSC culture reagent and an alternative to Y27632. 
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Figure 3.10- Relative expression of pluripotency and differentiation markers. H1 hESC cells treated with either T16 or Y27632 for 1, 5, 10 or 15 passages had 
mRNA expression analysed via qRT-PCR based TLDA assays. Data shows that the pluripotency markers POU5F1 (Oct4), Nanog, and SOX2 maintain steady 
expression over the 15 passages. Furthermore, differentiation markers PAX6, GATA4 and FOXA2 retain consistently low expression throughout the 15 passages. Data 
shown as mean 2
ΔCt
 x1000 ± SEM. Experiments were performed included 3 technical replicates, each with biological triplicates (n=3 in triplicate). 
 
 
3.3.5 Treatment with T16 does not affect the pluripotent potential 
of hPSC 
HPSC (hESC cell line H1) that had been enzymatically passaged with either T16 
or Y27632 for 30 consecutive passages were passively differentiated alongside 
mechanically maintained cells using a mixture of embryoid body based 
suspension culture and adherent culture as described in section 2.2.1.7. 
Differentiated cells were subsequently fixed and stained for markers from each 
of the three germ layers. Long term exposure to either survival compound did 
not block the differentiation towards mesoderm (smooth muscle actin; SMA), 
endoderm (alpha fetoprotein; AFP) or ectoderm (paired box protein; PAX6). As 
expected, untreated mechanically passaged control cells, included as a positive 
control, were also able to differentiate into each of the three germ layers 
(figure 3.11).  
 
 
Figure 3.11- Passive differentiation of hPSC after T16 treatment. HPSC (h1 hESC) treated for 
30 passages with T16 or Y27632 were passively differentiated for 2 weeks in suspension culture, 
followed by 2weeks adherent culture, fixed and stained for markers of the three germ layers. 
Control cells that had been mechanically passaged and unexposed to any survival compound were 
also differentiated and stained in the same way. Pax6 is stained red in the left hand column, AFP 
Green in the centre column and SMA red in the right hand column. All cells were co-stained with 
DAPI in Blue. Scale bar represents 100µm. 
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3.3.6 T16 does not prevent directed differentiation 
Previous results indicate that the use of either survival compound does not 
prevent the passive differentiation of hPSC into any of the three germ layers. To 
further investigate the potential effect on differentiation, the capacity of 
treated hPSC to undergo directed differentiation was also investigated. Cells 
(hiPSC, NMF-iPS6) that were treated with T16 or Y27632 for 20 consecutive 
passages were induced to differentiate towards the haematopoietic cell lineage 
using a feeder-free suspension based differentiation protocol (Mountford lab, 
patent filed). As a control, untreated cells that had been maintained using 
mechanical passage were differentiated alongside T16 and Y27632 treated cells. 
Flow cytometric analysis of haematopoietic markers such as CD34 (~40% positive 
cells) at day 10, as well as the more mature erythroid markers GlyA and CD71 at 
day 24 (>90% of cells positive) confirmed the capacity of cells to differentiate 
towards erythrocytes (figure 3.12A). Notably, the marker profile was unchanged 
between treatment type.  Furthermore, the cumulative expansion over the 
24days of differentiation (figure 3.12B) shows a greatly reduced expansion in 
Y27632 treated cells when compared to either T16 treated or control cells. This 
supports unpublished data (Mountford lab) suggesting that Y27632 treatment 
reduces the proliferative potential of hPSC differentiated towards RBC after 
Y27632 use raising concerns over the utility of Y27632 for large scale 
applications. Critically, data here show that T16 does not share this negative 
effect and further enhances the commercial usefulness of T16. 
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Figure 3.12- Directed differentiation of hPSC. HiPSC (NMF-iPS6) treated for 20 consecutive 
passages were differentiated towards RBC. (A) Cells were ~40% positive for CD34 at day 10 and 
>90% for GlyA and CD71 at day 24 regardless of treatment type. (B) The cumulative expansion of 
cells shows that Y27632 treated cells did not expand as well as T16 or untreated cells over the 
24days. Data shown from n=1. 
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3.4 T16 can be used transiently or as an additive to 
culture medium 
3.4.1 Cell survival 
To determine whether T16 could be added to culture medium as a permanent 
addition, allowing hPSC to be enzymatically passaged whenever necessary 
without pre-treatment, cells were treated in parallel either transiently as 
described above or with T16 or Y27632 included continuously i.e. included in 
basal medium during daily feeding. Cells were passaged at 100% confluence as 
described above, which was approximately every 4-5 days, with the experiment 
lasting approximately 12 weeks.  As can be seen in figure 3.13, cells treated 
continuously with T16 had survival comparable to that seen when cells were 
treated transiently. This was largely the case with Y27632 treatment; however, 
there were numerous passages where survival was lower than expected in the 
continuously treated cells. This was particularly evident between passages 10-12 
when survival was consistently lower than transiently treated cells. There were 
no differences thereafter which may be indicative of culture adaptation or the 
acquirement of chromosomal abnormalities.  
 
Figure 3.13- Continuous versus transient use of survival compounds. HiPSC (NMF-iPS6) 
were treated either transiently or continuously with T16 or Y27632 and cell survival assayed. 
HiPSC survival appears unchanged by transient or continuous use of T16, whereas there is a slight 
dip around P10 in cells treated continuously with Y27632. This data represents n=1. Red bars 
represent the average survival of untreated cells ±SEM, n=3.  
 
108 
 
 
3.4.2 Maintenance of pluripotency  
As with previous experiments testing the effect of transient use of T16 and 
Y27632 over 30 passages of H1 hESC, it was critical to confirm that continuous 
use of T16 did not impact negatively on the expression of pluripotency and 
differentiation related markers. Cells (hiPSC, NMFiPS6) treated either 
continuously or transiently with T16 or Y27632 expressed consistently high levels 
of pluripotency marker SSEA4 and low expression of the differentiation marker 
SSEA1 over 20 consecutive passages as determined by flow cytometry (figure 
3.14). This confirms that continuous use of T16 has no detrimental effect on the 
cell surface marker profile of hPSC. 
 
 
Figure 3.14- Expression of pluripotency markers after continuous exposure to T16 or 
Y27632. HiPSC (NMF-iPS6) treated either transiently or continuously with T16 or Y27632 were 
analysed at passage 1, 5, 10, 15 and 20 for the pluripotency marker SSEA4 and differentiation 
marker SSEA1. Continuous treatment with T16 or Y27632 had no negative effect on the 
expression of SSEA4 with all passages tested having greater than 95% positive cells. Similarly, the 
expression of SSEA1 was unchanged.  
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3.4.3 Karyotypic stability of continuously treated cells 
HPSC that had been treated for 20 consecutive passages either continuously or 
transiently with both T16 and Y27632 were also analysed for karyotypic stability. 
Cells treated with T16 were normal (46 XY) after continuous and transient 
treatments, however Y27632 treated cells were not. Unlike the experiment 
shown in Section3.3.1 (figure 3.7) above in which H1 hESC were used, in this 
case hiPSC treated either continuously or transiently with Y27632 has an 
additional copy of chromosome 12 in 2 of 20 cells and 1 of 20 cells analysed 
respectively (Figure 3.15). Although these results are only from a single 
experiment, all four conditions were initiated from the same well of normal 
hiPSC, which may suggest that T16 is better suited for supporting stable 
expansion of hPSC after enzymatic disaggregation. There may also be differnces 
in stability between hESC and hiPSC lines.   
 
3.4.4 Long term treatment with T16 does not affect the pluripotent 
potential of hPSC 
The inclusion of T16 in culture medium continuously for 20 passages did not 
negatively affect the differentiation into any of the three germ layers when cells 
were allowed to undergo passive differentiation as described previously. Figure 
3.15 shows cells treated continuously with either T16 or Y27632 were able to 
passively differentiate into ectoderm (PAX6), endoderm (AFP) and mesoderm 
(SMA). 
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Figure 3.15- Karyotypic stability of continuously and transiently treated hiPSC. Cells (NMF-
iPS6) treated either continuously or transiently with T16 or Y27632 were analysed for chromosomal 
abnormalities. T16 cells were normal (46 XY) regardless of treatment type. Y27632 treated cells 
had +12 in 1 out of 20 and 2 out of 20 when used transiently and continuously respectively.  
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Figure 3.16- Passive differentiation of hPSC treated continuously with survival compounds. 
HiPSC (NMF-iPS6) that had been cultured for 20 consecutive passages in the continued presence 
of T16 or Y27632, were passively differentiated and stained for markers of the three germ layers 
alongside untreated mechanically passaged control cells. PAX6 (ectoderm) staining red in the left 
hand column, AFP (endoderm) staining green in the centre column and SMA (mesoderm) staining 
red in the left hand column, positive cells were seen in all three conditions. Scale bar represents 
100µm. 
 
 
The data presented in this sections 3.2.7.1 to 3.2.7.4 show that T16 can be used 
either transiently at the point of passage, or can be added continuously to 
Stempro SFM culture medium. Continuous use supports similar survival, marker 
expression and differentiation potential to transient use and offers the very 
interesting possibility that T16 could be included in basal hPSC media 
formulations to facilitate routine enzymatic passaging at will. 
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3.5 Summary 
Presented within this chapter are data which further characterise the hPSC 
survival compound T16. The results show that T16 can be used in a number of 
culture mediums including completely undefined MEF conditioned medium and 
more chemically defined culture mediums such as StemPro SFM or mTeSR. 
Furthermore, T16 produces the same survival effect regardless of the ECM 
component used to facilitate adhesion. The response to T16 is not cell line 
specific; with the pro-survival effect being reproduced in 4 lines tested which 
include both hESC and hiPSC. T16 treatment results in cell survival equivalent to 
that of the commonly used ROCK inhibitor Y27632 and supports hPSC propagation 
for at least 30 consecutive passages without causing karyotypic instability when 
used transiently, or for at least 20 consecutive passages when used continuously.  
Furthermore, the use of T16 does not negatively affect the expression of 
pluripotency related genes at either the mRNA transcript level (qRT-PCR 
analysis) or the protein level (ICC and flow cytometry). In addition to this, a 
panel of differentiation related markers remained unchanged in response to T16 
treatment after 15 consecutive passages using the compound as determined by 
qRT-PCR analysis. 
These data also confirm that treatment with T16 either transiently or 
continuously has no effect on the differentiation capacity of hPSC which 
passively differentiated into derivatives of all three germ layers or successfully 
underwent directed differentiation to red blood cells. 
Taken together, the work detailed in this chapter suggests that T16 is at least as 
useful as Y27632 and may even prove to be more so given that it does not appear 
to have a negative impact on directed differentiation towards red blood cells. 
However, elucidating how T16 mediates its survival effect will be crucial in 
better understanding the survival/death mechanism in hPSC. 
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4 T16 pathway analysis: Potential for a RhoA 
independent survival axis 
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4.1 General Introduction 
There have been a number of studies performed recently with the intention of 
finding additional PSC survival compounds, however, even when using a high-
throughput approach this has been relatively unsuccessful. All recently identified 
compounds that have successfully supported enzymatic passage of hPSC have 
subsequently been shown to inhibit the ROCK signalling pathway (Andrews et al, 
2010; Xu et al, 2010; Barbaric et al, 2010).  
As previously stated, T16 was initially identified as a non-ROCK inhibitory hPSC 
survival compound (unpublished data).  Having optimised the performance of 
T16, and shown that it supports enzymatic passage of hPSC to a comparable 
degree to the Rho Kinase inhibitor Y27632 without any detrimental effects, 
experimentation was undertaken to further elucidate the mode of action of T16. 
The aims of these studies were to: 
 Confirm the kinase inhibition profile of T16 at the optimal concentration 
of 30µM (previous screen data was generated using a concentration of 
10µM).  
 Investigate the potential role of any kinases showing altered activity in 
response to T16 treatment. 
 Determine if T16 mediates its pro-survival effect via upstream or 
downstream regulation of the RhoA/ROCK/pMLC axis. 
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4.2 T16 is not a Rho kinase inhibitor 
To reaffirm that T16 did not inhibit ROCK or the closely related PRK2, the 
compound was rescreened at the Dundee International Centre for Kinase 
Profiling at both the standard 10µM and optimum 30µM concentrations. This 
screen utilises a radioactive filter-binding assay (33P-ATP) to assess kinase 
inhibition. Results confirmed that T16 had no inhibitory effect on ROCK2 at a 
concentration of 10µM (96% activity), and in fact slightly promoted the kinase 
activity of ROCK2 at the optimum concentration of 30µM (118% activity). T16 
also had very limited effect on PRK2, showing 76% and 98% activity when used at 
10µM and 30µM respectively (figure 4.1).  
 
 
Figure 4.1-T16 does not inhibit Rho kinase. T16 kinase inhibition was assayed using a 
radioactive filter-binding assay at the Dundee International Centre for Kinase Profiling. The 
optimum concentration of T16 (30µM) did not inhibit either ROCK2 or PRK2. 
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4.2.1 T16 has minimal effect on in vitro protein kinase activity 
From an expanded panel of 121 kinases, T16 only partially inhibited one 
particular kinase; receptor interacting protein kinase (RIPK2). The kinase 
inhibition profile of T16 shows 51% inhibition of RIPK2 when used at 10µM and 
72% when used at 30µM. The highest level of inhibition other than that of RIPK2 
was observed in EPH-B2 (ephrin type-B receptor 2) at 10µM (~45%). However at 
the optimum concentration of T16 this inhibition was reduced to only 3%, 
suggesting that EPH-B2 inhibition is unlikely to be the cause of T16 mediated cell 
survival. All other kinases were inhibited by <30% when tested at the optimum 
concentration of 30µM (Figure 4.2).  
 Potential role of RIPK2 4.2.1.1
RIPK2 is a serine/threonine kinase with a caspase recruitment domain (CARD) 
present in the c-terminal domain of the protein. RIPK2 has been reported to 
promote apoptosis via interactions with mediators of apoptosis such as CLARP 
(caspase-like apoptosis-regulatory protein) downstream of the death receptor 
CD95 (Inohara et al, 1998; Inohara et al, 1997). Given that RIPK2 was the only 
kinase that showed any level of inhibition in response to T16, and that it has a 
reported pro-apoptotic activity, the potential role of this protein in hPSC was 
investigated. Firstly expression of RIPK2 in hPSC was confirmed by qRT-PCR 
analysis. Untreated control cells as well as T16 and Y27632 treated hPSC 
expressed mRNA for RIPK2 the level of which was maintained after 3 consecutive 
enzymatic passages supported by either T16 or Y27632 (figure 4.3A). Although 
there was an increase in mRNA in Y27632 treated cells at passage 2 this was not 
significantly higher than any other measurement and was reduced by passage 3. 
Furthermore there were no significant differences in mRNA expression between 
treatment types suggesting T16 does not transcriptionally upregulate expression 
of RIPK2.  
Efforts were made to confirm the expression of endogenous RIPK2 protein using 
antibodies against the unphosphorylated, inactive state as well as the 
phosphorylated (ser176) active state, however antibodies from 2 separate 
suppliers produced no signal.  
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Figure 4.2- Kinase profile of T16 at 10µM and 30µM. Kinase inhibition on 121 kinases was assayed using a radioactive filter-binding assay at the Dundee 
International Centre for Kinase Profiling. T16 had only minor effects on all but one of the kinases tested. Receptor Interacting Protein Kinase 2 (RIPK2) (circled in red), 
which was inhibited by 51% and 72% when T16 was used at 10µM or 30µM respectively. 
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RIPK2 has been documented to have key roles in cells of both the innate and 
adaptive immune systems and has been shown to exert its effect via downstream 
activation of NFκB signalling (Hasegawa et al, 2008). NFκB is activated by IκB 
kinase (IκK)-mediated release of the IκB inhibitory subunit, therefore inhibition 
of IκK and the resulting suppression of NFκB might recapitulate the effect of 
inhibiting RIPK2. If T16 mediates its effect via inhibition of RIPK2 and the 
downstream NFκB pathway, inhibition of IκK may recapitulate this effect. A 
potent inhibitor of IκK; TPCA-1 was therefore used either alone or in 
combination with T16 or Y27632 treated hPSC (as described in sections  2.2.1.2 
and 2.2.1.4) to test the effect on survival and to test whether inhibition of  NFκB 
signalling abrogates the effect of T16. Inhibition of NFκB signalling had no effect 
on hPSC survival, as untreated control cells (no survival compound) + TPCA-1 did 
not show significantly higher survival when compared to DMSO controls. Similarly 
the inclusion of TPCA with T16 or Y27632 did not ameliorate the increase in 
survival seen in response to either compound (P=<0.001). These data also show 
that inhibition of IκK, and thus NFκB activity, by TPCA-1 did not impact hPSC 
survival per se or the pro-survival effect of T16 or Y27632 (figure 4.3B).  
As inhibition of signalling events downstream of RIPK2 activation had no effect 
on hPSC survival, this suggests that inhibition of RIPK2 is not the mode of action 
of T16. Also as T16 only partially inhibited RIPK2 at the effective dose and given 
the paucity of available resources to target this pathway, further investigations 
were not pursued at this time. 
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Figure 4.3- qRT-PCR analysis of RIPK2 and downstream signalling inhibition. Cells (H1 
hESC) treated with T16, Y27632 as well as untreated control cells were analysed for expression of 
RIPK2. RNA was isolated from cells at the point of passage (after the various treatments). Cells 
show steady expression independent of treatment type or length (A). Cells were treated with 10µM 
of the potent IκK inhibitor TPCA-1 in the presence or absence of T16 or Y27632. Inhibition of IκK 
had no effect on cell survival, with untreated control cells + TPCA-1 showing no significant increase 
in cell survival compared to the untreated control. There was no significant difference in cell 
survival in T16 or Y27632 treated ± TPCA-1. T16 and Y27632 treated cells ± TPCA-1 had 
significantly higher cell survival than Untreated ± TPCA-1 (P=<0.001). Data shown as mean values 
± SEM, n=3. 
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4.2.2 T16 does not inhibit the hyperphosphorylation of myosin 
light chain 
It has been suggested that the cause of dissociation induced apoptosis of hPSC is 
the hyperphosphorylation of myosin light chain (MLC) and that the protective 
activity of Y27632 is to prevent this phosphorylation (Chen et al, 2010; Ohgushi 
et al, 2010 and Walker et al, 2010), therefore western blot analysis was 
performed to test whether T16 shares this biochemical effect. The data shown in 
figure 4.4 show that as expected the untreated cells had significantly higher 
levels of pMLC 15mins post-dissociation and that Y27632 blocked the increase 
(P=<0.01), however cells treated with T16 showed high levels of pMLC equivalent 
to those in untreated cells (P=>0.05). The higher levels of pMLC were maintained 
in untreated and T16 treated cells compared to Y27632 treated cells at later 
time points with T16 vs Y27632 being significantly different at 30mins (P=<0.05), 
45mins (P=<0.05) and 1hr (P=<0.05). Although untreated cells did not reach 
significance versus Y27632 treated cells at these subsequent time points, the 
trend was towards increased levels of pMLC in untreated hPSC. 
These data from untreated and Y27632 treated cells are consistent with those 
observed by others (Chen et al, 2010; Ohgushi et al, 2010), confirming that in 
response to dissociation there is a sudden increase in phosphorylated MLC and 
that treatment with Y27632 is able to prevent this hyperphosphorylation. 
Importantly though, treatment with T16 did not inhibit the phosphorylation of 
MLC strongly suggesting that T16 does not share the same mechanistic 
downstream target reported for Y27632. These findings also clearly uncouple the 
inhibition of MLC hyperphosphorylation and hPSC cell survival supporting the 
hypothesis that there is an additional novel pro-survival pathway in these cells 
that may be elucidated using T16. 
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Figure 4.4- Analysis of levels of pMLC after treatment and dissociation of hPSC. Protein 
samples were taken from cells (NMF-iPS6) that were treated with T16, Y27632 or had no treatment 
(control) before being dissociated. Samples were harvested 15mins, 30mins, 45mins, 1hr, 2hr and 
4hr post dissociation. Western blot analysis was performed. (A) Shows representative immunoblots 
for pMLC and α-tubulin. (B) Expression of pMLC relative to α-tubulin analysed via densitometry. 
Both T16 treated and untreated cells had significantly higher levels of pMLC 15mins post 
dissociation when compared to Y27632 treated cells (P=<0.001 and P=<0.01 respectively). T16 
treated cells had significantly higher levels of pMLC when compared to Y27632 treated cells after 
30mins (P=<0.05), 45mins (P=<0.05) and 1hr (P=<0.001). Data shown as mean ± SEM, n=3. 
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4.2.3 T16 does not inhibit RhoA, the upstream regulator of ROCK 
Although it has been shown that T16 does not inhibit ROCK, it was possible that 
T16 was mediating survival by targeting the same pathway but acting upstream 
of ROCK. ROCK is a key effector of the small GTPase RhoA, therefore 
experiments were undertaken to test whether T16 inhibited RhoA activation. G-
LISA assays, which measure levels of GTP bound (active) RhoA, were performed 
as described in section 2.4.6 with the percentage of GTP bound RhoA obtained 
by expressing the relative luminescence unit (RLU) value of samples relative to 
the RLU value of the RhoA control sample.  
It has been reported by others (Ohgushi et al, 2010) that in response to 
dissociation there is a sudden increase in levels of GTP bound RhoA in hPSC. In 
order to validate the assay, untreated (DMSO only) hPSC were analysed alongside 
cells treated with the RhoA activator LPA and the RhoA inhibitor C3 (24hr pre-
treatment). Cells were lysed directly on the plate to determine basal levels of 
GTP bound RhoA (0min), or dissociated and replated onto fibronectin coated 
plates for 30minuts before being harvested. As expected, there was a significant 
increase in GTP bound RhoA in untreated cells 30mins post dissociation when 
compared to the 0min samples (p=<0.05). Inhibition of RhoA with C3 prevented 
any significant rise in GTP bound RhoA 30minutes post dissociation compared to 
the 0min sample (P=>0.05), and LPA effectively induced RhoA activation with 
0min samples having significantly higher levels of GTP bound RhoA (P=<0.05) 
than those treated with C3 or DMSO alone (figure 4.5A).  
Having validated the assay, the effect on T16 and Y27632 treatment on GTP 
activation was investigated using both hiPSC and the hESC line H1. The 
experiment was performed as above with samples being harvested at 0mins, 
15mins, 30mins and 45mins post dissociation. 
When hiPSC were used, all three conditions had similar baseline levels of active 
RhoA prior to dissociation (0mins). Furthermore, all treatment types resulted in 
a general trend towards increased RhoA activity after dissociation. T16 and 
untreated cells had significantly increased levels of GTP bound RhoA 15mins, 
30mins and 45mins post dissociation when compared to the time 0 sample 
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(P=<0.05) (figure 4.5B), with Y27632 treated cells similarly showing increased 
levels of GTP bound RhoA at each time point, although only reaching significance 
at 30mins and 45mins when compared to the time 0 samples (P=<0.05).  
The repeated experiment with hESC showed a similar pattern to that seen in 
hiPSC, with samples 30mins and 45mins post dissociation having significantly 
higher levels of GTP bound RhoA versus the time 0 samples regardless of 
treatment (P=<0.05) (figure 4.5C). The similarity between cell types suggests 
that this response is not cell type specific and therefore likely to be biologically 
relevant.  
These data are consistent with the literature, confirming that dissociation 
resulted in a sudden increase in GTP bound RhoA in hPSC. However, these 
findings expand on this and demonstrate that treatment with either T16 or 
Y27632 is unable to prevent this activation. These data support the hypothesis 
that T16 does not mediate its effect by inhibiting RhoA activation, and provides 
further evidence that there is a RhoA/ROCK independent mechanism of hPSC 
survival. 
  
Figure 4.5- Continued overleaf 
 
 
 
 
124 
 
 
 
 
 
 
 
Figure 4.5- Levels of GTP bound RhoA in response to dissociation. G-LISA assays were 
performed on hPSC to assess the levels of GTP bound RhoA in response to dissociation. (A) 
Untreated control cells and the RhoA activator LPA and inhibitor C3 were used to validate the 
assay. Dissociation of untreated cells led to an increase in GTP bound RhoA when compared to 
the 0min samples (P=<0.05). The assay confirmed the capacity of C3 and LPA to inhibit and 
induce RhoA activation respectively. (B) Treatment with either survival compound was unable to 
prevent the increased activation of RhoA in hiPSC (NMF-iPS6) in response to dissociation, with 
increased GTP bound RhoA being observed 15, 30 and 45mins post dissociation in T16 treated 
cells (P=<0.05), and 30 and 45mins post dissociation in Y27632 treated cells (P=<0.05) when 
compared to time 0 samples. (C) Similarly, in the hESC line H1 there was a significant increase in 
GTP bound RhoA regardless of treatment type in 30min and 45min post dissociation samples 
compared to time 0 samples (P=<0.05). 
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 Inhibition or forced activation of RhoA has no effect on T16 mediated 4.2.3.1
cell survival. 
Having shown that the RhoA inhibitor C3 and activator LPA, have the expected 
effect on RhoA activation status, (figure 4.5A), the effect on cell survival when 
used on hiPSC either alone or in combination with T16 was investigated. Cells 
were treated as described previously, with the inclusion of LPA and C3 at the 
same point as T16 (24 hours prior to dissociation) to maximise the effect. Cells 
were dissociated and replated in the presence of T16 ± C3 or LPA and cell 
survival was assessed 24 hours post dissociation. As expected, treatment with C3 
alone leads to significantly increased cell survival versus untreated control cells 
(P=<0.001) (figure 4.6A). This can be attributed to its downstream effect on 
ROCK activation (inhibition of RhoA leads to a decrease in activation of ROCK 
which subsequently leads to a decrease in myosin hyperphosphorylation). The 
addition of C3 to T16 treated hPSC had no effect on cell survival which might be 
expected since both treatments appear to have beneficial effect on cell survival.  
Further experimentation utilised the RhoA activator LPA and showed that 
treatment of hPSC with 5µM, 10µM or 20µM of LPA alone had no effect on cell 
survival (figure 4.6B), with all doses of LPA resulting in similar levels of survival 
to those seen in untreated cells. Also, when LPA was used in combination with 
T16 or Y27632, there was no effect on the pro-survival effect of either molecule 
(P=>0.05) at any dose of LPA. 
These data suggests that T16 is able to support hPSC survival even in the 
presence of active RhoA which further supports a non RhoA dependent 
mechanism of survival. 
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Figure 4.6- Effect of C3 and LPA treatment on survival. (A) HiPSC (NMF-iPS6) were treated 
with T16, Y27632, C3, C3 + T16 or left untreated, before being dissociated and replated. Survival 
was assayed 24hrs post passage. C3 treatment alone was sufficient to significantly increase cell 
survival compared to untreated control cells (P=<0.001). (B) A combination of T16 and C3 
treatments had no significant effect on hiPSC survival. T16, Y27632 or untreated hiPSC were used 
in combination with various concentrations of the RhoA activator LPA. LPA treatment had no 
significant effect on the cell survival produced by any of the treatments, with untreated samples 
regardless of LPA concentrations, producing significantly lower cell survival (P=<0.001). Data 
shown as mean cell survival ± SEM, n=3.   
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4.2.4 T16 and Y27632 do not produce an additive effect 
If T16 and Y27632 were targeting the same survival mechanism, it might be 
expected that using a sub-optimal concentration of either in combination would 
produce the optimal survival effect. However, this was not the case, when used 
together there was no additive effect on cell survival (figure 4.7). As expected, 
a 10µM treatment with Y27632 or 30µM T16 alone produced cell survival above 
60%; a similar result was seen when these 2 doses were used in combination. 
Suboptimal concentrations (5µM Y27632 or 20µM T16) of either inhibitor resulted 
in survival figures greater than that of the untreated control, but still lower than 
those with the full treatment. Importantly however, the combination of low 
concentrations (2µM Y27632 or 10µM T16) of both, also resulted in survival of 
less than 30%. This apparent lack of an additive effect suggests that these 
survival compounds are not inhibitors of the same target kinase or pathway 
(ROCK for example). It is interesting to note that when used in excess (30µM) 
Y27632 treatment results in cytotoxicity. If T16 was targeting the same kinase as 
Y27632 it would be expected that full treatments of T16 and Y27632 (30µM and 
10µM respectively) would also result in cytotoxicity, however this is not the 
case. This further suggests that T16 is not targeting the ROCK signalling 
pathway.  
 
Figure 4.7-T16 and Y27632 used in combination. H1 (hESC) cells were treated in combination 
with various concentrations of T16 and Y27632 before being enzymatically passaged to determine 
if there was any additive between the survival compounds. Cells that had no survival compound, or 
with only 2µM Y27632 had cell survival of <30% as expected. Similarly, cells with 30µM T16 or 
10µM Y27632 had >60% cell survival. Cells with sub-optimal concentrations of either compound 
had cell survival between 30-60%, even when used in combination. The high concentration of 
Y27632 impacted negatively on cell survival, which was <30%. Data shown as the mean survival, 
n=3.   
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4.2.5 T16 treatment does not result in the activation of Rac1 
signalling 
It has been reported that forced expression of GTP bound Rac1 could to protect 
hPSC from dissociation induced apoptosis (Ohgushi et al, 2010). Therefore, 
another potential mechanism through which T16 might act on the 
RhoA/ROCK/MLC axis is via the switch from high RhoA activity to high Rac1 
activity.  In order to analyse the levels of GTP bound Rac1 in response to 
dissociation, and to investigate if treatment with T16 alters this, an affinity 
bead based assay that specifically detected only GTP bound Rac1 was performed 
as described in section 2.4.5. The activation level of Rac1 was assayed 15mins, 
30mins, 45mins, 2hrs and 8hrs post dissociation. Basal levels of GTP bound Rac1 
was determined by lysing cells directly on the culture dish (not dissociated). 
Figure 4.8A shows representative immunoblots produced by western blotting. 
The data shows that levels of GTP bound Rac1 were unchanged between 
treatment types, with no significant differences observed at any of the time 
points analysed. All samples show some expression of GTP bound Rac1, with 
there being a general trend (although not significant) towards decreased activity 
in the final time point (figure 4.8B). This data suggests that treatment with T16 
does not mediate its pro-survival effect by increasing the levels of GTP bound 
Rac1 and also shows that Y27632 treatment does not result in increased activity 
of Rac1 via antagonism of RhoA as reported in other cell types (Tang et al, 
2012).    
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Figure 4.8- Levels of GTP bound Rac1 in response to dissociation. HiPSC (NMF-iPS6) were 
treated with T16, Y27632 or left untreated before being dissociated and harvested after 15mins, 
30mins, 45mins, 2hrs and 8hrs. Samples were analysed for GTP bound Rac1 using Rac1 
activation assay. Representative immunoblots produced show levels of GTP bound Rac1, total 
Rac1 and the loading control α-tubulin (A). Densitometry analysis of GTP bound Rac1 relative to 
total Rac1 expression (B). Data shown as mean values ± SEM, n=3. 
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4.2.6 T16 and Y27632 treated hPSC exhibit distinct morphologies 
Upon replating, hPSC treated with the Rho kinase inhibitor Y27632 exhibited a 
very characteristic morphology. The cells appeared less well spread and had 
numerous spindle like projections when compared to untreated control cells. 
Notably, T16 treated cells did not exhibit this morphology, instead, they more 
closely resembled the untreated control cells. This can be seen in the phase 
contrast images below (figure 4.9). Untreated as well as T16 and Y27632 treated 
hPSC were enzymatically passaged as described previously and images taken 
24hrs post passage. 
The clearly identifiable differences in morphology between T16 and Y27632 
treated cells is further evidence of discrete intracellular targets. The 
morphological difference is likely caused directly by ROCK inhibition in the 
Y27632 treated cells and downstream modification of cytoskeletal structure due 
to the established role of ROCK in regulation of the actin cytoskeleton, an 
activity that does not seem to be shared by T16.    
 
Figure 4.9- Distinct morphologies of T16 and Y27632 treated cells. HiPSC (NMF-iPS6) treated 
with T16, Y27632 or untreated control cells were passaged enzymatically and imaged under phase 
contrast microscopy 24hrs post passage. Scale bars represent 50µm.   
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4.2.7 Inhibition of the RhoA/ROCK/MLC axis is the cause of the 
spindle like phenotype 
The prevention of the hyperphosphorylation of MLC has been reported as the 
cause of dissociation induced apoptosis of hPSC. As well as Y27632 mediated 
ROCK inhibition, the inhibitor blebbistatin has been shown to promote cell 
survival equivalent to that seen with Y27632 (Walker et al, 2010). Blebbistatin is 
a selective myosin II inhibitor which is also able to prevent the actinmyosin 
induced contractility reported to result in apoptosis of hPSC. To further 
investigate this characteristic morphology post dissociation in response to these 
established survival molecules, phase microscopy and immunocytochemistry 
were employed, with the FITC conjugated phallotoxin phalloidin used to image 
the F-actin within the cells.  
Blebbistatin treated cells exhibit the same morphology as Y27632 treated cells 
(figure 4.10 c, h and m) and furthermore, inhibition of RhoA activation by C3 
also results in this characteristic spikey morphology (figure 4.10 b, g and l). Only 
untreated (figure 4.10 e, j and o) and T16 treated cells (figure 4.10 a, f and k) 
exhibit a well spread morphology with well organised F-actin rich structures. 
As hPSC treated with Y27632, Blebbistatin or C3 all exhibit this characteristic 
morphology, it is likely that the cause of this is the inhibition of downstream 
actinmyosin based contractility. Although the images shown in figure 4.10 were 
produced using hiPSC, these are representative of that observed with other hPSC 
lines such as H1, H9 and RC9.These findings are further evidence that T16 does 
not mediate its pro-survival effect via inhibition of the RhoA/ROCK/MLC axis, as 
treated cells do not exert the morphology associated with other inhibitors of this 
pathway. 
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Figure 4.10- Morphological differences of T16 treated hPSC with alternative survival compounds. HiPSC (NMF-iPS6)) treated with T16 (a, f and k), C3 (b, g and 
l), Blebbistatin c, h and m), Y27632 (d, I and n) or untreated (e, j and o) were passaged enzymatically and were imaged by phase microscopy 24hr post passage 
before being fixed and stained with phalloidin (green) to target F-actin, and the nuclear stain DAPI (blue). The top row (a-e) shows 40X phase contrast microscopy 
images. The centre (f-j) and bottom (k-o) rows show immunofluorescence images at 4X and 40X magnifications. Scale bars represent 50µm on the top and bottom 
rows and 100µm in the centre row. 
133 
 
4.2.8 Survival of T16 treated cells is adhesion dependent.  
During the original characterisation of Y27632, Watanabe et al (2007), described 
that in the absence of a suitable ECM or in non-adherent culture conditions, 
hPSC treated with Y27632 re-aggregate to form cell clusters in suspension. In 
order to test if this phenomena is observed after T16 treatment, hPSC were 
dissociated and replated in culture dishes which had no ECM coating, and could 
therefore not support attachment, and the formation of cell aggregates was 
assessed. To determine cell survival in response to this suspension culture, 
apoptosis assays were performed 24hr post dissociation as described in section 
2.5.1. Phase microscopy images of hPSC 24hr post dissociation are shown in 
figure 4.11A. Only cells treated with Y27632 were able to form cell aggregates, 
with T16 treated and untreated cells remaining in single cell suspension. As 
observed by Krawetz et al (2009), the use of the calcium chelator EGTA (0.5mM) 
prevented Y27632 treated cells from forming cell aggregates (figure 4.11A).  
Figure 4.11B shows representative flow cytometry plots showing that in the 
absence of a suitable ECM, T16 treatment is insufficient to prevent apoptosis, 
with 79.9% of cells being late apoptotic after 24hrs in suspension culture. 
Similarly, 85.4% of untreated cells are positive for both annexin V and propidium 
iodide and are therefore also late apoptotic. The formation of EB like clusters in 
response to Y27632 treatment prevented apoptosis in suspension culture with 
only 18.7% of cells being late apoptotic, however prevention of cell-cell 
adhesion by EGTA diminished the pro-survival effect of Y27632 treatment, with 
85.4% of Y27632 + EGTA cells being late apoptotic (figure 4.12B).  
The mean percentage of late apoptotic cells shows that there was a significant 
increase (p=<0.001) in survival of cells in suspension culture with Y27632 when 
compared T16, untreated or Y27632 + EGTA treated cell (figure 4.11C). This data 
shows a clear difference between drug treatments in response to suspension 
culture, which suggests a novel adhesion dependent mechanism of action for 
T16. These data are in agreement with that reported by others (Krawetz et al, 
2009) also highlighted the importance of cell-matrix or cell-cell adhesion in the 
survival mechanism of Y27632, as if these adhesions are prevented, ROCK 
inhibition alone is insufficient to support hPSC survival despite the inhibition of 
pMLC.     
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Figure 4.11- Continued overleaf 
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Figure 4.11- Response to suspension culture. Untreated, T16, Y27632 or Y27632 + EGTA 
treated hPSC (h1 hESC) were enzymatically passaged and replated in the absence of a suitable 
ECM. (A) Phase microscopy images (x4) show only hPSC treated with Y27632 alone were able to 
form cell aggregates resembling embryoid bodies. (B) Untreated, T16 and Y27632 + EGTA treated 
cells are >70% late apoptotic, staining positive for both annexin V and propidium iodide, whereas 
<20% of Y27632 treated cells are double positive. (C) Mean % of late apoptotic cells ± SEM (n=3) 
after the various treatment types. Treatment with Y27632 resulted in significantly reduced 
percentage of late apoptotic hPSC when compared to all other conditions (P=<0.001).  
 
. 
4.2.9 Rac1 activity is essential for adherence of hPSC post 
dissociation 
As discussed earlier, the small GTPase Rac1 is a key component of the 
RhoA/ROCK/MLC axis and is often antagonistic to RhoA (Tang et al, 2012). Active 
GTP bound Rac1 has been shown to be a key component of cellular adhesion 
dynamics in a number of cell types, as well as being shown to have a protective 
effect on dissociated hPSC (Ohgushi et al, 2010), so to further investigate the 
role of Rac1 in hPSC attachment post dissociation, the Rac1 inhibitor NSC23766 
was used. NSC23766 works by potent inhibition of Rac1 interaction with the Rac1 
specific GEFs Tiam1 and Trio. Untreated, T16 and Y27632 treated cells (hiPSC) 
were enzymatically passaged in the presence or absence of various 
concentrations of NSC23766. Rac1 activity appears to be critical in the 
attachment and subsequent survival of hPSC, with concentrations of 50µM, 
70µM, 100µM and 200µM NSC23766 all resulting in significantly reduction in the 
survival effect of T16 and Y27632 (P=<0.05 at 50µM, and P=<0.001 at 70µM, 
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100µM and 200µM). Additionally, NSC23766 when used at 70µM, 100µM and 
200µM also significantly reduced the survival of control cells that had not 
received survival molecules (P=<0.05) (figure 4.12B). This observed decrease in 
survival was dose dependent and was unlikely to be a result of toxicity caused by 
NSC23766 as the inhibitor was incubated with the cells for 24hrs prior to 
dissociation without any adverse effects even at the highest concentration of 
200µM, shown by healthy, normal monolayer of cells as imaged by phase 
microscopy (Figure 4.12A a, b and c).  
Previous data has shown that in the absence of cell-ECM adhesion, Y27632 
treated cells are dependent on cell-cell adhesion to promote survival (figure 
4.11). Surprisingly, in the presence of NSC23766, Y27632 treated cells were 
prevented from forming both cell-ECM and cell-cell adhesions and remained in 
single cell suspension (figure 4.12 b and e). 
These data confirm the critical importance of Rac1 mediated adhesion signalling 
in promoting the survival of hPSC, and also highlight an important role for Rac1 
in forming cell-cell adhesions in Y27632 treated cells.  
 
 
Figure 4.12 –continued overleaf
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Figure 4.12- Active Rac1 is essential for hPSC attachment post passage. Phase microscopy images of hiPSC (NMF-iPS6) taken after 24hr incubation with 200µM 
Rac1 inhibitor NSC23766, showing no adverse effect on cell morphology or attachment (a,b and c). Phase microscopy images of T16, Y27632 and untreated hPSC in 
the presence of 200µM NSC23766, taken 24hr post dissociation (d, e and f) (A). Untreated cells and cells treated with T16 or Y27632 were enzymatically passaged in 
the presence or absence of various concentrations of the NSC23766 (B). A concentration of 50µM resulted in decrease in cell survival in T16 and Y27632 treated cells 
compared to the control cells with no NSC23766 (P=<0.05). Treatments of 70µM, 100µM and 200µM lead to decreased cell survival in T16 and Y27632 treated cells 
compared to the control cells with no NSC23766 (P=<0.001). Untreated control cells in the presence of NSC23766 resulted in decreased cell survival when compared 
to untreated control cells when used at a concentration of 70µM, 100µM and 200µM. Data shown as mean survival ±SEM , n=3.  
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4.3 Summary 
Presented within this chapter are data that further characterise the pro-survival 
compound T16. An in vitro kinase assay showed that that T16 has very little 
effect on kinase activity, with RIPK2 the only kinase showing any degree of 
inhibition (72% inhibition at 30uM T16). The potential role of RIPK2 has been 
investigated using potent inhibitor of the downstream signalling complex NFκB, 
although endogenous RIPK2 protein expression could not be confirmed due to a 
paucity of reagents. Potential upstream or downstream modification of the RhoA 
signalling pathway by T16 was further investigated using western blots, RhoA and 
Rac1 activation assays and a combination of ICC and phase microscopy. 
Collectively these experiments have shown that T16 does not inhibit RhoA 
activation nor does it interfere with the activation state of Rac1 in response to 
dissociation. Furthermore T16 does not lead to a reduction in levels of 
phosphorylated MLC2, which is the previously published mode of action for 
Y27632, and the only mechanism by which hPSC avoid dissociation induced cell 
death that has been reported to date. Morphological studies showed distinct 
phenotypes in response to the different small molecules, with inhibition of 
actinmyosin induced contractility being strongly linked to the characteristic 
spikey morphology of Y27632 treated cells. Apoptosis assays demonstrated that 
the T16 mediated survival of disaggregated hPSC is dependent upon the 
reattachment of hPSC and may therefore be orchestrated by adhesion related 
proteins such as integrins. In addition, these data have highlighted an 
undescribed but critical role for Rac1 in mediating adhesion of both T16 and 
Y27632 treated hPSC to the ECM (and cell-cell in Y27632 treated cells). The data 
presented within this chapter provide strong evidence that T16 mediates is pro-
survival effect via a novel RhoA/ROCK/MLC independent mechanism that is 
dependent upon cell-ECM adhesion. 
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5 T16 pathway analysis: T16 supports hPSC 
survival through an adhesion and Src-kinase 
dependent mechanism 
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5.1 General introduction 
The body of data presented within chapters 3 and 4 shows that, despite 
promoting survival of disaggregated hPSC as efficiently as the commonly used 
ROCK inhibitor Y27632, T16 does not inhibit ROCK and has no effect on upstream 
regulators (RhoA and Rac1) or downstream mediators (MLC) of ROCK activity. 
This therefore suggests that T16 mediates its pro-survival effect in a 
RhoA/ROCK/MLC independent manner.  
The survival effect of T16 has been shown to be dependent on signalling 
mediated by adhesion to the ECM, as in the absence of a suitable ECM, hPSC 
treated with T16 are still vulnerable to dissociation induced apoptosis. 
Experimentation was undertaken to further investigate the adhesion dependent 
survival mechanism mediated by T16. 
The aims of these studies were to: 
 Determine if treatment with T16 alters the expression of key mediators of 
cell adhesion either transcriptionally or at the protein level. 
 Identify pathways of interest via kinase inhibition studies. 
 Further investigate any pathways identified as potential mediators of the 
pro-survival effect of T16.  
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5.2 T16 treatment does not alter expression at the 
transcriptional level of a panel of adhesion related 
genes 
Given that the pro-survival effect mediated by T16 has been shown to be 
dependent upon the reformation of cellular adhesions, expression of a panel of 
common adhesion related genes was examined via qRT-PCR. This gene list was 
chosen to include cell-cell and cell-matrix associated genes, as well as genes 
involved in scaffolding, focal adhesion complexes and downstream adhesion 
signalling. HPSC (hiPSC) were treated with T16, Y27632 or given no treatment 
before being lysed on the plate. RNA was harvested, cDNA produced as described 
in sections 2.3.1 to 2.3.3 and analysis performed using TLDA cards on the 7900 
HT Fast Real-Time PCR System as describes in section 2.3.4. This method of 
quantification uses the ΔCt value to calculate a 2
ΔCt x 1000 value which is plotted 
on graphs. Using this this method, a relatively high 2ΔCt x 1000 of 400, would be 
indicative of a signal being detected within 1 cycle of the housekeeper, whereas 
a value of less than 0.1 would result from a signal being detected more than 15 
cycles after the housekeeper. This method is particularly useful to give an 
indication of the absolute level of expression and relative quantification when 
an appropriate denominator is not available for the 2-ΔΔCT method, for example 
when a gene is not expressed in the control undifferentiated cells but is induced 
by treatment and therefore comparing expression would result in an infinite fold 
increase. 
5.2.1 Transcriptional analysis of Integrin expression 
Integrins are a very well characterised family of transmembrane proteins that 
play a central role in cell-matrix based adhesions. Integrins consist of both α and 
β subunits and are major components of many signal transductions pathways, 
functioning both as ‘inside-out’ and ‘outside-in’ signalling proteins (Hu and Luo, 
2012). Although there is a range of α-integrin subunits expressed in hPSC, there 
were no significant differences in expression in response to treatment type 
(figure 5.1A). ITGA6 (integrin α6) was the most highly expressed of the α-
subunits, and although the difference did not reach significance, there was a 
trend towards increased expression in cells treated with T16. ITGA8 (integrin α8) 
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and ITGAL (integrin αL) were also included in the analysis, however there was no 
detectable expression of these subunits (up to 40 cycles). Analysis of the β-
integrin subunits analysed showed that there was no detectable expression of β2 
or β3 integrins, and, as with the α-subunits, treatment with T16 or Y27632 did 
not induce any significant difference in the expression of β-subunits (figure 
5.1B). These data demonstrate that at the transcriptional level, treatment with 
T16 did not alter the expression of either α or β integrin subunits.  
 
 
 
 
Figure 5.1- Transcriptional analysis of integrin expression. RNA was isolated from untreated, 
T16 or Y27632 treated hiPSC (NMF-iPS6) and analysed for integrin expression via qRT-PCR. (A) 
Shows there are a number of sub-units expressed, but that there were no significant differences in 
α-integrin expression between drug treatments and (B) shows no differences in β-integrin subunit 
expression. Data shown as mean 2
ΔCt
 x1000 ± SEM, n=3 in triplicate.  
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5.2.2 Transcriptional analysis of cadherin related proteins 
The cadherin family of proteins are involved in homotypic cell-cell adhesions and 
have a number of intracellular binding partners associated with their function, 
including β-catenin. Cadherins are known to play critical roles in signalling 
pathways mediated by GTPases such as Rac1 and RhoA (Wheelok and Johnson, 
2003).  In particular, CDH1 (E-cadherin) has been implicated in hPSC cell-cell 
adhesion (Ohgushi et al, 2010). PSC were found to have  substantial expression 
of CDH1, CDH2 (N-cadherin) and CTNNB1 (β-catenin) with CDH1 and CTNNB1 
being  more highly expressed than CDH2, however there were no significant 
differences in expression in response to the small molecule survival factors 
(figure 5.2).  
 
 
Figure 5.2- Transcriptional analysis of cadherin related proteins. RNA was isolated from 
untreated, T16 or Y27632 treated hiPSC (NMF-iPS6) and analysed for CDH1 (E-cadherin), CDH2 
(N-cadherin) and CTNNB1 (β-catenin) expression via qRT-PCR. CDH1 was the most highly 
expressed gene, however there were no significant differences in CDH1, CDH2 or CTNNB1 
expression over the three treatment types. Data shown as the mean 2
ΔCt
 x1000 ± SEM, n=3 in 
triplicate.  
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5.2.3 Transcriptional analysis of extracellular matrix related 
proteins 
Expression of a range of the ECM related collagens and laminins was also 
analysed. Again, although there were detectable levels of many ECM related 
proteins (Figure 5.3), there were no significant differences between treatments 
in any of these genes. The most highly expressed ECM related genes were 
LAMA1, LAMB1 and LAMB2 (laminin α1, β1 and β2 subunits) (figure 5.3). This 
analysis also included the ECM proteins fibronectin and vitronectin, however 
there was no detectable expression of either of these matrix components. 
 
 
Figure 5.3- Transcriptional analysis of ECM proteins. RNA was isolated from untreated, T16 or 
Y27632 treated hiPSC (NMF-iPS6) and analysed for expression of genes associated with ECM 
proteins. Although there was expression in a number of these genes, there were no significant 
differences between drug treatments. Data shown as the mean 2
ΔCt
 x1000 ± SEM, n=3 in triplicate. 
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5.2.4 Transcriptional analysis of focal adhesion related proteins 
As cell adhesion seems to play a critical role in survival, expression of key 
components of focal adhesion complexes such as PTK2 (FAK), VCL (vinculin), PXN 
(paxillin) and members of the Src-family of tyrosine kinases were also analysed. 
Figure 5.4A shows that each of the genes relating to focal adhesions were highly 
expressed in hPSC, however there were no significant differences after 
treatment with either pro-survival compound. There was also detectable 
expression of each of the Src-family kinases tested, Src, Fyn and Lyn (Figure 
5.4B), with Fyn showing the highest level of expression of those family members 
that were analysed.  As seen with the integrins and other adhesion molecules 
there were no significant difference in expression between treatment groups.  
5.2.5 Connexin 43 and RACK1 were the most highly expressed 
adhesion related genes tested 
From the analysis of this expanded panel of adhesion related genes, the gap 
junction protein GJA1 (connexion 43) and GNB2L1 (receptor of activated protein 
kinase C or RACK1) were the most readily detected, having a 2ΔCt x1000 value of 
at least 3-fold greater than any other gene analysed. However, as with other 
genes analysed, there were no significant differences in the expression of these 
genes between treatments used (Figure 5.5). 
The data presented in sections 5.2.1 through 5.2.5 show that at the 
transcriptional level, treatment with T16 or Y27632 does not significantly up-
regulate or down-regulate the expression of any target in this extended panel of 
adhesion related genes. However, these data also provide more insight into the 
expression of adhesion related genes that are expressed by hPSC maintained in 
feeder-free culture conditions and highlight connexin 43 and RACK1 as extremely 
highly expressed genes in hPSC.  
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Figure 5.4-Transcriptional analysis of focal adhesion related proteins and Src-family 
kinases. RNA was isolated from untreated, T16 or Y27632 treated hiPSC and analysed for 
expression of genes associated with focal adhesions (A) or Src-family kinases (B). Although there 
was expression in each of these genes, there were no significant differences between drug 
treatments. Data shown as the mean 2
ΔCt
 x1000 ± SEM, n=3 in triplicate. 
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Figure 5.5- Expression of RACK1 and connexin 43. RNA was isolated from untreated, T16 or 
Y27632 treated hiPSC and analysed for expression of genes associated with cell adhesion. Of this 
panel of genes, connexion 43 (GJA1) and RACK1 (GNB2L1) had the highest expression, however 
there was no significant difference in expression between treatment types.  
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5.3 T16 treatment does not alter the expression of 
integrin proteins 
Although T16 and Y27632 did not induce any change in the expression level of 
integrins at the transcriptional level, it was not clear whether there were any 
differences at the protein level. As it well established that the abundance of 
integrins at the cell surface can be regulated by recycling via endocytosis (as 
reviewed by Caswell et al (2009)), rather than by transcriptional control, it was 
particularly important to assess protein expression. It was possible that 
treatment with T16 or Y27632 prevented this internalisation and could thereby 
result in increased adhesion (and survival). Flow cytometry was employed to 
confirm the expression of integrin proteins at the cell surface and to determine 
if there were any differences in response to T16 treatment.  SSEA4 was used as a 
control to confirm that the cells were pluripotent at the point of analysis. 
Untreated as well as T16 and Y27632 treated hPSC (hiPSC) were enzymatically 
dissociated and either analysed immediately, or left in suspension culture for 
2hours then analysed. Greater than 95% of hPSC expressed the integrins β1, α2 
and α6 (figure 5.6A) regardless of treatment type. Additionally, >80% of hPSC 
had expression of integrin αV and 40-50% of cells expressed integrin α5. As seen 
in mRNA analyses, there was no significant difference in integrin expression 
between control and treated cells. Integrins β2, β5 and α4 were all expressed on 
fewer than 10% of cells in any condition. 
As integrin internalisation and recycling may have altered the amount of protein 
expressed per cell rather than the % of cells that are positive, the mean 
fluorescent Index (MFI) for was also calculated for each sample.  As illustrated in 
Figure 5.6B, using Integrin α6 as an example, no differences were observed in 
the MFI in any condition.   
These data confirm that untreated hPSC do not internalise integrins (at least 
within the 2hr time frame used in this experiment) as there were no differences 
in the density of integrins detected at the cell surface, or in the % of cells 
expressing the integrin,  after 2hrs in suspension culture (figure 5.6). These data 
therefore demonstrate that T16 does not mediate survival by up-regulating 
integrin expression or by preventing integrin internalisation upon dissociation. 
149 
 
 
 
Figure 5.6- continued overleaf
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Figure 5.6- Changes in integrin expression between drug treatment and time post 
dissociation. HiPSC were treated with T16, Y27632 or left untreated before being dissociated and 
analysed by flow cytometry for expression of integrins. Cells were analysed immediately after 
dissociation and after a 2hr incubation under suspension culture conditions. SSEA4 was included 
to confirm the cells were pluripotent at the point of analysis. There were no significant differences in 
integrin expression between treatments or between time points (A). Histograms with MFI showing 
no difference in the amount of integrin α6 expressed in response to each treatment (B). Data 
shown as mean % of positive cells ±SEM, n=3. 
 
5.3.1 Expression of integrins differ between hiPSC and hESC 
Given the different methods by which hiPSC and hESC are obtained and initially 
cultured, it was possible that there would be a difference in the expression 
levels of integrins between these different cell types. To see if this was the 
case, hESC (H1) were compared to hiPSC for integrin expression as described 
above. Figure 5.7 shows that integrin expression between H1 and hiPSC was 
consistent for all integrins chains except integrin α5, with significantly fewer 
cells expressing integrin α5 in hiPSC (p=<0.001) despite the cells being 
maintained in similar feeder-free culture conditions for >10 passages before 
analysis.  
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Figure 5.7- Integrin expression comparison between cell lines. H1 and hiPSC (NMF-iPS6) cells were analysed by flow cytometry to determine if there 
were differences in the expression of integrins. It can be seen that the expression of all integrins with the exception of integrin α5 have consistent expression 
between lines. Integrin α5 has significantly lower expression in hiPSC when compared to H1 cells (P=<0.001). SSEA4 was included to confirm the cells were 
pluripotent at the point of analysis. Data shown as the mean % of positive cells ± SEM, n=3. 
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5.4 Inhibition of potential pathways involved in survival 
highlights a role for Src kinase 
Having shown that, despite its clear effect on cell-matrix adhesion, T16 does not 
appear to up regulate the expression of the adhesion related integrin proteins at 
either the mRNA or protein level, potential downstream signalling events were 
investigated. HPSC were pre-treated with T16 or Y27632 as previously described, 
and the survival factors were used in combination with a number of kinase 
inhibitors to test whether any of the inhibitors supported PSC survival alone or 
were able to abrogate the pro-survival effect of T16 or Y27632. Cells were then 
enzymatically passaged, with cell survival being assessed at 24hr post passage. 
The kinase inhibitors: LY364947 (TGF-βR1), GF109203X (PKC α and β1), API-2 
(Akt), BIBX1382 (EGFR), PI-828 (Pi3K), ML-7 (MLCK) and PP2 (Src-family kinases) 
were used as described in section 2.2.1.4. 
Treatment with LY364947, API-2, BIBX1382 or ML-7 had no effect on hPSC 
survival in the control cells, and did not alter the response of hPSC to either T16 
or Y27632 treatment. Treatment of cells with the Pi3K inhibitor PI-828 resulted 
in a reduced capacity for T16 and Y27632 to support survival, with there being a 
significant decrease in hPSC survival in the presence of PI-828 compared to T16 
or Y27632 alone (P=<0.001). In contrast, treatment with GF109203X had a 
significantpro-survival effect on untreated hPSC, resulting in an increase in cell 
survival from ~20% to ~45% (P=<0.001), however, this level of survival was still 
lower than that in reposnse to either T16 or Y27632 (figure 5.8).  
However, the use of PP2 led to the greatest differential response. Inhibition of 
Src-family kinases by PP2 led to a significant decrease in cell survival of T16 
treated cells (P=<0.001 versus all other T16 treatments) but had no effect on 
Y27632 mediated cell survival (figure 5.8) or control cells.  
This specific abrogation of T16 mediated survival strongly supports a critical role 
for Src-family kinases in T16 mediated survival post dissociation and highlight 
another clear difference between T16 and Y27632. The findings also 
demonstrate that Pi3K and PKC signalling pathways have a role in the 
dissociation induced apoptosis of hPSC, with Pi3K activity supporting survival and 
PKC activity being pro-apoptotic.  
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Figure 5.8- Effect on hPSC survival in response to kinase inhibition of various pathways.  HiPSC (NMF-iPS6) were treated with T16 or Y27632 or left untreated 
and enzymatically passaged in the presence or absence of additional kinase inhibitors. Kinase inhibitors used were LY364947 (TGF-βR1), GF109203X (PKC α and 
β1), API-2 (Akt), BIBX1382 (EGFR), PI-828 (Pi3K), ML-7 (MLCK) and PP2 (Src-family kinases). PI-828 significantly decreased survival of Y27632 and T16 treated 
cells (P=<0.001) compared to all other Y27632 or T16 treatments. PP2 significantly decreased the survival of only T16 treated cells when compared to all other T16 
treatments (P=<0.001). Inhibition of PKC through the use of GF109203X resulted in an increase in cell survival in untreated control cells  compared to all other control 
treatments (P=<0.001). Data shown as the mean survival ± SEM, n=3.
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5.4.1 Inhibiton of Src-kinases ablates the T16 survival effect in 
hESC and hiPSC 
Given the striking effect of Src-kinases inhibition of T16 mediated survival in the 
hiPSC line used above, it was important to determine whether the inhibition of 
Src-kinases also resulted in a loss of the pro-survival effect of T16 in other hPSC 
lines. Therefore, the effect of Src-kinase inhibition on RC9, H1 and H9 hESC lines 
was tested by enzymatic passage with T16 or Y27632 in the absence or presence 
of PP2. Figure 5.9 shows that PP2 treatment has the same effect regardless of 
cell line used, ablating the pro-survival effect of T16 completely, and reducing 
cell survival to that of untreated control cells (P=<0.001). There was no 
significant decrease in Y27632 treated cells, confirming that this response was 
specific to T16 treatment. 
5.4.2 The effect of Src inhibition is time dependent 
Src-family kinases have well-known roles in adhesion and are major components 
of focal adhesions (Parsons et al, 2010). Given that the effect of T16 is 
dependent on adherence, experiments were undertaken to determine whether 
inhibition of Src-family kinases decreases survival by impacting adhesion related 
signalling. To do this, a time course experiment was performed during which PP2 
was added to hiPSC at various time points. These included the standard 2hr pre-
treatment, inclusion of PP2 directly after dissociation (0mins), and as addition of 
PP2 to cultures 30mins, 1hr, 2hr, 4hr and 8hr post dissociation. This experiment 
was performed with DMSO only (untreated) in addition to T16 and Y27632 
treated cells. 
As seen previously, addition of PP2 before or up to 2 hour post dissociation 
severely reduced T16-mediated survival, however addition of PP2 to cultures 
either 4hr or 8hr post dissociation resulted in a diminished effect of PP2, with 
hPSC survival of T16 treated cells being ~45% and ~60% respectively (figure 
5.10).  At the 8hr time point, the addition of PP2 had no significant effect on 
cell survival compared to T16 treatment alone. In the earlier time points (up to 
4hrs post dissociation), survival was significantly lower than T16 treatment alone 
(P=<0.001), but there was a gradual increases that was dependent on the time 
post passage at which PP2 was added.  During routine passage using survival 
155 
 
 
compounds, T16 treated hPSC begin to adhere to the ECM within the first 1-4 
hours following dissociation, therefore, these results could suggest that Src-
family kinase activity is required for this initial T16 mediated adhesion to the 
ECM, but that once cells have re-established contact with the ECM Src activity is 
dispensable.   
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Figure 5.9- Effect of Src inhibition on hESC and hiPSC. H1, H9, RC9 and hiPSC were untreated or treated with T16 or Y27632 in the presence or absence of the 
Src-kinase family inhibitor PP2. In all cell types, PP2 significantly decreased the survival of T16 treated cells when compared to T16 alone, Y27632 alone and Y27632 
with PP2 (P=<0.001). PP2 treatment had no effect on Y27632 treated cells.  Data shown as the mean survival ± SEM, n=3.
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Figure 5.10- Time dependent response to Src inhibition. HiPSC (NMF-iPS6) were treated with T16, Y27632 or left untreated and passaged enzymatically. The Src-
kinase inhibitor PP2 was added at various time points ranging from 2hr prior to passage to 8hrs post passage. T16 treated cells that had PP2 added between -2hrs and 
4hrs post passage had significantly reduced cell survival compared to T16 treated cells without PP2 (P=<0.001). Data shown as the mean survival ± SEM, n=3.   
158 
 
 
5.4.3 T16 treatment does not alter the phosphorylation of src-
kinases 
The results of previous investigations demonstrate that Src-kinase activity is 
critical to the pro-survival effect of T16 in hPSC. In order to investigate if T16 
treatment increased phosphorylation and therefore actvity of Src-kinases, T16, 
Y27632 or control hiPSC were enzymatically passaged and reseeded at a density 
of 7.5x105 cells per well. Cells were harvested after 15mins, 30mins, 45mins, 
1hr, 2hrs and 4hrs post dissociation and protein lysates produced as described in 
section 2.4.1. Gel electrophoresis and western blot analysis was performed as 
described in sections 2.4.3 and 2.4.4, and the resulting nitrocellulose 
membranes were probed with a pan-Src kinase antibody,  a second antibody that 
recognisesphorphoylatyion at Y416 on multiple Src-kinases or the loading control 
α-tubulin antibody.  Figure 5.11A shows example immunoblots for each protein 
target and figure5.11B shows mean densitometry data of pSrc relative to total 
Src-kinase. There was detectable expression of pSrc at each time point 
regardless of treatment type, however, there were no reproducible differences 
in expression between treatments or with increasing time post dissociation.  
Further experiments were undertaken to confirm that treatment with the Src-
kinase inhibitor PP2 (10µM) did result in the reduction Src-kinase 
phosphorylation that was expected and thus to validate the activity of this 
inhibitor. This was examined by performing western blot analysis on cells that 
were also treated with PP2 (figure 5.11C). The data produced confirms the 
capacity of PP2 to prevent phosphorylation of Src-kinase, with clear inhibition of 
pSrc but maintained detection of total Src-kinase in cells treated with PP2.     
These data suggest that although Src-kinase activity is vital, T16 does not up-
regulate the phosphorylation of this kinase and may therefore be influencing Src-
kinase activity indirectly. Alternatively, it may suggest that T16 promotes 
survival downstream of Src-kinase, and that basal levels of phosphorylation are 
required for this activity. Although unusual this mode of action might be 
expected as it has previously been shown that T16 does not have significant 
kinase inhibitory activity (Chapter 4).   
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Figure 5.11- Western blot of Src-kinases activity. HiPSC (NMF-iPS6) were treated with T16, 
Y27632 or DMSO (untreated) before being enzymatically passaged. Cells were harvested and 
protein lysates made 0mins, 15mins, 30mins, 45mins, 1hr, 2hrs and 4hrs post dissociation. 
Western blots were performed and immunoblots produced. (A) Shows example immunoblots. (B) 
Shows densitometry analysis showing mean levels of pSrc relative to total Src (±SEM, n=3). 
Densitometry analysis showed there were no significant changes in the levels of active Src in 
response to treatment type. (C) Shows immunoblots confirming the inhibition of Src 
phosphorylation by PP2.   
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5.5 Proteome Profiler™ Antibody Array analysis of 
signalling pathways 
The preceding work shows that Src-kinase plays a critical role in T16 mediated 
hPSC survival, however, there were similar levels of phosphorylated Src present 
untreated hPSC that died post dissociation as in T16 and Y27632 treated cells 
which survived. It is therefore possible that the pro-survival effect of T16 is 
mediated either upstream or downstream of Src activation, and not via directly 
impacting the phosphorylation status of Src. The Src-family of kinases are 
involved in a wide range of cellular processes and are part of many signal 
transduction pathways. Given the large number of possible interactions, to 
further explore the pathways impacted by Src kinases and its inhibition by PP2 
during hPSC dissociation, Proteome Profiler™ Antibody Arrays were used to 
investigate the activation state of 45 different phospho-kinases as well as a 
further 26 kinases involved in MAPK signalling. HPSC (hiPSC) were treated with 
T16, Y27632, T16 + PP2 or left untreated before being enzymatically passaged as 
described previously. Cells were harvested after a 2hr recovery period in 
fibronectin coated wells and then analysed using the Proteome Profiler kits as 
described in section 2.4.9.  Proteome Profiler kits use nitrocellulose membranes 
that are spotted in duplicate with each protein of interest and the expression of 
each kinase can be subsequently determined by densitometry. The resulting 
immunoblots from the phospho-MAPK and phospho-kinase kits can be seen in 
figure 5.12A and B respectively. The immunoblots produced from the phospho-
MAPK kit shows that the phosphorylation status of the majority of proteins was 
similar between the treatment groups. The only difference that was clearly 
identifiable by eye in pJnk1 and pJnk2, which appeared to have higher 
abundance in the untreated control cells and the T16 + PP2 cells. As with many 
MAPK proteins, Jnk proteins have been reported to play a role in apoptosis, 
however depending on cell type and family member, Jnk activity can be either 
pro or anti-apoptotic (Hochedlinger et al, 2002; Tafolla et al, 2005; Ries  et al, 
2008). Densitometry was performed on the nitrocellulose membranes and the 
mean pixel density plotted as shown in figure 5.12D. The densitometry 
unsurprisingly highlights those which were visible by eye, but also highlights 
other proteins with more modest changes such as a lower pAkt in control cells 
and an increase in pGSK3 in cells treated with T16 + PP2. These data provide 
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interesting insight, however as they are based on duplicate spots from an n of 1, 
care must be taken not to over interpret the data.  
The same analysis was performed using the phospho-kinase array, and the 
resulting immunoblots can be seen in figure 5.12B. The most obvious difference 
on these immunoblots was that the T16 + PP2 sample had reduced 
phosphorylation in a large number of these kinases. There were no immediately 
obvious differences between the other conditions (T16, Y27632 and untreated 
control). When densitometry was performed on these immunoblots, the results, 
shown in figure 5.12C (i) and C (ii) confirmed that there was a decrease in many 
proteins in response to PP2. PP2 treatment not only reduced phosphorylation of 
Src-family kinases such as Src, Fyn and Lyn, but also reduced the 
phosphorylation of a number of other kinases such as FAK, PDGFR (platelet 
derived growth factor receptor), Erk1/2 and β-catenin. This could be attributed 
to off-target inhibition by PP2, however it may also be a consequence of Src-
kinase inhibition, given that many of these proteins are themselves targets of 
Src-family kinases. As with the MAPK array, it is important not to over analyse 
these data as they are from a single experiment, however there are a number of 
interesting differences highlighted they could be further investigated. For 
example, pChk-2 (checkpoint kinase 2) was higher in T16 treated cells than 
untreated or Y27632 treated cells, and expression of pChk-2 was substantially 
reduced in response to PP2 treatment. Chk-2 is involved in regulation of the cell 
cycle, and has a reported role in apoptosis (Janck et al, 2004), although largely 
thought to be pro-apoptotic, Chk-2 could have a novel role in hPSC behaviour 
post dissociation. 
There is also increased detection of pRSK1/2/3 (ribosomal s6 kinase) in T16 
treated cells compared to all other treatment types. RSK has been reported to 
prevent, or desensitise cells to, the release of cytochrome c and thereby 
reduces the apoptotic response (Kim et al, 2012). Between the 2 separate kits 
used, there was a certain degree of overlap between targets. The phospho-
kinase kit utilises a pan pRSK antibody (RSK1/2/3) and shows T16 treated cells 
had the highest expression and that treatment with PP2 caused a decrease, 
however the MAPK kit used separate RSK1 and RSK2 antibodies which show no 
detectable expression in any treatment type.  Taken together this would suggest 
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that RSK3 was therefore, the phospho-protein detected with the pan-RSK 
antibody in the phospho-kinase array and might have been a target for further 
investigation if time had permitted.   
 
 
Figure 5.12- Continued overleaf.
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Figure 5.12- Continued overleaf 
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Figure 5.12- continued overleaf  
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Figure 5.12- Proteome Profiler™ analysis. Untreated hiPSC (NMF-iPS6) as well as those treated with T16 ± PP2 and Y27632 were enzymatically passaged and 
cells harvested after a 2hr recovery period. Protein lysates were produced and analysed using Proteome Profiler kits. (A) and (B) show immunoblots produced by each 
of the kits. C(i) and (ii) show mean pixel density of targets from the phospho-kinase kit. (D) Shows mean pixel density of targets from the MAPK kit. Data shown as the 
mean pixel density from duplicate spots, n=1.  
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5.6 Potential role for RACK1 and Src interaction 
5.6.1 HPSC express endogenous RACK1 
Previous investigation using qRT-PCR had identified RACK1 as the most highly 
expressed adhesion-associated gene in hPSC (figure 5.5). RACK1 has been 
reported to have the capacity to bind members of the Src-kinase family and 
consequently to be able to mediate the activation of signalling pathways 
downstream of Src-kinase including those involved in adhesion and apoptosis, for 
example Pi3K/Akt signalling (Liu, et al, 2011; Mamidipudi et al, 2006). 
Experiments were undertaken to investigate whether there is any direct 
interaction between the RACK1 and Src proteins in hPSC. Firstly, in order to 
confirm if hPSC express RACK1 protein, hPSC were grown to confluence before 
being lysed as described in section 2.4.1. Western blot analysis of RACK1 in the 
hESC lines H1 and H9, as well as hiPSC, was performed as described in section 
2.4.4. As shown in figure 5.13, all of the hPSC lines expressed significant 
amounts of RACK1. 
 
Figure 5.13- HPSC express endogenous RACK1. H1 (hESC), H9 (hESC) and hiPSC (NMF-
iPS6) were lysed and protein lysates produced. SDS PAGE and western blot analysis were 
performed and the resulting nitrocellulose membranes probed for RACK1 and α-tubulin. RACK1 
was present in each cell line tested (n=1). 
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5.6.2 T16 treatment alters Src binding capacity to RACK1 
To assess if Src-family kinases had the capacity to bind  RACK1 in hPSC, a GST 
RACK1 fusion protein was produced and purified as described in section 2.4.8. 
T16, Y27632 and untreated control cells were used to produce protein lysates 
using non-denaturing lysis buffer. An aliquot of each was taken as a total lysate 
control before the remaining lysate was incubated with the GST RACK1 fusion 
protein for 1hr at 37°C in the presence of ATP and kinase buffer. This was done 
to ensure the phosphorylation of the RACK1 fusion protein, which is reported to 
be necessary for association with Src-family members, and to facilitate binding 
of any free cytoplasmic Src-family kinases (Chang et al, 2002). Glutathione 
beads were then used to separate the GST RACK1 and any binding partners from 
the lysate before denaturing SDS-PAGE and western blots were performed on 
both the pull-down samples and total lysates. The resulting immunoblots were 
probed with anti-Src (total, pan-Src), anti-RACK1 and anti-α-tubulin antibodies, 
with representative immunoblots shown in figure 5.14A. These immunoblots 
confirm that the GST RACK1 fusion protein successfully binds to endogenous Src 
proteins in hPSC, although with varying levels. Densitometry analysis of pulled 
down Src proteins is shown in figure 5.14B and demonstrates  that the Y27632 
treated and the untreated control cells GST-RACK1 pulled down significantly 
more Src protein compared to the T16 treated cells (P=<0.01 and P=<0.001 
respectively). This difference is not a result of differing levels of input Src-
family kinase as there was no significant difference in expression between the 
three treatment types (figure 5.14C), thus T16, but not Y27632, does appear to 
modulate the interaction of RACK1 and Src-family kinases in dissociated hPSC. 
Although the introduction of exogenous RACK1 makes this system somewhat 
artificial, these data highlight an interesting difference between the treatment 
types, and suggest that T16 treatment reduces the capacity of one or more Src-
kinases to bind to RACK1. This is likely a result of Src proteins already being 
bound to other intracellular targets such as integrins, FAK or other survival 
related proteins.  
It was also possible that reduced level of Src-family kinases was pulled down by 
GST-RACK1 in T16 treated hPSC because Src family members were already bound 
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to endogenous RACK1 and therefore not available to the fusion protein. The 
association of endogenous proteins was therefore further investigated.  
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Figure 5.14- Pull down of Src-kinases using GST-RACK1 fusion protein. A GST fusion protein 
was incubated with lysates produced with T16, Y27632 or untreated cells (NMF-iPS6) for 1hr in the 
presence of ATP and kinase buffer before being analysed by western blotting. (A) Representative 
immunoblots produced. (B) Densitometry analysis showing significantly less Src proteins pulled 
down in T16 treated cells when compared to Y27632 (P=<0.01) or untreated (P=<0.001) samples. 
(C) Densitometry analysis of total lysates showing equal loading of total Src protein.  
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5.6.3 T16 treated hPSC have less intracellular Src-kinases bound 
to RACK1 
Considering the lack of kinase inhibition of T16, it is possible that it mediates its 
pro-survival effect by disrupting signalling complexes. To determine if RACK1 
and Src-family members interact directly in hPSC and whether T16 disrupts this 
relationship, co-immunoprecipitations (co-IP) were performed. Untreated cells 
(hiPSC) as well as cells treated with T16 or Y27632 were grown to confluence 
and non-denaturing lysis buffer used to produce protein lysates without 
disrupting protein-protein interactions. Anti-RACK1 antibody was used to pull 
down endogenous RACK1, which should remain bound to any binding partners, 
and was then processed using denaturing SDS-PAGE and western blotting as 
described in section 2.4.7. The resulting nitrocellulose membranes were probed 
with antibodies against RACK1 and total Src proteins. Total lysates were used as 
controls (co-IP was not performed on these). Figure 5.15A shows representative 
immunoblots produced, confirming successful pull-down of RACK and co-IP of Src 
proteins in untreated cells and those treated with Y27632 or T16.   
The densitometry analysis (figure 5.15B) shows that T16 treatment resulted in 
significantly lower levels of pulled-down Src-kinases when compared to the 
untreated controls (P=<0.01). Treatment with Y27632 also resulted in reduced 
Src-kinases bound to RACK1, however this did not reach significance. Figure 
5.16C shows levels of total Src proteins relative to α-tubulin. This confirms that 
the lysates that co-IP was performed on had equal levels of Src protein and that 
the reduced pull down of Src-family members observed was not a result of lower 
levels of starting Src proteins.  
These data suggest that T16 treatment either reduces the binding of src-family 
kinases to RACK1 (possibly via competition for the Src binding site on RACK1) or 
initiates signalling events that result in the release of Src-family members from 
the RACK1 complex. The results also suggest that treatment with Y27632 may 
cause the release of Src-family members from RACK1; however previous results 
indicate that this may not be essential in Y27632 mediated survival of hPSC.  
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Taken together, the data garnered in sections 5.6.1 through 5.6.3 shows that 
hPSC express RACK1 and that RACK1 and Src-family kinases are bound to each 
other in hPSC. These data also show conclusively that T16 treatment results in 
reduced Src-family members binding to endogenous RACK1. Furthermore, T16 
treatment resulted in decreased Src-family kinases binding to a GST-RACK1 
fusion protein, which suggests that there may be less freely-availably Src 
proteins in the cytoplasm of the T16 treated cells, possibly due to Src-family 
members binding to alternative intracellular proteins and thereby eliciting a 
specific response to T16. 
 
   
 
 
 
 
 
Figure 5.15- Continued overleaf 
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Figure 5.15- Co-IP of Src with RACK1. Untreated as well as T16 and Y27632 treated hiPSC 
(NMF-iPS6) were harvested and co-IPs performed using RACK1 antibody. SDS-PAGE and 
western blots were performed and membranes probed for Src-family kinases and RACK1. (A) 
Representative Immunoblots produced showing pulled down Src family kinases and RACK1 as 
well as Src-family kinases and α-tubulin from control lysates (no co-IP performed). (B) Shows 
levels of pulled down Src proteins relative to pulled down RACK1 as determined by densitometry. 
T16 treated cells had significantly reduced Src family kinases pulled down when compared to 
untreated cells (P=<0.01). (C) Control lysate Src proteins relative to α-tubulin as determined by 
densitometry. This shows that there were equal volumes of Src in each lysate that co-IP was 
performed on. Data shown as the mean value ± SEM, n=3. 
 
 
5.7 Summary 
Presented within this chapter are data that further elucidate the mechanism 
through which T16 mediates its pro-survival effect on hPSC. It has been shown 
that hPSC express a wide range of adhesion related genes including many α and 
β integrin sub-units, cadherins and Src-family kinases. The data shows that T16 
does not upregulate expression of any of these genes at the transcriptional level, 
and had no effect on any integrins tested at the protein level. A number of 
pathways have been shown to have critical roles in the apoptotic response to 
dissociation in hPSC such as PKC signalling which appears to be pro-apoptotic, 
and Pi3K signalling which seems to have a protective effect in hPSC as 
determined by kinase inhibition studies. The greatest difference between 
treatment types was observed in the response of hPSC to the Src family inhibitor 
PP2, which completely ablated the pro-survival effect seen in response to T16 
treatment, but had no effect on Y27632 treated cells. This detrimental effect of 
PP2 is time-dependent, with Src-family kinase activity being essential 
immediately following dissociation, but being dispensable once the cells have 
formed cell-matrix adhesions. T16 treatment does not lead to increased 
phosphorylation of endogenous Src-family kinase within hPSC, however it may 
173 
 
 
alter the relationship between Src-family kinase and binding partners. The data 
produced in this chapter confirms RACK1, which was most highly expressed 
adhesion related protein at the transcriptional level, as a binding partner for 
Src-family kinases in hPSC, and suggests that T16 treatment may mediate its 
pro-survival effect by altering this relationship and potentially by making Src 
more available to interact with other intracellular partners. Elucidation of this 
critical role of Src/Src containing signalling complexes in response to T16 would 
have been the priority for any additional studies had time permitted.  
 
 
 
 
 
 
 
 
 
 
6 Transcriptional analysis of T16 treated HPSC in 
response to dissociation 
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6.1 General introduction 
As T16 is not a kinase inhibitor and prolonged pre-treatment time (>4hrs) 
enhanced the pro-survival effect, it was possible that it acts via transcriptional 
regulation rather than post-translational modification of signalling components. 
In an effort to better understand the transcriptional response to dissociation and 
also to determine if there was any differential expression in response to 
treatment with T16 or Y27632, an Affymetrix based microarray experiment was 
designed and performed using human iPSC. To our knowledge, no previous 
publications have investigated the complete transcriptional response to 
dissociation in hPSC.  
The aims of this study were to: 
 Determine if T16 transcriptionally primes hPSC for survival upon 
dissociation 
 Highlight any major pathways implicated in the T16 mediated response to 
dissociation 
 Further characterise the transcriptional response of hPSC to enzymatic 
dissociation 
The work described in this chapter was performed in conjunction with the 
Glasgow Polyomics Facility, and analysis aided by the valuable input from Dr 
Martin McBride, Dr John McClure and Mr Mohammed Dashti (ICAMS, University of 
Glasgow).  
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6.2 Experimental design 
In order to determine whether T16 was transcriptionally ‘priming’ hPSC for 
survival and to gain a better understanding of the transcriptional response of 
hPSC to dissociation, an Affymetrix HuGene ST 1.0 Human Array platform based 
microarray experiment was designed. This experiment was designed to compare 
untreated hPSC to hPSC that were treated with either T16 or Y27632 over 
various critical time points. Cells were harvested for the first time point 
(designated control -24hr) 24hr prior to passage and prior to the addition of any 
survival compound. It is at this point that T16 is usually added to cells, so this 
sample would act as an untreated baseline control. The next cohort of samples 
was collected immediately preceding dissociation via direct on the plate lysis to 
avoid any effect of harvesting. Samples were taken from T16 treated (for 
24hours), Y27632 treated (for 2hours) and untreated cells (24hours DMSO only). 
The next group of samples were harvested immediately after dissociation to 
single cells and following a brief wash step (<10mins post dissociation). Again 
samples were harvested from T16, Y27632 and untreated cells. The final cohort 
of samples was harvested from cells after an 8hr recovery period (on fibronectin 
coated wells in Stempro SFM culture medium) with their respective treatments. 
At this last time point there were clear differneces between treatment groups, 
with T16 and Y27632 treated cells being largely adherent, and untreated cells 
remaining mainly in suspension. There were a total of 10 samples which were 
collected from each of 3 separate experiments that were performed on cells 
from consecutive passages from hiPSC that had been mechanically maintained as 
described in section 2.2.1.1.Each sample was taken from a pooled collection 
from 2 wells at each time point to reduce variation and to include sufficient 
material for high quality RNA preparation. A schematic of this experiment can be 
seen in figure 6.1. Arrows represent the most relevant comparisons that could be 
made between groups.  
Samples were processed for analysis as described in section 2.3.6.  
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Figure 6.1- Schematic of experimental design. Samples were collected from hiPSC 24hours 
prior to dissociation. Untreated samples as well as T16 and Y27632 treated samples were 
harvested at 3 further time points. These were immediately before and after dissociation and after 
an 8hr recovery period. Arrows represent the comparisons that were made.  
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6.3 Quality control 
6.3.1 HPSC were karyotypically normal at the point of sample 
collection 
In order to ensure accurate and reproducible results, cells were analysed for 
cytogenetic stability prior to use. This was performed at the Medical Genetics 
department at Yorkhill Hospital (NHS Greater Glasgow & Clyde) as described 
previously. As can be seen, cells were karyotypically normal (46 XY) prior to use 
in this experiment (figure 6.2).  
 
Figure 6.2- Cytogenetic stability of hPSC. Cells were analysed for cytogenetic stability prior to 
sample collection. Results show that cells retained a normal karyotype of 46 XY. Analysis was 
performed at Yorkhill Hospital (NHS Greater Glasgow & Clyde). 
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6.3.2 Untreated hPSC were apoptotic after 8hr recovery period 
To confirm that an 8hr recovery period was sufficient to observe the various 
phenotypes associated with the different treatment types, i.e. untreated cells 
are apoptotic whilst T16 and Y27632 treated cells are not, an apoptosis assay 
was performed on hPSC 8hrs post dissociation. HiPSC were harvested after 8hr 
and analysed using the flow cytometer as described in section 2.5.1.  
Cells treated with T16 or Y27632 had only 7% of late apoptotic cells (positive for 
both PI and Annexin V), whereas untreated cells were 76% late apoptotic. This 
confirms that an 8hr recovery period is sufficient time for cells to show signs of 
apoptosis, or to recover, and is consistent with that seen by other groups 
(Ohgushi et al, 2010). 
 
Figure 6.3- Apoptosis assays on hPSC 8hr post dissociation. HPSC were treated with T16, 
Y27632 or untreated and then enzymatically dissociated to single cell. Cells were replated into 
fibronectin coated culture plates and allowed to recover for 8hrs. Cells were harvested and 
analysed using flow cytometry. Data shows that the majority of untreated cells are late apoptotic 
(76%) whereas T16 treated and Y27632 showed only 7% and 23% of late apoptotic cells 
respectively.  
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6.3.3 HPSC expressed high levels of pluripotency markers 
It was critical that the cells used to produce samples for analysis were of high 
quality and expressed sufficient levels of pluripotency markers. To confirm that 
the cells were pluripotent at the point of use, flow cytometry was performed on 
hPSC prior to use to confirm the expression of pluripotency and lack of 
differentiation markers. Samples were processed and analysed as described 
previously immediately following enzymatic dissociation. The pluripotency 
marker SSEA4 was expressed on >90% of cells and the differentiation marker 
SSEA1 detected on <5% in all samples (figure 6.4), confirming that hPSC cultures 
were pluripotent and of high quality. 
6.3.4 RNA quality 
Again, in order to optimise performance, the RNA used had to be of sufficiently 
high quality, having a RIN or RNA integrity number >7. This was assessed by 
running samples on the Agilent® 2100 bioanalyser as described in section 2.3.2.1. 
Agilent analysis not only produced RIN values, but also generated electrophoresis 
(figure 6.5A) and elecrtopherograms (figure 6.5B) for each sample. The clean 
bands and distinct peaks seen are indicative of high quality RNA, representing 
18S and 28S ribosomal RNA (rRNA) that had not been degraded in any way. All 30 
samples produced RIN values >9. 
 
  
 
 
 
Figure 6.4- Expression of pluripotency markers on hPSC used for microarray. The expression of pluripotency and differentiation markers on hPSC (NMF-iPS6) to 
be used in the microarray analysis was by flow cytometry. In each of the samples the expression of the pluripotency marker SSEA4 >90% and the differentiation 
marker was <5%.  
 
 
 
 
 
 
 
Figure 6.5- Agilent Bioanalyzer 2100 analysis of RNA quality. Each of the 30 samples to be 
used was subjected to analysis prior to use to confirm sufficient RNA quality. (A) Shows 
representative electrophoresis plots, with each column representing a single sample. 2 distinct 
bands can be seen in each sample representing 18S and 28S ribosomal RNA (rRNA). (B) Shows 
representative electropherogram from a single sample with the distinct peaks again representing 
18S and 28S rRNA.  
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6.4 Data normalisation and analysis 
Once the appropriate quality control steps had been performed and samples 
processed as described in section 2.3.6, the resulting data (in the form of .cel 
files) was uploaded into the Partek analysis software program. Data was 
normalised using the Robust Multiarray Average (RMA) method and was subject 
to principal component analysis (PCA). An analysis of variance (ANOVA) model 
was then produced which took into consideration the batch to batch variability 
relating to the separate chip run dates as well the separate treatments and time 
points. This allowed for multiple pairwise comparisons to be performed and for 
step-up false discovery rates (FDR) to be generated.   
6.4.1 Principle component analysis 
Principle component analysis is a mathematical model that performs linear 
transformation on the variables within the data to produce uncorrelated 
variables known as principal components (PCs). These PCs account for all the 
variability within the data set and allows samples to be visualised in PCA maps 
(figure 6.6). The PCA maps show that the 8hr recovery samples from all 
treatment groups were separate from the other conditions (figure 6.6A) and that 
each of the repeats were clustered sufficiently close to proceed with the 
analysis (figure 6.6B). From this initial analysis it was expected that the 8hr 
recovery samples would have many differences when compared to the other 
sample groups.  
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Figure 6.6- Principle component analysis. Data produced using Affymetrix HuGene ST 1.0 
Human Array chips were subject to PCA. It can be seen that the cohort of samples obtained after 
the 8hr recovery period were distinct to the other samples (A). PCA map showing treatment type 
(B). Data shows the principle components for all 30 samples.    
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6.4.2 Ingenuity Pathway Analysis 
The raw data produced by the ANOVA was uploaded and analysed by the 
Ingenuity Pathway Analysis (IPA) software which is able to compare the data sets 
to information within the Ingenuity Pathways Knowledge Base. The software 
produces a list of canonical pathways that are most affected by the gene 
changes within the data set. These canonical pathways are presented alongside 
a ratio which represents the number of genes in each particular pathway 
differentially regulated in the data set, divided by total number of genes in that 
pathway. Therefore, higher ratios are seen in pathways that have changes in 
expression in a greater number of genes within that pathway. The pathways are 
also presented with a P value produced using Fishers exact test right tailed 
which represents the likelihood that the changes in genes within the particular 
pathway could have resulted by chance alone.  
Additionally, IPA is able to produce heat maps that give an overview of biological 
functions that are impacted by the changes in the data set. IPA makes 
predictions for each function based on its z-score and functions with a z-score ≥2 
are predicted to be increased where as those ≤-2 are predicted to be decreased. 
Functions cover a range of biological processes such as adhesion, apoptosis, 
cytoskeletal organisation and developmental processes.  
 
6.5 Pairwise comparisons 
As previously stated, the ANOVA model generated makes multiple pairwise 
comparisons between the groups and produces a list of differentially expressed 
probe sets between each comparison group. Only those with a FDR of <0.05 were 
included in the generated list of probe sets. The arrows in figure 6.1 show the 
large number of comparisons that can be made. However not all comparisons 
produced any significantly differentially expressed probes. The comparisons that 
produced significant differences are detailed in table 6.1.  
 
 
 
Comparison FDR Differentially expressed probes 
T16 Lyse on plate vs. Y27632 lyse on plate <0.05 4 
T16 8hr recovery vs. Untreated 8hr recovery <0.05 151 
Untreated 8hr recovery vs. Y27632 8hr recovery <0.05 1900 
T16 8hr recovery vs. Y27632 8hr recovery <0.05 52 
Untreated dissociated vs. -24hr control <0.05 7 
T16 dissociated vs. -24hr control <0.05 8 
Y27632 dissociated vs. -24hr control <0.05 18 
Untreated 8hr recovery vs. untreated lysed on plate <0.05 7251 
T16 8hr recovery vs.  T16 lysed on plate  <0.05 7616 
Y27632 8hr recovery vs. Y27632 lysed on plate <0.05 7711 
Untreated 8hr recovery vs. Untreated dissociated <0.05 8594 
T16 8hr recovery vs. T16 dissociated <0.05 8254 
Y27632 8hr recovery vs. Y27632 dissociated <0.05 9379 
Table 6.1- Differentially expressed probes.. Data shows those comparisons which resulted in differentially expressed probe sets. Only probes with an FDR of <0.05 
are shown.
 
 
6.5.1 T16 treatment does not alter gene expression prior to 
dissociation 
Given that T16 treatment requires 24hr pre-treatment to produce optimal cell 
survival, it was thought that it may be exerting its effect via transcriptional 
regulation of genes important to cell survival. The comparison between T16 
treated cells pre dissociation (lysed on plate) and the -24hr control sample 
showed no significant changes suggesting that there was no transcriptional 
effect of T16. Additionally, there were no significant differences between hPSC 
treated with T16 and the untreated control cells when lysed prior to dissociation 
(table 6.1), again showing that it was unlikely that T16 altered gene expression 
to make the cells more resistant to dissociation.  
The samples collected immediately following dissociation were compared to 
those collected prior to dissociation to determine if T16 prevented an immediate 
up or down regulation of any genes which may be associated with the process of 
dissociation and harvesting, however there were no significant differences 
between these groups regardless of treatment type. The dissociated samples 
were also compared to the -24hr control sample and resulted in 7, 8 and 18 
differentially regulated probes for untreated, T16 and Y27632 treated cells 
respectively. None of the changes were related to genes of interest and had no 
common relationship when uploaded onto IPA. Furthermore, the few changes 
seen were very small with the highest change in expression in any of these 
probes being only a 1.7 fold increase.  
The highest number of changes in expression were seen in the comparison of 
hPSC after the 8hr recovery period to cells immediately pre or post dissociation, 
with comparisons between these samples having >7000 differentially expressed 
probes (i.e T16 8hr recovery vs T16 lysed on plate). The comparison between the 
8hr recovery samples and the dissociated cells had the greatest number of 
changes and was therefore the focus for subsequent analysis. This comparison 
group should encompass all the relevant biological changes related to the 
dissociation and recovery processes given that there were no changes between -
24hr control cells and the lysed on the plate samples (therefore no probes would 
be missed). There were also differentially expressed probes between T16, 
Y27632 and untreated hPSC at the 8hr recovery point and these differences were 
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also further investigated (i.e T16 8hr recovery vs Control 8hr recovery) as they 
may reveal gene changes related to the pro-survival effects of either or both 
molecules.  
Although there were significant changes detected between comparison groups, 
the fold changes observed were surprisingly small regardless of the comparisons 
being made. For example the highest fold change observed within the entire 
data set was between T16 treated 8hr recovery cells and T16 treated cells post 
dissociation cells, where a 16-fold increase in TRIM43 (tripartite motif containing 
protein 43) was detected. However, the vast majority of changes within each of 
the comparison groups were <1.5 fold. With such small fold changes, it was 
predicted that it might be difficult to successfully validate any targets of 
interest, however many small changes within a single pathway could still lead to 
a significant modification of the activity of that pathway. 
6.6 Canonical pathway analysis 
As previously stated, IPA creates a list of canonical pathways that the data sets 
are impacting. Data sets were uploaded to IPA to compare the 8hr recovery cells 
to the cells immediately following dissociation for each treatment type. It was 
notable that although there are a number of pathways that are present in the 
top 20 pathways influenced by each treatment, there are also a number of 
pathways that are only present in one or two treatment types (Figure 6.7). The 
top canonical pathway in T16 treated cells was the molecular mechanisms of 
cancer; however this particular pathway is also highly affected in Y27632 and 
untreated cells, showing as the 5th and 2nd pathways respectively. The top 
pathway in Y27632 treated cells was the protein kinase A (PKA) pathway, which 
was again in the top 20 pathways for T16 and untreated cells. The super 
pathway of cholesterol biosynthesis was the top canonical pathway in untreated 
cells. However, cholesterol biosynthesis was also common to T16 and Y27632 
treated cells. We therefore focussed on pathways that were not common to all 
three to highlight pathways that may be differentially regulated in and thus 
important in the response of hPSC to dissociation.
 
 
.  
 
Figure 6.7- Continued overleaf
 
 
 
Figure 6.7- Continued overleaf
 
 
 
Figure 6.7- Canonical pathway comparison. IPA was used to compare the canonical pathways altered in response to T16 (A), Y27632 (B) and no treatment (C). 
Data shows the top 20 pathways for each comparison group. The yellow line shows  the ratio which represents the number of genes in each particular pathway 
differentially regulated in the data sets, divided by total number of genes in that pathway.
 
 
6.6.1 Pi3k/Akt signalling pathway 
The first canonical pathway that may be of relevance is the Pi3K/Akt signalling 
pathway, which was the 3rd most affected canonical pathway in both T16 and 
Y27632 treated cells whereas it does not appear in the top 20 canonical 
pathways in untreated cells. This is particularly relevant given that Pi3k 
signalling has a known role in cell survival (Eiselleova et al, 2009) and that 
previous studies within this thesis indicated that inhibition of Pi3K signalling 
reduces cell survival in hPSC (Figure 5.8). Although no change in expression was 
greater than ± 4-fold within this pathway (with the majority being <2), the 
canonical pathways generated by IPA show that treatment with T16 or Y27632 
resulted in differential expression in a large proportion of genes within the 
Pi3K/Akt signalling pathway (Figure 6.9). The data showed that there was 
upregulation of several Pi3K family members which could be activated in 
response to integrin activation or downstream of receptor tyrosine kinases (RTK) 
such as FGFR. PiK3AP1 (phosphoinositide 3 kinase adapter protein 1) and PiK3R1 
(phosphoinositide 3 kinase regulatory sub-unit) which can function together to 
activate Pi3K signalling were both upregulated in the 8hr recovery cells in 
response to T16 treatment when compared to the dissociated cells (1.5 and 1.9 
fold respectively) but not in untreated cells. PiK3AP1 was also upregulated in 
Y27632 treated cells in the 8hr recovery cells (1.4 fold) but Pi3KR1 was not.  
In addition to this, the expression of another family member, PiK3C2B 
(Phosphatidylinositol-4-Phosphate 3-Kinase), was upregulated in both T16 and 
Y27632 treated cells in the 8hr recovery time point (1.7 and 1.6 fold increase 
respectively), but not in the untreated cells.  
The data produced also supports the link between Pi3K signalling and 
pluripotency. In both the Y27632 and T16 data sets, Nanog expression was 
increased (1.4 and 1.5 fold respectively) in the 8hr recovery cells, which may be 
a result of downstream Pi3K signalling which has been reported lead to Nanog 
activation in hPSC (Wi et al, 2007; Wang et al, 2009). This may also indicate that 
Nanog is only maintained in cells that successfully re-attach to the ECM post 
dissociation.  
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 Validation of gene targets within the Pi3K/Akt pathway 6.6.1.1
In order to validate selected targets from the Pi3K/Akt pathway, qRT-PCR 
analysis was performed using the RNA extracted from the original samples. 
PiK3R1, PiK3AP1 and PiK3C2B were chosen as suitable targets for validation. 
Results from the validation (figure 6.8) show that although there were 
statistically significant increases (P=<0.05) between the time points for PiK3R1 
and PiK3AP1, the increases were not treatment specific, with all treatments 
resulting in upregulation in these genes, even the untreated cells in which ~80% 
are undergoing apoptosis. 
When validating the changes in expression of PiK3C2B, none of the original 
changes observed were validated using qRT-PCR, with no significant difference 
in expression observed between the treatments or time points.  
A complete summary of validation targets can be seen in table 6.2. 
 
Figure 6.8- Validation of Pi3k/akt target genes. Several members of Pi3K/Akt signalling pathway 
were selected for validation. Targets were validated using the original RNA from the array by qRT-
PCR. Data shows significant increase (P=<0.05) in expression of PiK3AP1 and PiK3R1 in the 8hr 
recovery cells compared to cells immediately post dissociation in each of the treatment types. 
There were no significant differences observed in the expression of Pik3C2B. Data shown as mean 
2
ΔCt
 x1000 ± SEM. Experiments were performed with technical and biological triplicates (n=3 in 
triplicate). 
 
 
 
 
Figure 6.9- Continued overleaf 
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Figure 6.9- Pi3K signalling canonical pathways.  (A) The Pi3K signalling pathway showing genes that were upregulated (red) or downregulated (green) in T16 8hr 
recovery cells when compared to T16 dissociated cells. (B) Shows the same pathway in response to Y27632 treatment. 
 
 
6.6.2 Integrin signalling 
A further canonical pathway of interest was the integrin signalling pathway, 
which was in the top 20 canonical pathways of both T16 and Y27632 treated 
cells. Again, as seen with Pi3K/Akt signalling, integrin signalling was not one of 
the top 20 pathways affected in untreated cells and could therefore be part of 
the pro-survival response seen with both small molecules. The canonical 
pathways produced by IPA (figure 6.10) show that a large fraction of the genes 
within the pathway were differentially expressed in cells treated with either T16 
or Y27632. This was perhaps unsurprising given that during the 8hr recovery 
period the hPSC are actively adhering and spreading on the ECM in response to 
T16 or Y27632 treatment, whereas the untreated cells mostly stay in suspension 
and begin to undergo apoptosis. Genes differentially regulated in response to 
Y27632 or T16 treatment included the integrin sub-units α6 and β1 as well as 
components of focal adhesions such as FAK and paxillin. Again, although 
statistically significant, all of the fold changes observed were <3-fold.  
These results highlight the importance of integrin signalling in response to 
dissociation and clearly show that hPSC are transcriptionally regulating many 
components of the integrin signalling pathway in response to dissociation and 
subsequent re-adherence. Given the adhesion dependent nature of T16 
mediated survival, a number of these targets were of great interest, such as the 
aforementioned integrins and components of focal adhesions and were 
subsequently validated.   
 Integrin signalling pathway validation 6.6.2.1
As before, selected targets were validated using the RNA used during the original 
analysis. The results generated show that there were significant changes in these 
validation targets between the time points, but again show that the changes 
were not specific to treatment type. Figure 6.11 shows that all the 8hr recovery 
cells had significantly increased expression (P<0.05) of ITGA6 (integrin α6), 
ITGB1 (integrin β1), PTK2 (FAK) and PXN (paxillin) when compared to the post 
dissociation cells. The fold changes were 2-3fold for ITGA6, ITGB1 and PTK2, and 
between 6-7fold increases in PXN. A summary of validation targets can be seen 
in table 6.2. 
 
 
 
Figure 6.10- Continued overleaf 
 
 
 
Figure 6.10- Integrin signalling canonical pathways. (A) The integrin signalling pathway showing genes that were upregulated (red) or downregulated (green) in T16 
8hr recovery cells when compared to T16 dissociated cells. (B) Shows the same signalling pathway in response to Y27632 treatment at the same time points. 
 
 
 
Figure 6.11- Validation of integrin signalling pathway targets. Several members of the integrin 
signalling pathway were selected for validation. Targets were validated using the original RNA from 
the array by qRT-PCR. Data shows significant increase (P=<0.05) in expression of ITGA6, ITGB1, 
PTK2 and PXN in the 8hr recovery cells compared to cells immediately post dissociation in each of 
the treatment types. Data shown as mean 2
ΔCt
 x1000 ± SEM. Experiments were performed with 
technical and biological triplicates (n=3 in triplicate). 
 
6.7 Function changes 
IPA software also generated a list of function it predicts to be increased or 
decreased as a result of the gene changes within the data set. As described in 
section 6.4.2, only functions that had a sufficient z-score were listed as 
changed. IPA predicted a total of 101 functions to be increased between the 
three treatment groups when the 8hr recovery cells were compared to the post 
dissociation cells. In order to see which functions were shared between the 
treatment types, a Venn diagram was produced (figure 6.12A), which showed 
that ~20% of the functions were shared between the treatment groups. Of those 
functions unique to each treatment, a number were related to cellular shape 
change such as the organisation of cytoskeleton and morphology of cells, and 
consequently shared many of the differentially expressed probes including some 
of those already observed within the integrin signalling pathway as discussed 
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above. Interestingly, T16 treated cells were predicted to have increased cell 
viability, whereas Y27632 treated cells were predicted to have increased 
attachment of cells. IPA predicted increased cell survival in each treatment 
group, however, the z-score was lowest for untreated cells (2.164) and highest 
in T16 treated cells (2.532), with the z-score for Y27632 treated cells being 
2.238, which suggest there is a stronger link between the gene changes observed 
and increased survival in T16 treated cells. Another interesting function was 
increased self-renewal of ESC lines, which was shared between T16 and Y27632 
treated cells but not the untreated cells. This again may be due to the increased 
activation of the Pi3K/Akt signalling pathway and in particular Nanog activation, 
or may be indicative that only those cells that successfully re-attach maintain 
Nanog expression. 
There were less overall functions predicted to be decreased between these data 
sets (16 in total) however, all 5 functions shared by T16 and Y27632 were 
relating to cell death and apoptosis, which would result in increased cell survival 
(figure 6.12B). Interestingly, T16 and untreated cells shared anoikis as a function 
that was predicted to be decreased. Anoikis is a potential mechanism through 
which dissociated hPSC can evade apoptosis and it appears untreated and T16 
treated cells are regulating genes with known roles in this process in response to 
dissociation. 
  
201 
 
 
 
 
 
Figure 6.12- Predicted function changes between treatments. (A) Venn diagram showing 
functions predicted to be increased in each data set. Samples shown are 8hr recovery cells 
compared to dissociated cells with after each treatment. Functions of interest are listed outside of 
diagram (B) Venn diagram showing the functions predicted to be decreased based on the data 
sets. 
 
6.7.1 Validation of functions relating to apoptosis 
The most interesting functions were those which suggesting decreased apoptosis 
or increased cell survival, so a number of genes within these functions were 
validated. From within the functions shared between T16 and Y27632 treatments 
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that predicted decreased apoptosis, FGF2, MAP2K6 (mitogen activated protein 
kinase 6), SPP1 (secreted phosphoprotein 1) and ADAMTS1 (ADAM 
metallopeptidase with thrombospondin type 1 motif) were chosen for validation. 
Figure 6.13A shows that both ADAMTS1 and SPP1 had significantly increased 
expression in the 8hr recovery cells when compared to the post dissociation cells 
(P=<0.05), however, as observed with other validation targets, this was not 
treatment specific. Although the differences were not significant, the fold 
increases observed were lower in untreated cells than in T16 or Y27632 treated 
cells for both ADAMTS1 and SPP1. T16 and Y27632 treated cells had ~13 fold 
increase in ADAMTS1 compared to ~6 in untreated cells. The fold increase in 
SPP1 was ~31 fold in T16 and Y27632 treated cells and ~20 fold in untreated 
cells. The changes observed in FGF2 and MAP2K6 were not reproduced during the 
validation process. 
In addition, as anoikis is a potential mechanism through which T16 could be 
mediating the pro-survival effect, genes from that pathway were also chosen for 
validation, these were CDCP1 (CUB domain containing protein 1), BMF (Bcl2 
modifying factor), CDH1 (E-cadherin) and TGFB1 (transforming growth factor 
β1). The changes in expression observed in CDCP1, BMF and CDH1 from the array 
were reproduced during the validation process, with 8hr recovery cells having 
significantly increased expression of CDCP1 and CDH1 and significantly reduced 
BMF when compared to the post dissociated cells (P=<0.05), but again these 
were not specific to treatment type. When analysed by qRT-PCR the scale of 
change (fold change) was slightly higher than that detected during the array, 
which may suggest difference in sensitivity between procedures. For example, in 
the original array, CDH1 was predicted to be increased by 2.5-fold in T16 8hr 
recovery cells, however the fold change when validated showed an 11.8-fold 
increase. The changes seen in TGFB1 expression did not validate as there was no 
significant difference in expression between treatments or over time (Figure 
6.13B).  
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Figure 6.13- Validation of function changes. IPA predicted several functions to be either 
increased or decreased in response to each of the data sets. (A) From the functions predicted to 
decrease apoptosis shared by T16 and Y277632 treatments, there were significant increases in 
expression of both ADAMTS1 and SPP1 in the 8hr recovery cells compared to the post 
dissociation cells (P<0.05), however this was also the case in untreated cells. The changes in 
expression in FGF2 and MAP2K6 did not validate. (B) Genes relating to the function of decreased 
anoikis were validated and show significant decrease in BMF expression in all 8hr recovery 
samples. CDCP1 expression was significantly increased in all treatment types in the 8hr recovery 
cells when compared to post dissociation cells (P=<0.05). Data shown as mean 2
ΔCt
 x1000 ± SEM. 
Experiments were performed with technical and biological triplicates (n=3 in triplicate). 
 
204 
 
6.8 Gene expression unique to T16 
Although there were a number of canonical pathways and functions that were 
predicted to be altered in these data sets, the gene changes that were unique to 
the T16 8hr recovery cells had yet to be investigated. Using the raw data file 
produced from the ANOVA, all significantly differentially expressed genes with 
fold changes greater than 1.2 or less than -1.2 were used to compile the Venn 
diagram below (figure 6.14). The data show that ~26% of differentially expressed 
genes were common to all three treatments and that a further 30% were shared 
between T16 and untreated cells. However there were 1009, 1098 and 650 genes 
that were unique to T16, untreated or Y27632 treated cells respectively. From 
the cohort of probe targets unique to T16 treated cells at the 8hr recovery 
period, a number had known roles in cell adhesion and cell survival; AMIGO2 
(adhesion molecule with Ig-like domain), ANGPT1 (angiopoietin 1) and CYR61 
(cysteine rich angiogenic inducer 61). Each of these genes was significantly 
upregulated in T16 treated hPSC in the 8hr recovery cells when compared to the 
dissociated cells, with relatively large fold changes of 4.6, 2.6 and 3.8 fold 
respectively.  
The changes in expression in these genes would be predicted to result in 
increased adhesion and survival and were therefore validated using qRT-PCR 
(figure 6.15). The results, as with previous validation targets, show there was 
significant upregulation of these genes (P=<0.05) in the 8hr recovery cells when 
compared to the cells lysed immediately following dissociation, however, these 
did not turn out to be unique to T16, with there being no significant difference 
between treatment groups.  
Although these targets do not appear to be unique to T16 treated cells, these 
results highlight a number of genes that are clearly upregulated by hPSC in 
response to dissociation and may be interesting targets to investigate at the 
protein level.  
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Figure 6.14- Venn diagram of gene expression after 8hr recovery period. Differentially 
expressed cells from 8hr recovery cells in response to each treatment type were used to create a 
Venn diagram showing genes unique to each treatment. Only genes with fold changes of >1.2 or <-
1.2 were included. 
 
  
Figure 6.15- Validation of genes unique to T16 treatment in 8hr recovery hPSC. Candidate 
genes with high fold changes and functions relating to adhesion and cell survival which were 
unique to T16 treated cells were validated by qRT-PCR. The results show that although AMIGO2, 
ANGPT1 and CYR61 were significantly upregulated in the 8hr recovery cells when compared to 
dissociated cells, both Y27632 and untreated control cells also had significantly increased 
expression (P=<0.05). Data shown as mean 2
ΔCt
 x1000 ± SEM. Experiments were performed with 
technical and biological triplicates (n=3 in triplicate). 
 
 
 
 
8hr recovery vs dissociated microarray 
fold changes 
 
Gene T16 Y27632 Untreated Validation 
PiK3AP1 1.5↑ 1.4↑ n/a Significantly increased expression in 8hr samples regardless of treatment type 
PiK3R1 1.9↑ n/a n/a Significantly increased expression in 8hr samples regardless of treatment type 
PiK3C2B 1.7↑ 1.6↑ n/a Target did not validate 
ITGA6 1.2↑ n/a n/a Significantly increased expression in 8hr samples regardless of treatment type 
ITGB1 1.6↑ 1.4↑ n/a Significantly increased expression in 8hr samples regardless of treatment type 
PTK2 1.3↑ n/a 1.2↑ Significantly increased expression in 8hr samples regardless of treatment type 
PXN 1.4↑ 1.4↑ n/a Significantly increased expression in 8hr samples regardless of treatment type 
ADAMTS1 4.7↑ n/a n/a Significantly increased expression in 8hr samples regardless of treatment type 
BMF 2↓ 2.6↓ n/a Significantly decreased expression in 8hr samples regardless of treatment type 
CDCP1 2.3↑ n/a n/a Significantly increased expression in 8hr samples regardless of treatment type 
CDH1 2.5↑ n/a n/a Significantly increased expression in 8hr samples regardless of treatment type 
FGFR2 2.6↓ 2.5↓ n/a Target did not validate 
MAP2K6 2.3↓ 2.8↓ n/a Target did not validate 
SPP1 4.2↑ n/a 3.8↑ Significantly increased expression in 8hr samples regardless of treatment type 
TGFB2 1.4↑ 2.1↑ n/a Target did not validate 
AMIGO2 4.6↑ n/a n/a Significantly increased expression in 8hr samples regardless of treatment type 
ANGPT1 2.6↑ n/a n/a Significantly increased expression in 8hr samples regardless of treatment type 
CYR61 3.8↑ n/a n/a Significantly increased expression in 8hr samples regardless of treatment type 
Table 6.2- Summary of validation targets. Table showing the fold changes observed in genes of interest in the initial data set alongside the validation results for 8hr 
recovery cells compared to dissociated cells in each treatment type.
 
 
6.9 Summary 
Presented within this chapter are the results gained from an Affymetrix based 
microarray experiment, performed to better understand the transcriptional 
response of hPSC to dissociation, and to determine if T16 treatment 
transcriptionally primed hPSC for survival post dissociation. The data produced 
suggests that T16 does not mediate its pro-survival effect via transcriptionally 
priming cells for survival as there were no differentially expressed probes when 
T16 treated cells were compared to cells that had received no treatment. 
Furthermore these data confirm the importance of the Pi3K/Akt and integrin 
signalling pathways in hPSC and show that they are highly regulated pathways in 
the response to dissociation. The data also highlights a number of genes such as 
SPP1, AMIGO2 and CYR61 as potential important regulators of adhesion in hPSC. 
 
 
 
 
 
 
 
 
 
 
 
 
7 Discussion 
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Human pluripotent stem cells (hPSC) such as hESC and hiPSC have great 
potential in a number of scientific fields, including developmental biology, 
toxicology, pathobiology and regenerative medicine. Since the initial isolation of 
hESC in 1998 (Thomson et al, 1998) and derivation of human iPSC in 2007 
(Takahashi et al, 2007), huge strides have been made in driving these cell types 
towards the clinic. However, the culture of hPSC remains a limiting factor, with 
their sensitivity to enzymatic dissociation and dependence on the Rho-kinase 
(ROCK) inhibitor Y27632 being particularly troublesome for the move to larger-
scale applications (Watanabe et al, 2007; Ohgushi et al, 2010).  
In 2007, Watanabe and colleagues initially described that the Rho-kinase 
inhibitor Y27632 supported the survival of dissociated hESC (Watanabe et al, 
2007). Since then Y27632 has become an indispensable tool in hPSC culture and 
manipulation. The mechanistic action of Y27632 has until recently been largely 
unknown, however in 2010 a number of publications implicated ROCK induced 
actin-myosin contractility as the cause of dissociation induced apoptosis. Y27632 
treatment circumvents this by reducing the ROCK mediated 
hyperphosphorylation of myosin light chain 2 (MLC2) (Chen et al, 2010; Ohgushi 
et al, 2010; Walker et al, 2010).  
ROCK inhibitors have proven to be incredibly useful, however there have been 
recent concerns that use of Y27632 may result in some undesirable outcomes. 
The small GTPase RhoA is a ubiquitously expressed protein involved in a number 
of fundamental biological processes including differentiation, cell division, 
apoptosis, adhesion and cytoskeletal regulation (Jaffe and Hall, 2005; Visvikis et 
al, 2010). Interference with such a diverse range of processes can interfere with 
normal cell functions, has been shown to decrease cell proliferative potential 
(Zweigerdt et al, 2011) and has been associated with an increased risk of 
transformation (Riento and Ridley, 2003; Liu et al, 2012). Furthermore, the 
inhibition of Rho signalling has been shown to have various lineage specific 
effects on cell differentiation; with inhibition being shown to enhance 
differentiation into endothelial cells, whilst preventing differentiation towards 
others such as haematopoietic cell lineages (Joo et al, 2012; Yung et al, 2011; 
Chen et al, 2012).  
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A number of studies that aimed to identify alternative pro-survival compounds 
have been reported. A large throughput study by Xu et al (2010) found only 2 
compounds from a screen of over 50,000 that had a pro-survival effect on hPSC. 
The first of these compounds, Thiazovivin was subsequently shown to have 
significant inhibitory effect on ROCK when used at concentrations as low as 2µM. 
The second of the highlighted compounds, Tyrintegin, did not inhibit ROCK as 
assessed by an in vitro kinase assay but the authors did not investigate any 
alternative impact on the ROCK signalling pathway such as MLC phosphorylation. 
They reported that the use of a Pi3K inhibitor completely ablated the protective 
effect of Tyrintegin (Xu et al, 2010) and concluded that this pathway has a role 
in hPSC survival.  
A further study, performed by Barbaric et al (2010) demonstrated that pinacidil 
and HA-1077, as well as 3 other compounds also had a pro-survival effect on 
hPSC, but again each of these were subsequently shown to be inhibitors of 
ROCK. Thus, despite employing these high-throughput strategies, a suitable hPSC 
survival compound that does not inhibit ROCK has not yet been identified (Xu et 
al, 2010; Barbaric et al, 2010) and no other mechanism mediating for stem cell 
death/survival during dissociation has been elucidated.  
Our lab recently performed a high throughout assay screening over 20,000 
compounds for any positive effect on hPSC survival. This published work 
(Andrews et al, 2010) identified a further 18 survival compounds that were able 
to promote survival of dissociated hPSC. As with previous work, in vitro kinase 
assays were performed and the results revealed that although some of the 
compounds were more selective, each of the identified molecules were also 
inhibitors of ROCK. However, this project identified an additional 19th compound 
that had no inhibitory effect on ROCK. Further characterisation of this 
compound, referred to as T16, was not within the scope of that project and it 
was therefore omitted from the resulting publication.       
This thesis describes the characterisation of T16, a novel pluripotent stem cell 
survival compound that did not inhibit ROCK in an in vitro kinase assay, and 
which will allow not only further investigation in to the pathways involved in 
dissociation induced cell death but may also provide a platform to accelerate 
the translation of hPSC derived therapies and products.  
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The experiments described in chapter 3 of this thesis aimed to further 
characterise the survival benefits of T16 and to determine if T16 could be used 
as an alternative to the commonly used Y27632.  
The first step taken was to optimise the performance of T16. Although there 
were significant increases in cell survival when used between 10µM and 40µM, 
T16 was shown to be most effective at 30µM. A concentration of 50µM resulted 
in cell survival similar to that of untreated cells, which suggests that at this high 
concentration T16 may be toxic to hPSC. Pre-treatments ranging from 2hrs to 
24hrs resulted in significantly increased cell survival when compared to no pre-
treatment, with survival increasing with the length of pre-treatment towards the 
optimal point at 24hrs. Based on these observations, all subsequent experiments 
were performed at a concentration of 30µM and with a 24hr pre-treatment. This 
differs from Y27632 which, in keeping with its known activity as a kinase 
inhibitor, has been shown to work optimally at 10µM, with a short (1-2hr) pre-
treatment followed by use immediately post dissociation (Watanabe et al, 2007). 
Y27632 has also been used to successfully support hPSC survival when added 
after dissociation but with no pre-treatment (Singh et al, 2010). The 
requirement for pre-treatment as well as the maximum effect at 24hr pre-
treatment is perhaps indicative that T16 does not function via direct kinase 
inhibition (at least as an ATP competitive inhibitor), which is supported by the in 
vitro kinase assay which showed T16 had no inhibitory effect on 120 of the 121 
kinases assayed and only a minor effect on RIPK2.  
In order for T16 to be accepted as a valid alternative to Y27632, it would be 
necessary to demonstrate a pro-survival effect comparable to that of Y27632. 
The body of data generated and presented in chapter 3 shows that T16 
treatment not only significantly increased cell survival compared to untreated 
control cells, but also resulted in cell survival equivalent to Y27632 treatment. 
Furthermore, T16 can be used to support enzymatic passage of hPSC for at least 
30 consecutive passages when used transiently at the point of passage or for at 
least 20 passages when included continuously in culture medium.   
It is important to appreciate the inherent variability of hPSC lines as well as the 
differences between hiPSC and hESC (Allegrucci and Young, 2007). It is therefore 
reassuring that the response to T16 was consistent over a number of hESC lines 
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including the original Wisconsin cell lines H1 and H9 (Thomson et al, 1998) as 
well as a GMP grade cell line; RC9 (Roslin Cells Ltd, Edinburgh). Additionally, the 
pro-survival effect was observed when a hiPSC (NMF-iPS6) line reprogrammed by 
Sullivan and colleagues, using retroviruses containing c-Myc, Klf4, Sox2 and 
Oct4, was used (Sullivan et al, 2010).  
Similarly, the ability of T16 to support survival regardless of ECM (FN, VN, CS or 
Matrigel) or culture medium used (StemPro hESC SFM, mTeSR1 or MEF-CM) 
suggests that the pro-survival effect observed in response to T16 treatment is 
not an artefact of cell culture but is in fact a direct response to the molecule.  
The effect of prolonged exposure to T16 on the expression of key pluripotency 
related markers was also examined. SSEA4 and SSEA1 have been used as positive 
and negative markers of pluripotency respectively in a number of publications 
such as in Thomson et al (1998). Critically, both transient and continuous use of 
T16 had no effect on the expression of pluripotency marker SSEA4 which had 
consistent expression on >95% of cells for at least 30 passages (20 for continuous 
use) as determined by flow cytometry. Furthermore, the proportion of cells 
expressing the differentiation marker SSEA1 remained at <5% throughout, again 
determined by flow cytometry. In addition, T16 treated cells retained high 
expression of the core pluripotency transcription factor Oct4 (Babaie et al, 2007; 
Boyer et al, 2005) and of the pluripotency associated cell-surface marker Tra-1-
81, as assessed by immunocytochemistry.  
An expanded panel of genes with known roles in regulation of pluripotency and 
the stem cell state, as well as those expressed in differentiated cell types, were 
also examined at the transcriptional level via qRT-PCR using the TLDA platform. 
The resulting data showed that treatment with T16 did not result in differential 
expression of any of the genes tested after 15 consecutive passages. Expression 
of differentiation markers such as GATA4, FOXA2 and PAX6 remained 
consistently low whilst components of the core transcriptional regulators of 
pluripotency such as Oct4, Nanog and Sox2 remained high. Furthermore, there 
were no significant differences in expression when compared to Y27632 treated 
cells. This data is further evidence that T16 is a suitable alternative to Y27632 
treatment as it does not alter the transcriptional profile of these critical 
regulators of stem cell identity.   
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Whenever a new reagent is used in pluripotent hPSC culture systems, it must be 
shown that it does not interfere with the multi-lineage differentiation capacity 
of the cells. When Y27632 was first described, Watanabe et al (2007) confirmed 
the pluripotent potential of hESC by teratoma formation in mice as well as via 
passive differentiation into multiple lineages. However, the method of passive 
differentiation alone is now more commonly used (Hasegawa et al, 2006; Burton 
et al, 2010) as alternatives that reduce animal use are sought. HPSC treated for 
multiple consecutive passages either transiently or continuously were able to 
differentiate towards mesoderm shown by staining for  smooth muscle actin 
(SMA), ectoderm (PAX6) and endoderm (alpha fetoprotein, AFP) thereby 
confirming that prolonged and continuous exposure to T16 does not negatively 
impact their capacity for multi-lineage differentiation. Furthermore, treated 
cells were able to undergo differentiation towards red blood cells (RBC) using a 
feeder-free suspension based protocol (Mountford lab, patent filed).  
Having demonstrated that T16 treatment supports hPSC survival upon enzymatic 
disaggregation without negatively impacting the expression of pluripotency and 
differentiation markers at both the protein and mRNA transcript level, it was 
important to determine if T16 treatment lead to abnormal karyotype. Prolonged 
culture of hPSC can result in chromosomal abnormalities, often the acquisition 
of an additional copy of chromosomes 12 or 17 (Maitra et al, 2005), and the 
enzymatic passage of hPSC using reagents such as Y27632 has been shown to 
result in increased incidence of abnormalities (Mitalipova et al, 2005). 
Karyotypic stability, as assessed by G-banding analysis, confirmed that H1 hESC 
cells treated with T16 or Y27632 remained karyotypically normal for at least 30 
passages when used the molecules were used transiently during passage. 
Furthermore, hiPSC remained normal for at least 20 consecutive passages when 
T16 was used continuously as a culture medium supplement. However, hiPSC 
treated continuously with Y27632 had an additional copy of chromosome 12 in 2 
of 20 cells analysed at passage 20 (P20). This is likely to be the result of stress 
and the resulting adaptation caused by continuous use of Y27632. This is 
supported by data showing a dip in survival of cells continuously treated with 
Y27632 between passages 10-12 which subsequently recovered. Also in this set of 
experiments with hiPSC transient use of Y27632 over multiple passages also 
resulted in an extra copy of chromosome 12 in 1 of the 20 cells analysed at P20, 
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which is contrasting to results from the earlier separate experiment shown 
earlier in chapter 3 in which H1 hESC treated transiently with Y27632 retained 
normal karyotype at P20. These differences might also reflect differential 
sensitivity to karotypic instability between hESC and hiPSC. Although the 
abnormalities observed in response to Y27632 treatment could be a result of 
tissue culture adaptation (Matalipova et al, 2005) rather than a consequence of 
Y27632 treatment, other studies have warned of an increased incidence of 
aneuploidy in response to treatment with Y27632 (Riento and Ridley, 2003; Liu 
et al, 2012). As all cells in these two experiments originated from the same 
karyotypically normal hPSC populations (H1 hESC or hiPSC), and only those 
treated with Y27632 developed any abnormalities, this data could suggest T16 is 
better suited than Y27632 at supporting normal expansion of hPSC.  
The data garnered during the characterisation phase of this study raises 
interesting and potentially very useful applications for T16. The culture of hPSC 
is continually evolving and the development of fully defined, xeno free and 
scalable culture systems is at the heart of the drive to realise the great hope of 
clinical applications for hPSC (Chen et al, 2011; Ludwig et al, 2007). We have 
shown that T16 supports survival of dissociated hPSC in undefined MEF 
conditioned medium as well as in more defined commercial culture systems such 
as Stempro and mTeSR. Currently, all of the available media systems rely on 
additional treatment with Y27632 if single cell suspensions are required and 
mechanical or partial dissociation methods, that require a significant degree of 
skill and experience, are widely used during passage to avoid dissociation 
induced apoptosis. However the use of partial dissociation methods limits the 
use of the cells for transfection, cloning and cell sorting applications. T16 was 
added to Stempro™ medium as a continuous supplement with no detectable 
adverse effects, which allowed the passage and manipulation of hPSC without 
the requirement of additional drug treatments. This could reduce the complexity 
of hPSC culture and may aid the development of even more defined ‘all purpose’ 
culture media that permit the single cell preparation or passage of healthy hPSC 
whenever they are needed without pre-treatment.  
T16 was initially found to lack kinase inhibitor activity and to confirm the result 
of the previous kinase screen, was retested with an expanded panel of kinases 
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(performed at The International Centre for Kinase Profiling, Dundee). These 
results confirmed that T16 did not have any inhibitory effect on ROCK. However, 
they did highlight some inhibition of RIPK2 (receptor interacting protein kinase). 
RIPK2 has been implicated in cytokine responses of cells from both the adaptive 
and innate immune systems via activation of NFκB. RIPK2 consists of an N-
terminal kinase domain, linked to a C-terminal caspase activation and 
recruitment domain (CARD) via an intermediate region and has been reported to 
induce apoptosis in immune cell types (Moreira and Zamboni, 2012; Tigno-
Aranjuez et al, 2013; Navas et al, 1999). Given the downstream signalling 
associated with RIPK2, an inhibitor of IκK (TPCA-1) was used to disrupt activation 
of NFκB mediated signalling, however, this had no effect on hPSC survival (with 
or without T16 treatment). Western blot analysis was performed on hPSC to 
confirm the expression of RIPK2, but despite testing numerous antibodies, no 
positive signal was detected. As T16 was only a weak inhibitor of RIPK2, and 
given the poor supply of reagents available to investigate this pathway, we 
decided not to investigate any further. However, RIPK2 is activated by 
nucleotide oligomerization domain protein 2 (NOD2) a key mediator of 
homeostasis in the immunological mucosa, and over-activity of this NOD2/RIPK2 
pathway is implicated in aberrant inflammatory responses. The inhibition of 
RIPK2 is therefore a clinically important target for drug development to treat a 
variety of auto-immune diseases including  Crohn’s Disease and sarcoidosis 
(Tigno-Aranjuez et al, 2010) and future investigations of T16’s capacity to very 
specifically inhibit RIPK2 could be interesting in this regard. 
After reaffirming that T16 was not an inhibitor of ROCK by repeating the in vitro 
kinase assay on an expanded panel, we next set out to determine if T16 
mediates its effect independently of the well described RhoA/ROCK/MLC axis. 
It is widely believed that the ROCK mediated hyperphosphorylation of MLC and 
the resulting actinmyosin induced contractility is the direct cause of dissociation 
induced apoptosis of hPSC (Chen et al, 2010; Ohgushi et al, 2010; Walker et al, 
2010). Treatment with Y27632 leads to a reduction in levels of phosphorylated 
(active) MLC and thereby increases the proportion of cells that survive. 
Interaction of T16 with this signalling pathway either upstream or downstream of 
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ROCK was investigated and the findings were documented in chapter 4 of this 
thesis. 
To investigate whether T16 had the same mechanistic target as Y27632, western 
blot analysis was used to evaluate expression levels of pMLC in response to 
dissociation. Strikingly, T16 did not significantly reduce the phosphorylation of 
MLC when compared to untreated control cells and at several time points 
resulted in levels of pMLC higher than that seen in control cells; T16 treated 
cells also had significantly increased levels of pMLC when compared to Y27632 
treated cells. The data resulting from Y27632 and untreated control hPSC were 
consistent with that observed by other groups (Chen et al, 2010; Ohgushi et al, 
2010) which not only confirmed the reliability of these results, but also gave 
further support to the documented mechanistic action of Y27632, whilst 
suggesting an alternative mechanism for T16. This was the first evidence for a 
non-pMLC dependent mechanism for hPSC survival after dissociation. 
It has been shown previously that the small GTPases RhoA and Rac1 have an 
antagonistic relationship through which activation of one can lead to a decrease 
in the other (Tang et al, 2012). Also, Ohgushi et al (2010) have suggested that a 
RhoA-high/Rac1-low status occurs upon dissociation and that constitutively 
active Rac1 can rescue hPSC from dissociation induced apoptosis. Although 
previous results suggest that T16 promotes hPSC survival regardless of the 
phosphorylation status of MLC, the possibility that upstream interaction with the 
Rho/ROCK/MLC axis, which perhaps favoured a Rac1-high/RhoA-low status, 
could not be ruled out. Therefore GTPase activation assays were used to 
determine the activation status of both RhoA and Rac1 in response to 
dissociation.  
The data generated were in agreement with the findings of Ohgushi et al (2010), 
showing a sudden and significant increase in RhoA activation in untreated cells 
upon enzymatic disaggregation. However, the data presented within this thesis 
expanded upon this published data and showed that, despite the recent 
evidence suggesting a possible feedback mechanism through which ROCK 
inhibition can decrease RhoA activation in a TIAM1 dependent manner (Tang et 
al, 2012), treatment with Y27632 was unable to prevent the sudden activation of 
RhoA. Similarly, treatment of hPSC with T16 was also unable to prevent the 
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sudden activation of RhoA in response to dissociation. These data suggested that 
T16 does not prevent the hyperphosphorylation of pMLC by targeting proteins 
upstream from ROCK and further supports the hypothesis that T16 mediates 
survival of hPSC independent of the RhoA/ROCK/MLC axis.  
Although activation of RhoA is undeniably a principle component of apoptosis in 
dissociated hPSC, its activation does not necessarily result in apoptosis. 
Experiments in chapter 4 showed that treatment with LPA, a well-documented 
RhoA activator (Frisca et al, 2013), resulted in significantly increased levels of 
GTP bound RhoA in hPSC. However this chemically induced activation did not 
negatively impact the survival of cells treated with T16 or Y27632. This is not 
surprising in Y27632 treated cells given that the mechanistic target, ROCK, is 
downstream of RhoA and Y27632 is therefore, able to block terminal signalling 
events despite RhoA activation. However, this provided strong evidence that T16 
mediated its pro-survival effect independently of the RhoA/ROCK/MLC axis as 
the activity of both the upstream regulator (RhoA), and downstream target 
(MLC), were unaffected by T16 treatment.   
When the activation status of Rac1 was investigated, there were no significant 
differences in the levels of GTP bound Rac1 in response to dissociation of 
untreated cells or those treated with either small molecule survival compound. 
Although there were detectible levels of active Rac1 in each of the time points 
measured, the dissociation of hPSC did not result in significant up or down 
regulation of Rac1 activity (although there was a trend towards decreased 
activity after 2hrs). These findings suggested that T16 did not mediate its 
protective effect by promoting Rac1 activity, and are different to those reported 
by Ohgushi et al (2010), who observed a decrease in active Rac1 30minutes post 
dissociation in untreated cells. This may be due to differences between cell 
types as the data presented here was generated using hiPSC whereas Ohgushi 
and colleagues used hESC. However it should be noted that Ohgushi and 
colleagues did not measure the activation status of Rac1 beyond 30minutes post 
dissociation and it is unclear if the results reported were reproducible as only a 
single image is shown. During experimentation, the activation status of Rac1 was 
highly variable, however, although the data did not reach significance, levels of 
GTP bound Rac1 did decrease with increasing time post dissociation.  
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Although this data suggested that T16 did not promote survival via modulation of 
Rac1 activity, we performed experiments that reaffirmed the critical importance 
of signalling mediated by Rac1. The use of the Rac1 inhibitor NSC23766 to 
specifically inhibit the interaction between Rac1 and its associated GEFs, TIAM1 
and Trio, resulted in a significant, dose dependent decrease in hPSC survival 
post dissociation even in the presence of the pro-survival compounds T16 or 
Y27632. Under normal physiological conditions, integrin dependent cell adhesion 
is associated with high levels of GTP bound Rac1 which allows the formation of 
cell protrusions and nascent adhesions which eventually develop into the major 
signalling complexes known as focal adhesions (Parsons et al, 2010; Iden and 
Collard, 2008; Etienne-Manneville Hall, 2002; Ridley, 2001). The inability to re-
establish these cell-to-matrix adhesions clearly has massive implications on the 
survival of hPSC which cannot be overcome by either of the survival compounds. 
A key observation in the response to Y27632 treatment is that in the absence of 
a suitable ECM or when low attachment culture dishes are used, hPSC form small 
cell aggregates that not only remain viable (>70%), but under the appropriate 
conditions will remain pluripotent or can be induced to differentiate (Watanabe 
et al, 2007). In contrast, T16 or untreated cells failed to form cell aggregates 
when dissociated and placed into suspension culture in standard pluripotency 
culture medium. Furthermore, within 24hrs these cells in non-adherent culture 
wells, are largely apoptotic (> 80%) as determined by annexin V/PI assays. This 
not only highlights a key difference between these two survival compounds but 
critically shows that survival promoted by T16 was dependent upon cell-matrix 
adhesion in contrast to Y27632, which can enhance cell-cell adhesion and 
subsequent survival. However, when NSC23766 was used in combination with 
Y27632 the hPSC did not re-aggregate and were unable to evade apoptosis. This 
suggested that the inhibition of ROCK and the subsequent actinmyosin based 
contractility alone was not sufficient to prevent apoptosis, but rather that it the 
re-establishment of cell-matrix or cell-cell adhesions that was the critical factor 
in preventing hPSC from dissociation induced apoptosis. 
Although these findings were in disagreement with the dogma that Y27632 acts 
via inhibition of pMLC, further evidence for the role of cell-cell adhesion has 
been provided by Krawetz et al (2009). They used Y27632 in combination with 
219 
 
the Ca2+ chelator EGTA and found that blocking the cadherin based cell-cell 
adhesion ablated the pro-survival effect of Y27632.  Their findings were 
reproduced when this experiment was repeated within this thesis.  
Many groups have linked RhoA activity to the regulation of E-cadherin signalling 
with conflicting results showing ROCK inhibition increasing or decreasing cell-cell 
adhesion (Sahai and Marshall, 2002; Harb et al, 2008 and Krawetz et al, 2009). 
Overall, the data described in this thesis suggest that in addition to RhoA, Rac1 
may also play a critical role in regulating E-cadherin dependent cell-cell 
adhesion in hPSC. This raises important questions about the pro-survival 
mechanism of Y27632 as these results suggest that the re-establishment of cell-
cell contact is more important than the inhibition of MLC hyperphosphorylation, 
and that supporting/triggering this may be the pro-survival mechanism of 
Y27632. 
During this study the morphological appearance of Y27632 and T16 treated hPSC 
post passage was found to be strikingly different. Whilst T16 treated cells 
remained well spread and closely resembled untreated control cells, Y27632 
treated cells exhibited a characteristic spikey morphology, with numerous 
spindle-like projections. These morphological differences were further 
investigated this using the myosin inhibitor Blebbistatin or the RhoA inhibitor C3. 
HPSC treated with Y27632, C3 or Blebbistatin resulted in this characteristic 
spikey morphology, reduced cytoskeletal organisation and reduced stress fibres 
as imaged by both phase microscopy and phalloidin staining of F-actin. This 
morphology was somewhat expected as a result of C3 or Y27632 treatment given 
the role of RhoA in actin cytoskeleton organisation (Bristow et al, 2009; Parsons 
et al, 2010 and Jaffe and Hall, 2005). However, as Blebbistatin does not inhibit 
ROCK this phenotype was unexpected and suggests that the cause of this 
phenotype could be the inhibition of actinmyosin induced contractility rather 
than upstream RhoA signalling. This hypothesis is further supported by data from 
Chen et al (2010), who observed the same phenotype following RNAi mediated 
knockdown of MLC and the myosin heavy chain.  In contrast, both untreated and 
T16 treated hPSC resulted in a well spread morphology with well organised, F-
actin rich cytoskeleton which further supports the western blot data showing 
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T16 does not inhibit the hyperphosphorylation of MLC or affect cytoskeletal 
organisation.  
The data presented in chapter 4 indicated that T16 did not have the same 
mechanistic target as Y27632 (ROCK) and did not appear to interact either 
upstream (RhoA/Rac1) or downstream (MLC) of the RhoA/ROCK/MLC pathway 
that has been shown to be critical for Y27632 mediated survival of hPSC. This 
may make T16 incredibly useful as it will avoid many of the off target effects 
associated with interference of such a complex signalling pathway 
Having concluded that T16 supports survival in a manner independent of the 
RhoA signalling pathway, the work described in chapter 5 of this thesis focussed 
on determining the mode of action of T16. Apoptosis assays performed under 
non-adherent conditions had shown that the pro-survival effect of T16 was 
dependent upon cell-matrix adhesion. For this reason, investigations into the 
expression levels of genes with known roles in cell adhesion including integrins, 
cadherins, and a number of adapter and scaffolding proteins thought to be 
involved in adhesion dynamics, were performed. Previous groups have reported a 
critical role for integrins in hPSC maintenance and have shown widespread 
expression of family members (Meng et al, 2010; Rowland et al, 2010; Rodin et 
al, 2010 and Miyazaki et al, 2012). Using integrin blocking antibodies, Meng and 
colleagues suggested that the most important integrins for hPSC adhesion were 
αVβ3, α6, β1, and α2β1. Analysis of mRNA levels by qRT-PCR confirmed the 
expression of a number of α and β integrin sub-units including those above, 
however, T16 treatment did not significantly alter the expression of any of these 
integrins at least at the transcriptional level. Flow cytometric analysis of 
integrin proteins at the cell surface confirmed endogenous expression of a 
number of these integrins, however, result also showed that T16 did not alter 
their expression when compared to untreated or Y27632 treated cells. Similar to 
that seen by Meng and colleagues, >90% of cells were positive for β1, α2 and α6 
and >80% positive for αV when assessed by flow cytometry and the MFI were 
similar showing that recycling of integrins at the cell surface was unlikely to be 
affected. Unexpectedly, neither H1 hESC cells nor hiPSC had detectable 
expression of integrin β3 as assessed by mRNA or protein level.  Analyses in this 
study were performed with cells cultured on fibronectin, whereas Meng et al 
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used Matrigel. This difference in culture system may account for the difference 
in expression of integrin β3 as Matrigel is a more complex undefined product in 
contrast to fibronectin, and other studies have also reported little or no 
detectable expression of integrin β3 in hPSC (Braam et al, 2008). Although 
undoubtedly important, these results suggest that T16 does not directly 
modulate integrin expression.  
As with the analysis of integrin expression, none of the other adhesion related 
genes analysed were differentially regulated in response to treatment with T16 
or Y27632. We therefore targeted intracellular pathways with known roles in 
adhesion or pro-survival pathways by using kinase inhibitors (Pi3k/Akt, EGFR, 
Src, PKC and TGFβ). The kinase inhibitors were used in the same way as Y27632 
in that the cells were given a 2hr pre-treatment with each inhibitor, and the 
medium was supplemented with each inhibitor post passage and survival was 
assessed 24hr post dissociation. The results of these studies revealed a role for 
PKC in survival of hPSC. Inhibition of PKC signalling resulted in increased survival 
when compared to untreated control cells (2-fold increase in survival) which is 
consistent with the effect reported by Damoiseaux et al (2009) who also 
observed that inhibitors of PKC increased survival in hPSC. Although inhibition of 
PKC supported survival, it did not do so as efficiently as either T16 or Y27632. It 
therefore seemed likely that PKC is part of a complex signalling network which 
results in hPSC death rather than a direct target of T16, this is supported by the 
in vitro kinase data which showed T16 had no effect on several PKC isoforms 
included within the panel.  
In contrast, the use of the Src-family inhibitor PP2 resulted in very clear 
difference in the response of T16 and Y27632 treated hPSC. PP2 treatment had 
no effect on the survival of Y27632 treated hPSC, however when used in 
combination with T16, PP2 completely ablated the pro-survival effect. This 
observation was consistent regardless of the cell line used. To further 
investigate hPSC were treated with PP2 at various time points before and after 
dissociation and it was clear that the capacity of PP2 to reduce cell survival in a 
time dependent manner.  Untreated hPSC, as well as those treated with T16 or 
Y27632, had PP2 added either 2hrs pre dissociation (and thereafter), at the 
point of passage, or 30mins, 1hr, 2hr, 4hr, or 8hr post passage. Addition of PP2 
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to cultures either 4hr or 8hr post dissociation resulted in a diminished effect of 
PP2 (~45% and ~60% respectively), with the latter showing no significant 
difference to T16 alone. However, when used at earlier timepoints post-
dissociation, PP2 over-rode T16 mediated survival and resulted in cell death. 
During routine passage using survival compounds, hPSC begin to adhere to the 
ECM within the first 1-4 hours following dissociation, therefore, these results 
could suggest that Src-family kinase activity is required for T16 mediated 
adhesion to the ECM during this initial time period, but that once cells have re-
established contact with the ECM (after 4hours) this activity of Src-kinases is 
dispensable. Src-family kinases have a well-established role in adhesion 
signalling and can be activated following integrin activation or downstream of 
receptor tyrosine kinases (RTK) such EGFR and FGFR (Ray et al, 2012; Parsons et 
al, 2010 and Moro et al, 2002). Once activated Src can not only facilitate the 
formation of focal adhesions, but can signal downstream of adhesions to 
promote activation of a number of pathways implicated in cell survival such as 
Pi3K/Akt and MAPK signalling (Mahajan and Mahajan, 2012; Guo et al, 2013; 
Osaka and Gama, 2013). Src signalling can also interact with components of the 
RhoA pathway and has been shown to modulate the activation status of RhoA via 
activation of various GAPs and GEFs such as P190RhoGAP (Papadimitriou et al, 
2011; Parsons et al, 2010). However, upstream regulation of RhoA is unlikely to 
be the mode of action responsible for increased cell survival when considering 
results discussed from chapter 4, which demonstrated that RhoA signalling is not 
altered by treatment with T16.  
Having shown the detrimental effect of PP2 on T16 mediated survival, 
implicating Src-family kinases in the mode of action of this small molecule, the 
expression and phosphorylation state of Src-kinases was investigated by western 
blot using a pan-Src antibody. Src kinases can be phosphorylated (tyrosine) at 
multiple sites; but, phosphorylation of tyrosine 416 within the kinase domain has 
been reported to upregulate activity of members of the family (Hunter, 1987). 
The western blot analysis confirmed that hPSC do express Src-kinases, but 
surprisingly showed there was no increase in phosphorylation in response to T16 
treatment. In fact, although not statistically significant, at many of the critical 
early time points there was a higher level of phosphorylated Src in the untreated 
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control cells. This suggests that although the survival mechanism supported by 
T16 is Src dependent, T16 is not directly regulating Src phosphorylation.  
It is important to appreciate that PP2 is a Src-kinase family inhibitor and it 
remains unclear which specific protein may be causing the effect. The Src-family 
kinases have extensive structural homology and have been shown to have similar 
activation loops. As experienced by other groups (Ding et al, 2011), this makes 
the identification of distinct family members difficult. Although both the total 
Src and pSrc antibodies used in this experiment were directed towards Src, they 
are reported to also bind other family members including total Fyn, Lyn, Yes and 
Hck which can also be phosphorylated at the same site (Y416). Transcriptional 
analysis (qRT-PCR) of a number of these family members confirmed the presence 
of mRNA for Hck, Fyn, Lyn, Yes as well as Src in hPSC and the use of T16 did not 
result in any change in transcript levels of any of the family members. Given the 
non-specific nature of PP2 and that of other reported inhibitors of Src, in order 
to further investigate which family members may be important in mediating the 
pro-survival effect of T16, a more interventional approach may be required. 
Numerous groups have used RNAi as a means through which to further 
deconvolute signalling pathways which involve Src-family members, and this is a 
strategy that may be useful for future studies to determine which family 
members are important in hPSC survival in response to T16 treatment (Taniguchi 
et al, 2013; Iida et al, 2013; Tyner et al, 2009). 
Src family kinases are involved in a plethora of signalling pathways, so in order 
to further investigate the role of Src-kinases in hPSC survival a higher throughput 
approach was taken. Using Proteome Profiler™ Antibody Array kits, the 
activation state of 45 common protein kinases and a further 26 kinases more 
specifically related to MAPK signalling, were assessed in control and T16, T16 + 
PP2 or Y27632 treated cells. Expression profiles of interest were predicted to 
show that PP2 either reduced phosphorylation of kinases that are active in 
response to T16 treatment or increase activity of those that are not. The data 
produced by the proteome profilers was problematic to analyse as it is based on 
mean pixel density of duplicate spots from a single experiment, making it 
difficult to identify any obvious targets. However, it is reassuring to see that PP2 
treatment resulted in a decrease in phosphorylation of Src-family kinases as well 
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as many downstream Src targets such as FAK, EGFR, PDGFR and Akt. Also, given 
that T16 was not seen to inhibit kinases in an in vitro assay, it is reassuring, if 
not surprising, that there were no gross changes in response to T16 treatment.   
Based on the observation that there was no significant differential regulation of 
Src-kinase phosphorylation by T16, we began to consider the possibility that T16 
may alter the relationship between Src-kinases and their upstream or 
downstream targets and/or alter sub-cellular localisation of Src-kinases. 
Receptor for activated protein kinase C (RACK1) was the most highly expressed 
adhesion-related factor identified during our custom adhesion array (qRT-PCR) 
and was confirmed to be expressed at the protein level in both hESC and hiPSC 
by western blotting. RACK1 is a very well conserved scaffold protein thought to 
be expressed in all mammalian cells and was original discovered as a binding 
partner for PKC (isoform βII). However, it has recently been shown to be 
involved more widely in signal transduction pathways either directly or by 
modulation of its binding partners (Adams et al, 2011; Ron et al, 2013; Cox et 
al, 2003; Sutton et al, 2013). RACK1 has also been implicated in the regulation 
of cell adhesion, morphology and migration mainly via its interactions with Src- 
family kinases and integrins (Doan and Huttenlocher, 2007; Mamidipudi and 
Cartwright, 2009; Kiely et al, 2005; Trerotola et al, 2012; Levesque et al, 2006). 
Mamidipudi and Cartwright (2009) have suggested that RACK1 is able to inhibit 
Src activity by binding to it, this subsequently reduces the activation of the anti-
apoptotic Pi3K/Akt signalling pathway. The role of cell-matrix adhesions, 
mediated primarily by integrins, has been heavily associated with not only the 
regulation of pluripotency in hPSC, but also in the activation and suppression of 
various signalling pathways triggered by dissociation (Ohgushi et al, 2010; 
Watanabe et al, 2007; Krawetz et al, 2009; Meng et al, 2010). Therefore, it is 
possible that RACK1 is a mediator of these critical pathways in hPSC, possibly via 
binding to and reducing the activity of Src-kinases, and that T16 may alter this 
interaction and thereby increase stem cell survival. Regulation of this type is not 
uncommon in cells and has been alluded to earlier when discussing the roles of 
GDIs in regulation of small GTPases, wherein GDIs bind GTP bound RhoA and 
alter its sub-cellular localisation, thereby preventing it from binding to (and 
activating) its targets (Garcia-Mata et al, 2011). Furthermore, in a comparative 
transcriptome analyses comparing pluripotent cells from human and mice to that 
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of planarians, Labbe et al (2012) found that RACK1 was one of a small set of 
genes shown to be critical to the maintenance of all three pluripotent cell types 
(Labbe et al, 2012). RACK1, therefore, was a promising candidate factor in the 
mechanism by which Src-kinases modulate T16 mediated survival.  
To investigate this further we used a GST RACK1 fusion protein as well as 
immunoprecipitations with and without T16 treatment. We performed co-
immunoprecipitations using RACK1 to pull-down Src-kinases and found that 
treatment with T16 resulted in a significantly reduced level of Src-kinases bound 
to endogenous RACK1 within hPSC when compared to the untreated cells. 
Furthermore, when the GST RACK1 fusion protein was incubated with hPSC 
lysates, pulldowns from cells treated with T16 also  showed a decrease in 
precipitated total Src-kinases when compared to both the Y27632 treated and 
untreated cells.  
The identification of RACK1 as a potentially important mediator of apoptosis in 
dissociated hPSC may also partly explain why we and others have found PKC 
inhibition to have beneficial effect on hPSC survival (Damoiseaux et al, 2009). It 
has been documented that the activation of PKC results in the co-localisation 
and subsequent binding of Src and RACK1 (Chang et al, 2002). Inhibition of PKC 
may therefore lead to reduced binding between Src and RACK1 which would 
leave Src free to bind alternative intracellular substrates such as those 
promoting adhesion to the ECM such as integrins or FAK. 
The identification of a member, or members, of the Src-family kinases as 
important regulators of apoptosis in hPSC highlights a novel and alternative 
pathway which may further enhance the current understanding of dissociation 
induced apoptosis of hPSC. Src-family kinase signalling has been relatively poorly 
studied in hPSC and to the best of our knowledge has not been directly linked to 
apoptosis/survival in these cells. A number of groups have however implicated 
Src as a mediator of differentiation in hPSC. Using a Src-family inhibitor 
(SU6656), Lian et al (2013) were able to improve directed differentiation 
towards epithelial cells. This group observed increased expression of endothelial 
markers cytokeratin 8 and cytokeratin 18, which they attributed to altered sub-
cellular localisation of β-catenin in response to Src inhibition (Lian et al, 2013). 
Furthermore, treatment with PP2 was found to enhance differentiation toward 
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β-cells as measured by increased expression of transcription factors PAX4 and 
NEUROD1. The authors proposed that loss of Src activity led to a decrease in FAK 
activation which subsequently decreased activation of TGFβ mediated signalling 
pathways (Afrikanova et al, 2011). 
Take together these data highlight a potential and intriguing role for RACK1 as 
an in vivo regulator of Src-family activity and suggest that this relationship may 
be altered in response to T16 treatment. These data suggest that there is less 
intracellular Src bound to endogenous RACK1 or pulled down by GST RACK1 in 
cells treated with T16, and that a Src-kinase may therefore have altered sub-
cellular localisation in response to T16. This merits further investigation which 
could include co-IP of additional Src-kinases binding partners such as integrin β1 
or FAK. It is possible that T16 treatment results in the release of Src from 
RACK1, facilitating the interaction of Src-kinases with integrins, paxillin or FAK, 
which allows hPSC to more efficiently form the critical cell-matrix adhesions 
that support survival. Alternatively Src-kinases may activate pathways critical 
for protection of hPSC from apoptosis such as PI3K/Akt or EGFR signalling which 
could allow hPSC to survive for long enough to re-establish ‘normal’ signalling 
via cell-matrix or cell-cell interactions.  
The process of anoikis has in the past been associated with the dissociation 
induced apoptosis of hPSC (Watanabe et al, 2007; Krawetz et al, 2009). Anoikis 
is a specialised form of apoptosis triggered by loss of cell to matrix adherence 
and many proteins, including those shown within this thesis to be critical to T16 
mediated survival such as integrins and Src-kinases, have been heavily linked to 
anoikis. Work performed by Haenssen et al (2010) showed that both integrin α5 
and Src, which have been confirmed to be expressed in hPSC, were indispensable 
in the development of anchorage-independence in mammary epithelial cells. 
That work also suggested that the two act together to activate several anti-
apoptotic pathways via suppression of the pro-apoptotic Bim, which 
subsequently protects the cells from anoikis. Other groups have suggested that 
β1 integrin, Src and FAK are key orchestrators of both pro-apoptotic and anti-
apoptotic signalling in response to adhesion, or loss of, through regulation of 
multiple Bcl-2 family members and downstream signalling mediated by Pi3K/Akt 
and MEK/Erk (Bouchard et al, 2008). 
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Thus, given the well documented role of Src-kinases in resistance to anoikis, it is 
possible that if treatment with T16 results in less intracellular Src-kinases being 
bound to RACK1, the available kinase may instead promote resistance to anoikis 
via interactions with FAK, integrins and anti-apoptotic signalling pathways 
(Beausejour et al, 2012; Bolos et al, 2010). Given the plethora of pathways that 
can be directly or indirectly regulated by Src-family activity, a higher throughput 
proteomic or metabolomics approach may be required in order to further 
investigate the role of Src-kinases in T16 mediated survival that has been 
identified in this thesis. 
As T16 is not a kinase inhibitor and significant pre-treatment time (>4hrs) 
enhanced the pro-survival effect, it was possible that it was affecting 
transcriptional modulation rather than post-translational modification of 
signalling components. In an effort to better understand the transcriptional 
response to dissociation, and also to determine if there was any differential 
expression in response to treatment with T16 or Y27632, an Affymetrix based 
microarray experiment was designed and performed using hiPSC. To our 
knowledge, no previous publications have investigated the complete 
transcriptional response to dissociation in hPSC.  
To ensure results were as reliable as possible, the hPSC to be used were tested 
for normal karyotype and expression of pluripotency markers such as SSEA4 prior 
to use in the assay. Furthermore, to maximise the chance of observing changes, 
apoptosis assays were performed to confirm the differences in phenotype at the 
time points chosen for analysis. The results showed that 8hr post dissociation, 
T16 and Y27632 treated cells were largely negative for the marker of apoptosis 
annexin V, whereas untreated cells were mostly positive. This was consistent 
with that seen by other groups who also observed expression of apoptotic 
markers at this time point (Ohgushi et al, 2010). 
One of the aims of this study was to determine if T16 treatment transcriptionally 
primed hPSC for survival post dissociation. However when the results were 
analysed and compared, there was very little differential expression between 
surviving T16 treated cells compared to the Y27632 or untreated samples which 
suggested this was not the case. This pattern was similar when making 
comparisons between samples collected immediately before or following 
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dissociation. The lack of difference between any of the 3 treatment types at this 
point was somewhat surprising given that Rho GTPases are well known to 
influence gene expression (Evelyn et al, 2007; Bell et al, 2013). This data does 
however suggest that T16 does not interfere with normal transcriptional 
regulation even though it is present within the culture medium for 24hr prior to 
disaggregation.  
A very clear observation made whilst analysing the complete data set was that 
although there were several comparison groups with >1000 differential 
expressed probes (see table 6.1), the scale of the changes was very small. The 
vast majority of statistically significant changes were changed by <2 fold. 
Although a number of these changes were in genes with roles in adhesion or 
apoptosis and may therefore be biologically relevant, the size of the fold 
changes makes the validation of target genes more difficult.  
The comparison between the cells collected 8hr post-dissociation and those 
collected immediately following dissociation produced the most differentially 
expressed genes and was therefore the focus of all subsequent comparisons. As 
cells at this stage are going through the processes of adhesion and migration, or 
apoptosis in the case of untreated cells, it would be expected that a large set of 
these changes would have been observed in genes relating to these processes. 
The data sets were uploaded to the IPA software which generates a list of 
canonical pathways, functions and upstream regulators predicted to be altered 
in response to each data set. We initially focussed on the top 20 canonical 
pathways and observed that although there were similar pathways altered in 
response to each treatment type, there were some key differences. Amongst 
these were the Pi3K/Akt and integrin signalling pathways, which were both in 
the top 5 pathways impacted in response to T16 and Y27632 treatment, but not 
in the top 20 of untreated cells. The regulation of the integrin signalling 
pathway was interesting, but not altogether surprising given that the cells are 
actively re-attaching and migrating on the ECM following dissociation. 
Furthermore, previous data had shown a critical role for integrins in the survival 
mediated by T16 (figure 4.11). 
The regulation of the Pi3K/Akt pathway was also interesting as previous results 
have confirmed the critical importance of signalling mediated by Pi3K. When the 
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Pi3K inhibitor PI-828 was used, there was a significant decrease in survival 
mediated by both T16 and Y27632 (figure 5.8). Furthermore, previous groups 
have shown that Pi3K can be activated downstream of Src activation and that 
this can subsequently lead to decreased apoptosis (Bouchard et al, 2008; Guo et 
al, 2013). Additionally, Ohgushi et al (2010) highlighted Pi3K as a potential 
salvage pathway able to rescue hPSC downstream of the hyperphosphorylation of 
MLC. The transcriptional regulation of this pathway in response to dissociation is 
further evidence of the critical role that the Pi3K/Akt pathway pathways plays in 
the maintenance of hPSC and their response to dissociation (Eiselleova et al, 
2009; Ohgushi et al, 2010; Wang et al, 2009). 
We chose to validate (by qRT-PCR) a number of components of these pathways 
including several integrin sub-units, FAK, paxillin and Pi3K isoforms. These were 
validated using the original RNA used to perform the microarray. The validation 
results showed that although there were significant increases in expression of 
these genes between the time points, there are no significant differences 
between the three treatment groups. This suggests that although these pathways 
are highly regulated upon dissociation, the responses are not specific to 
treatment type, which was surprising. Given that the majority of untreated cells 
are in suspension and undergoing apoptosis at the 8hr time point, whereas T16 
and Y27632 treated cells are largely adherent, it would be expected that 
expression of adhesion related genes would be different. This may suggest that 
the effect mediated by the survival compounds is largely post translational 
rather than transcriptional. In addition to individual pathways, IPA predicted 
cellular functions that were affected by dissociation and survival compound 
treatments. IPA predicted 101 functions that were expected to have increased 
activity and 16 predicted to have decreased activity. Approximately 20% of the 
functions predicted to be increased were shared between the three treatment 
types, including increased cell survival. This suggests that although treatment 
with T16 and Y27632 results in vastly different outcomes when compared to 
untreated cells, the transcriptional response in many pathways is very similar. 
Of the relatively few functions predicted to be decreased, 5 of these were 
shared by T16 and Y27632 but not untreated cells, all of which were related to 
apoptosis, including cell death and apoptosis of embryonic cells. As might have 
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been expected, anoikis was one the function that was predicted to be decreased 
in response to T16 treatment. As discussed previously the pathways involved in 
resistance to anoikis may be potential targets of T16, particularly those involving 
Src-family kinases (Beausejour et al, 2012; Bolos et al, 2010). Surprisingly, 
anoikis was also predicted to be decreased in the untreated cells, but not the 
Y27632 treated cells. This could suggest that the transcriptional changes were 
significant enough to be detected from the relatively small population of 
untreated cells that go on to survive.  This could however be further evidence 
that the transcriptional response to apoptosis has similarities regardless of 
treatment type.  
We also investigated individual gene changes associated with the response to 
dissociation and found that 26% of these were shared regardless of treatment 
type and that a further 30% of these were shared between T16 and untreated 
cells. This again shows a surprisingly similar transcriptional response between 
the treatment groups. However there were 1008 gene changes associated with 
T16 treatment alone. We therefore chose to validate those that were associated 
with relevant cellular processes such as adhesion or apoptosis, including 
components of FGF, EGF, MAPK and integrin signalling pathways. As before, 
although a number of these targets resulted in increased expression following 
dissociation, they did not result in any significant differences between the three 
treatment groups during validation. The failure to validate targets may reflect 
the relatively small fold changes that were detected during the arrays.   
Taken together, the data garnered during the microarray analysis performed in 
this chapter further highlights the critical role that the Pi3K/Akt signalling 
pathway plays in the regulation of hPSC. The Pi3k/Akt pathway was one of the 
most highly regulated pathways in response to dissociation and treatment with 
either Y27632 or T16. The data also confirms the importance of integrin 
mediated signalling in response to dissociation, with many integrin sub-units 
being up-regulated in the generated data sets. The transcriptional response to 
dissociation was more similar between treatments than expected, however, it 
has been reported in the literature that apoptosis can proceed even in the 
absence of the nucleus (Schulze-Osthoff et al, 1994). This may suggest that the 
activation of apoptosis in untreated hPSC occurs mainly at the post-translational 
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level such as through the cleavage of proteins by caspases (Cohen, 1997). 
Overall, the data garnered from this array analysis suggests that it is unlikely 
that T16 mediates its pro-survival effect at the transcriptional level. 
The data generated within this thesis highlighted a novel Src-kinases dependent, 
RhoA independent pathway through which hPSC can mediate survival in response 
to dissociation. However it also creates a number of interesting questions that 
given more time would have been investigated. The use of the Src-family 
inhibitor PP2 initially demonstrated the critical role for Src-kinases, however this 
does not give any indication as to which family member (or members) are 
playing the critical role within hPSC. Therefore, an RNAi based investigation 
could be carried out to selectively knock down each family member to 
determine which are essential to T16 mediated survival of hPSC.   
Similarly, given the variety of Src-kinases that were found to be expressed in 
hPSC, pan-Src family antibodies were used give the best chance of detecting any 
association and change in binding to RACK1, however this approach precluded 
the identification of the specific Src-kinase, or kinases.  Naturally, additional 
studies to specifically identify and modulate the Src-family kinase(s) that are 
important in this system would have been undertaken if time had permitted and 
are a priority for any future studies. 
The data from co-IP studies also supported a critical role for RACK1 in regulating 
intracellular Src-kinase activity, this relationship could also be further 
investigated. To do this, a RACK1 mutant with a Y246F mutation that prevents 
the binding of Src-kinases could be used. This would require the use of viral 
vectors to transduce cells with the mutant protein and would require substantial 
optimisation. It would be expected that such a mutation would produce a similar 
result to that of T16 treatment.  
Intriguingly the data from pull down assays clearly demonstrated that whilst the 
total amount of Src-kinase protein was not altered by T16, the amount pulled-
down by RACK1 was significantly lower after T16 treatment. This finding 
suggested that the intracellular localisation and/or the binding of Src-kinases to 
other partners may be altered by T16. Given the well documented relationship 
between Src-kinases and integrins or FAK in the literature, as well as the 
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adhesion-dependent nature of survival mediated by T16, these would be the 
logical targets for further investigation. As performed with RACK1, co-IP assays 
could be undertaken using FAK or integrin β1.  Additionally, confocal microscopy 
or FRET analysis could be used to investigate the sub-cellular localisation and 
compartmentalisation of Src-kinases in response to T16. 
Although we have identified pathways that are critical in T16 mediated survival, 
the direct target of T16 has not yet been determined. For example it remains 
unclear whether T16 binds to RACK1 and effectively blocks the interaction of 
RACK1 and Src-kinases directly, or whether T16 targets upstream of RACK1 and 
indirectly reduces the capacity of the kinase to bind to RACK1. To address this 
issue, techniques such as that used by Ong et al (2009) could be employed. Here 
they coupled their identified small molecule to beads in order to identify binding 
partners, which they subsequently identified using mass spectrometry.  
As well as facilitating the survival of hPSC post dissociation, Y27632 has been 
reported to improve recovery from cryopreservation and to aid the recovery 
from hPSC following FACS. In addition, Y27632 has also been used during the 
reprogramming of somatic cell types towards pluripotency. At present we are 
unaware of the effects that T16 will have on such processes. It may be possible 
that T16 further improves the recovery of cells following cryopreservation, or 
may even be a useful small molecule that can further improve the reprograming 
efficiency and safety of hiPSC. Extending the possible uses of T16 in this way 
would make it an even more attractive molecule for commercialisation and 
widespread use. 
The structure of T16 was not disclosed during these studies, however the 
compound was identified from a screen of commercially available drug-like 
moieties and can be identified for future studies. Knowledge of the structure 
would allow a medicinal chemistry project to produce structural analogues of 
T16 and to test their capacity to promote hPSC survival. In this way a basic 
structure-activity relationship could be identified and may also be possible to 
produce a more potent analogue of T16. It is also probable that identification of 
the structural components of T16 that are responsible for its activity would help 
direct experimental design and give further insight into the biological 
mechanism of action of this important molecule. Furthermore, given the 
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potential commercial value of T16, developing the structure activity relationship 
will be critical in producing sufficient information to protect the structure and 
use of T16 by filing patent applications for the use of a series of active 
compounds, and additionally for intervention in any pathway identified. The 
importance of this commercial potential for T16 has precluded publication of the 
findings described in this thesis until such patent protection has been secured. 
HPSC have vast potential for a number of applications such as in drug discovery 
and as a source of replacement cells and tissues for use in regenerative 
medicine. Successful exploitation of this potential will ultimately require 
mechanised expansion of these cells in order to produce clinically relevant cell 
numbers. The most straighforward means of acheiving this scale up will involve 
the enzymatic passage of hPSC but, as discussed in this thesis, hPSC are 
incredibly sensitive to dissociation. It is therefore clear that compounds that 
promote survival post dissociation will play a critical role in facilitating the 
transition from small scale manual culture to large scale or mechanised culture 
systems. Currently, the inhibition of ROCK mediated signalling using Y27632 or 
alternative ROCK inhibitors remains the only available option to support survival 
upon enzymatic disaggregation of hPSC. However, as described previously, there 
are a number of drawbacks associated with the use of Y27632, as exemplified by 
the negative effect on cell proliferation and detrimental effect on the 
production of haematopoietic precursor cells (Joo et al, 2012; Yung et al, 2011; 
Zweigerdt et al, 2011; Singh et al, 2012). T16 therefore has huge potential as an 
alternative to Y27632 during the development of scalable culture systems.  
Suspension culture systems have recently become attractive options for the 
scale-up of hPSC, as culture without ECM components is inherrently less variable 
and also more cost effective (Wang et al, 2013; Chen et al, 2012; Larijani et al, 
2011). Although T16 does not facilitate the survival of hPSC in suspension 
culture, this issue is not insurmountable as it is probable that capacity of T16 to 
promote cell-matrix rather than cell-cell adhesions could be exploited to 
mediate the survival of hPSC by using ECM-coated bead/carrier based suspension 
culture systems which could also allow differentiation in the same vessels. 
Although the potential use of T16 as a reagent for large scale culture of hPSC is 
commercially very appealing, its use at small scale must not be overlooked. The 
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drive towards fully defined and GMP compliant culture media is critical to the 
successful exploitation of hPSC. The most promising example of this currently 
available is Essential 8 (Chen et al, 2011), which is entirely serum and xeno-free. 
However, Essential 8 relies on the use of partial dissociation methods using EGTA 
during passage. Such passage methods are heavily dependent upon the skill of 
each individual user, as even slight overexposure to EGTA will result in complete 
dissociation which will cause apoptosis of hPSC. At the time of development 
(2011) Y27632 was widely available, but the authors interestingly chose to omit 
it from the formulation of Essential8, possibly due to the adverse effects caused 
by continuous exposure to Y27632. As to the best of our knowledge, T16 does 
not result in these issues, it would be a prime candidate for inclusion within 
culture mediums such as Essential 8 as it considerably simplifies the culture of 
hPSC and permits manipulation of the cells whenever it is desired without the 
need for pre-treatment. 
7.1 Conclusion 
The work undertaken during this thesis aimed to characterise the effect of a 
novel pluripotent stem cell survival compound known as T16. The data presented 
within provide evidence that T16 has a previously unreported mode of action 
and, unlike other survival compounds described to date, does not mediate its 
pro-survival effect via ROCK inhibition or by interaction with other components 
of the RhoA/ROCK/MLC pathway. T16 not only supports long term culture of 
hPSC when used either transiently or continuously, but does so with no observed 
detrimental effect on the stem cell identity or function, with treated cells 
expressing high levels of pluripotency markers, maintaining normal karyotype 
and retaining multi-lineage differentiation capacity.  
Taken together, the investigations described within this thesis have identified a 
previously undescribed ROCK/pMLC independent, Src-kinase dependent 
mechanism of hPSC cell survival that can be manipulated to avoid dissociation 
induced cell death. The scaffold protein RACK1 has been identified as an 
intracellular binding partner of Src-kinases in hPSC and may play a critical role in 
the regulation of Src-kinase activity by modifying its sub-cellular localisation. 
Importantly, this newly identified pathway can be mediated by T16 resulting in 
hPSC survival after dissociation to single cells which is also dependent upon the 
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reattachment of cells to the ECM. This pathway can be further interrogated and 
elucidated using T16 and related compounds.  
The identification of T16 as an alternative survival compound, that can be used 
without the detrimental effects observed with Y27632, imparts significant 
scientific and commercial value to this molecule which will also be an important 
tool to improve stem cell media, culture and manipulation and may thereby 
accelerate the drive towards the use of hPSC derived therapies as a viable 
clinical option. 
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Table shows the 2ΔCt x1000 values of the entire list of genes analysed during 
experimentation performed in section 3.3.4. The data showed no differences in 
gene expression between drug treatment and passage number. Data shown as 
N/A had either an undetermined 2ΔCt x1000 value or a negligible value of <0.1.   
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    Y27632 (2
ΔCt
*1000) T16 (2ΔCt*1000) 
Gene Description Gene P0 P10 P15 P5 P0 P10 P15 P5 
Core pluripotency transcription 
factors 
NANOG 136.5 143.1 128.0 168.8 174.9 209.6 118.9 140.7 
POU5F1 4.1 2.7 2.7 4.1 4.5 4.3 3.4 2.9 
SOX2 53.0 35.0 32.8 50.9 50.0 50.2 40.3 47.5 
Expressed in undifferentiated cells 
TDGF1 113.0 103.1 96.9 118.3 118.4 100.9 78.8 95.4 
DNMT3B 381.0 598.2 526.2 510.5 490.5 629.0 581.5 419.8 
GABRB3 53.5 60.7 53.7 63.3 63.8 83.2 53.9 52.8 
GDF3 2.3 2.0 2.5 3.4 2.2 2.4 2.1 2.8 
Implicated in control of stemness 
BRIX 42.2 35.7 34.2 36.4 49.7 39.9 31.7 36.9 
CD9 83.6 102.1 114.9 110.7 96.6 118.3 99.8 91.1 
COMMD3 0.7 0.8 0.8 0.9 0.7 1.0 0.8 0.8 
CRABP2 151.3 247.9 141.4 142.8 163.4 164.6 251.0 147.3 
EBAF 5.7 2.2 0.6 1.2 11.4 1.8 1.3 3.2 
FGF4 N/A N/A N/A N/A N/A N/A N/A N/A 
FGF5 N/A N/A N/A N/A N/A N/A N/A N/A 
FOXD3 29.0 28.3 14.0 15.9 34.0 25.7 12.7 13.4 
GAL 55.9 51.8 35.7 85.5 59.4 87.7 30.6 41.4 
GBX2 0.6 0.7 0.2 0.1 0.5 2.5 0.1 0.4 
GRB7 23.7 39.6 28.0 28.8 26.1 30.4 27.7 24.0 
IFITM1 97.7 120.9 87.9 151.4 104.1 118.6 67.5 93.3 
IFITM2 55.4 64.9 59.8 81.2 63.6 70.5 43.9 57.2 
IL6ST 2.4 2.3 2.3 2.9 3.3 2.7 2.5 2.9 
IMP2 13.4 16.9 11.2 15.6 16.4 18.0 12.9 16.4 
KIT 5.7 6.2 5.1 5.4 7.5 5.8 5.1 3.9 
LEFTB 11.0 4.3 3.3 5.0 24.4 6.2 4.5 7.8 
LIFR N/A N/A N/A N/A N/A N/A N/A N/A 
LIN28 412.9 419.2 337.3 399.5 505.2 450.9 360.6 401.6 
NODAL 39.3 34.2 31.4 47.8 65.5 62.4 22.6 44.5 
NOG N/A N/A N/A N/A N/A N/A N/A N/A 
NR5A2 3.6 3.9 3.1 3.5 6.0 7.5 2.4 3.6 
NR6A1 48.7 50.0 43.8 49.1 51.2 62.4 46.7 48.8 
PODXL 322.2 467.0 341.5 323.0 389.1 486.9 403.9 388.3 
PTEN  1.3 1.4 1.0 1.7 1.6 1.3 1.3 1.5 
REST N/A N/A N/A N/A N/A N/A N/A N/A 
SEMA3A 17.8 16.5 20.4 24.9 23.3 23.4 15.2 19.8 
SFRP2 126.2 128.6 102.5 108.5 142.2 156.7 76.7 129.4 
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TERT 3.7 3.9 3.0 3.4 4.3 4.3 3.4 3.2 
TFCP2L1 1.1 1.3 0.8 0.9 1.6 1.8 0.8 0.9 
UTF1 2.2 2.8 1.9 1.9 2.6 3.3 1.9 2.7 
XIST N/A N/A N/A N/A N/A N/A N/A N/A 
ZFP42 104.7 124.5 94.1 92.3 108.5 145.3 101.7 92.6 
Differentiation marker 
ACTC 10.8 7.0 4.8 7.3 12.5 5.9 5.8 6.3 
AFP N/A N/A N/A N/A N/A N/A N/A N/A 
CD34 N/A N/A N/A N/A N/A N/A N/A N/A 
CDH5 N/A N/A N/A N/A N/A N/A N/A N/A 
CDX2 N/A N/A N/A N/A N/A N/A N/A N/A 
CGB 0.4 0.5 0.3 0.4 0.4 0.4 0.3 0.3 
COL1A1 95.0 157.7 150.2 114.1 117.0 176.7 199.5 155.2 
COL2A1 3.5 5.9 5.1 4.8 5.0 8.2 4.5 3.3 
DDX4 N/A N/A N/A N/A N/A N/A N/A N/A 
DES 2.9 5.6 4.2 5.0 3.8 5.1 5.0 7.7 
EOMES 5.6 4.3 1.2 3.8 5.0 4.1 1.7 4.8 
FLT1 6.1 8.4 6.7 7.2 6.2 7.3 7.5 5.8 
FN1 189.9 55.0 30.6 90.2 209.1 66.5 44.5 34.7 
FOXA2 0.7 0.4 0.1 0.5 0.8 0.4 0.6 0.4 
GATA4 1.6 0.2 0.1 0.9 1.8 0.2 0.6 0.1 
GATA6 2.0 0.1 0.1 2.9 2.0 0.2 0.4 0.2 
GCG N/A N/A N/A N/A N/A N/A N/A N/A 
GCM1 N/A N/A N/A N/A N/A N/A N/A N/A 
GFAP 0.3 0.2 0.2 0.2 0.3 0.3 0.2 0.2 
HBB N/A N/A N/A N/A N/A N/A N/A N/A 
HBZ N/A N/A N/A N/A N/A N/A N/A N/A 
HLXB9 N/A N/A N/A N/A N/A N/A N/A N/A 
IAPP N/A N/A N/A N/A N/A N/A N/A N/A 
INS N/A N/A N/A N/A N/A N/A N/A N/A 
IPF1 N/A N/A N/A N/A N/A N/A N/A N/A 
ISL1 N/A N/A N/A N/A N/A N/A N/A N/A 
KRT1 N/A N/A N/A N/A N/A N/A N/A N/A 
LAMA1 13.6 13.1 11.8 13.8 15.2 13.5 12.9 11.7 
LAMB1 11.3 13.5 11.2 13.9 13.6 17.5 14.3 11.8 
LAMC1 27.4 25.2 25.1 26.0 35.3 30.1 30.8 23.4 
MYF5 N/A N/A N/A N/A N/A N/A N/A N/A 
MYOD1 N/A N/A N/A N/A N/A N/A N/A N/A 
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NES 31.7 48.9 36.2 47.6 46.4 70.3 50.4 47.1 
NEUROD1 N/A N/A N/A N/A N/A N/A N/A N/A 
NPPA N/A N/A N/A N/A N/A N/A N/A N/A 
OLIG2 N/A N/A N/A N/A N/A N/A N/A N/A 
PAX4 N/A N/A N/A N/A N/A N/A N/A N/A 
PAX6 0.4 0.5 0.5 0.4 0.4 0.5 0.2 0.1 
PECAM1 N/A N/A N/A N/A N/A N/A N/A N/A 
PTF1A N/A N/A N/A N/A N/A N/A N/A N/A 
RUNX2 N/A N/A N/A N/A N/A N/A N/A N/A 
SERPINA1 N/A N/A N/A N/A N/A N/A N/A N/A 
SOX17 N/A N/A N/A N/A N/A N/A N/A N/A 
SST N/A N/A N/A N/A N/A N/A N/A N/A 
SYCP3 N/A N/A N/A N/A N/A N/A N/A N/A 
SYP 1.6 2.6 1.5 1.7 2.1 2.4 2.4 1.7 
T N/A N/A N/A N/A N/A N/A N/A N/A 
TAT N/A N/A N/A N/A N/A N/A N/A N/A 
TH N/A N/A N/A N/A N/A N/A N/A N/A 
WT1 N/A N/A N/A N/A N/A N/A N/A N/A 
Table A1- Summary of all 2ΔCt x1000 values from analysis of pluripotency related genes (Section 3.3.4)
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